

Prevalence and burden of overactive bladder in the Uni

World Journal of Urology

20, 327-336

DOI: 10.1007/s00345-002-0301-4

Citation Report

#	ARTICLE	IF	CITATIONS
1	Effects of Brainstem Lesions on Optokinetic Nystagmus in Monkeys. <i>Neurology</i> , 1958, 8, 22-22.	1.1	33
3	The impact on health-related quality of life of stress, urge and mixed urinary incontinence. <i>BJU International</i> , 2003, 92, 731-735.	2.5	318
4	Alterations in Voiding Frequency and Cystometry in the Clomipramine Induced Model of Endogenous Depression and Reversal With Fluoxetine. <i>Journal of Urology</i> , 2003, 170, 2067-2071.	0.4	50
5	OAB Evidence from the Urologist's Perspective. <i>European Urology Supplements</i> , 2003, 2, 10-15.	0.1	5
6	OAB Evidence from the Patient's Perspective. <i>European Urology Supplements</i> , 2003, 2, 16-22.	0.1	1
8	Botulinum toxin in urology: evaluation using an evidence-based medicine approach. <i>Nature Reviews Urology</i> , 2004, 1, 31-37.	1.4	18
9	Pharmacology of the Lower Urinary Tract: Basis for Current and Future Treatments of Urinary Incontinence. <i>Pharmacological Reviews</i> , 2004, 56, 581-631.	16.0	448
10	The wet patient: understanding patients with overactive bladder and incontinence. <i>Current Medical Research and Opinion</i> , 2004, 20, 791-801.	1.9	23
11	The Impact of Urinary Urgency and Frequency on Health-Related Quality of Life in Overactive Bladder: Results from a National Community Survey. <i>Value in Health</i> , 2004, 7, 455-463.	0.3	297
12	Antimuscarinics for treatment of overactive bladder. <i>Lancet Neurology</i> , The, 2004, 3, 46-53.	10.2	377
14	A review of quality-of-life questionnaires for urinary incontinence and overactive bladder: Which ones to use and why?. <i>Current Urology Reports</i> , 2004, 5, 336-342.	2.2	39
15	An appraisal of recently patented compounds for bladder overactivity and urinary incontinence. <i>Expert Opinion on Therapeutic Patents</i> , 2004, 14, 1041-1060.	5.0	3
16	Gender differences in sleep and sleep-disordered breathing. <i>Clinics in Chest Medicine</i> , 2004, 25, 257-268.	2.1	103
17	Costs of Urinary Incontinence and Overactive Bladder in the United States: A Comparative Study. <i>Journal of Urology</i> , 2004, 172, 1216-1216.	0.4	1
18	Economic and personal impact of fecal and urinary incontinence. <i>Gastroenterology</i> , 2004, 126, S8-S13.	1.3	203
19	Benefit-Risk Assessment of Tolterodine in the Treatment of Overactive Bladder in Adults. <i>Drug Safety</i> , 2004, 27, 1043-1057.	3.2	19
20	Oxybutynin Extended-Release. <i>Drugs</i> , 2004, 64, 885-912.	10.9	42
21	Drug Treatment of Overactive Bladder. <i>Drugs</i> , 2004, 64, 1643-1656.	10.9	70

#	ARTICLE	IF	CITATIONS
22	Trospium Chloride in the Management of Overactive Bladder. <i>Drugs</i> , 2004, 64, 2433-2446.	10.9	59
23	Management of Overactive Bladder. <i>Disease Management and Health Outcomes</i> , 2004, 12, 121-142.	0.4	3
24	Darifenacin. <i>Drugs and Aging</i> , 2004, 21, 885-892.	2.7	16
25	Darifenacin: a novel M3muscarinic selective receptor antagonist for the treatment of overactive bladder. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 1493-1500.	4.1	35
26	Comparison of Peripherally Acting Substance for Treatment of Detrusor Overactivity: What is New; What is in the Pipeline?. <i>EAU Update Series</i> , 2004, 2, 161-169.	0.5	10
27	Costs of urinary incontinence and overactive bladder in the United States: a comparative study. <i>Urology</i> , 2004, 63, 461-465.	1.0	389
28	Clinical and socioeconomic relevance of overactive bladder. <i>Urology</i> , 2004, 63, 42-44.	1.0	20
29	Mixed incontinence. <i>Urology</i> , 2004, 63, 51-57.	1.0	128
30	The patient's perspective: Redefining end points. <i>Urology</i> , 2004, 64, 17-20.	1.0	15
31	Defining overactive bladder: Epidemiology and burden of disease. <i>Urology</i> , 2004, 64, 2-6.	1.0	156
32	Urinary Incontinence in Men. <i>Nursing Research</i> , 2004, 53, S36-S41.	1.7	33
33	Acupuncture for Overactive Bladder. <i>Obstetrics and Gynecology</i> , 2005, 106, 138-143.	2.4	90
34	Overactive bladder: epidemiology and social impact. <i>Current Opinion in Obstetrics and Gynecology</i> , 2005, 17, 507-511.	2.0	34
35	Sacral Neuromodulation in Lower Urinary Tract Dysfunction. <i>Advances and Technical Standards in Neurosurgery</i> , 2005, 30, 177-224.	0.5	15
36	Employees With Overactive Bladder: Work Loss Burden. <i>Journal of Occupational and Environmental Medicine</i> , 2005, 47, 439-446.	1.7	44
37	Newer pharmacologic options in management of overactive bladder syndrome. <i>Current Opinion in Obstetrics and Gynecology</i> , 2005, 17, 495-506.	2.0	2
39	QT and QTc Interval With Standard and Supratherapeutic Doses of Darifenacin, a Muscarinic M3Selective Receptor Antagonist for the Treatment of Overactive Bladder. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 1038-1047.	2.0	51
40	Overactive Bladder. <i>Journal of Wound, Ostomy and Continence Nursing</i> , 2005, 32, S1-S5.	1.0	0

#	ARTICLE	IF	CITATIONS
41	Antimuscarinic Drugs for Overactive Bladder and Their Potential Effects on Cognitive Function in Older Patients. <i>Journal of the American Geriatrics Society</i> , 2005, 53, 2195-2201.	2.6	199
42	Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. <i>BJU International</i> , 2005, 95, 81-85.	2.5	133
43	Managing patients with an overactive bladder and glaucoma: a questionnaire survey of Japanese urologists on the use of anticholinergics. <i>BJU International</i> , 2005, 95, 98-101.	2.5	15
44	The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. <i>BJU International</i> , 2005, 95, 335-340.	2.5	208
45	An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. <i>BJU International</i> , 2005, 95, 580-586.	2.5	89
46	Validation of the Urgency Perception Scale. <i>BJU International</i> , 2005, 95, 591-596.	2.5	115
47	A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. <i>BJU International</i> , 2005, 95, 993-1001.	2.5	130
48	A novel surgical technique for implanting a new electrostimulation system for treating female overactive bladder: a preliminary report. <i>BJU International</i> , 2005, 95, 1253-1258.	2.5	12
49	Urgency: the key to defining the overactive bladder. <i>BJU International</i> , 2005, 96, 1-3.	2.5	32
50	Role of muscarinic receptor antagonists in urgency and nocturia. <i>BJU International</i> , 2005, 96, 37-42.	2.5	36
51	Health-related consequences of overactive bladder: an economic perspective. <i>BJU International</i> , 2005, 96, 43-45.	2.5	97
52	A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. <i>BJU International</i> , 2005, 96, 848-852.	2.5	108
53	Bladder-health diaries: an assessment of 3-day vs 7-day entries. <i>BJU International</i> , 2005, 96, 1049-1054.	2.5	61
54	An epidemiological survey of overactive bladder symptoms in Japan. <i>BJU International</i> , 2005, 96, 1314-1318.	2.5	192
55	Overactive bladder: achieving a differential diagnosis from other lower urinary tract conditions. <i>International Journal of Clinical Practice</i> , 2005, 59, 825-830.	1.7	5
56	Comparison of Symptom Severity and Treatment Response in Patients with Incontinent and Continent Overactive Bladder. <i>European Urology</i> , 2005, 48, 110-115.	1.9	43
57	Prevalence of the Overactive Bladder Syndrome by Applying the International Continence Society Definition. <i>European Urology</i> , 2005, 48, 622-627.	1.9	136
58	Treatment of Overactive Bladder in the Older Patient: Pooled Analysis of Three Phase III Studies of Darifenacin, an M3 Selective Receptor Antagonist. <i>European Urology</i> , 2005, 48, 471-477.	1.9	75

#	ARTICLE	IF	CITATIONS
59	Solifenacin Is Effective for the Treatment of OAB Dry Patients: A Pooled Analysis. <i>European Urology</i> , 2005, 48, 483-487.	1.9	59
60	Botulinum-A Toxin Detrusor and Sphincter Injection in Treatment of Overactive Bladder Syndrome: Objective Outcome and Patient Satisfaction. <i>European Urology</i> , 2005, 48, 984-990.	1.9	95
61	Overactive bladder. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2005, 19, 829-841.	2.8	18
62	Costs Associated with the Management of Overactive Bladder and Related Comorbidities. <i>Pharmacotherapy</i> , 2005, 25, 511-519.	2.6	85
63	Botulinum toxin for the treatment of lower urinary tract symptoms: A review. <i>Neurourology and Urodynamics</i> , 2005, 24, 2-12.	1.5	59
64	Test-retest reliability of four questionnaires for patients with overactive bladder: The overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). <i>Neurourology and Urodynamics</i> , 2005, 24, 215-225.	1.5	145
65	Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. <i>World Journal of Urology</i> , 2005, 23, 248-252.	2.2	84
67	Effects of ageing on muscarinic receptor subtypes and function in rat urinary bladder. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2005, 372, 71-78.	3.0	54
68	Urinary incontinence after multiple gestation and delivery: impact on quality of life. <i>International Urogynecology Journal</i> , 2005, 16, 334-336.	1.4	18
69	How urgent is urgency?. <i>International Urogynecology Journal</i> , 2005, 16, 93-95.	1.4	13
70	Validation of an overactive bladder awareness tool for use in primary care settings. <i>Advances in Therapy</i> , 2005, 22, 381-394.	2.9	162
71	Overactive bladder in the male patient: epidemiology, etiology, evaluation, and treatment. <i>Current Urology Reports</i> , 2005, 6, 410-418.	2.2	18
72	The responsiveness of the Overactive Bladder Questionnaire (OAB-q). <i>Quality of Life Research</i> , 2005, 14, 849-855.	3.1	119
73	Insomnia in men treated with radical prostatectomy for prostate cancer. <i>Psycho-Oncology</i> , 2005, 14, 147-156.	2.3	89
74	Undertreatment of Urinary Incontinence in General Practice. <i>Annals of Pharmacotherapy</i> , 2005, 39, 17-21.	1.9	27
75	Darifenacin for the Treatment of Overactive Bladder. <i>Women's Health</i> , 2005, 1, 331-343.	1.5	7
76	Duloxetine in the Treatment of Stress Urinary Incontinence. <i>Women's Health</i> , 2005, 1, 345-358.	1.5	17
77	Overactive bladder in women: symptom impact and treatment expectations. <i>Current Medical Research and Opinion</i> , 2005, 21, 1413-1421.	1.9	42

#	ARTICLE	IF	CITATIONS
78	Urinary Incontinence: Proper Assessment and Available Treatment Options. Journal of Women's Health, 2005, 14, 906-916.	3.3	6
79	Do continent patients with overactive bladder respond to muscarinic receptor antagonists?. Nature Reviews Urology, 2005, 2, 472-473.	1.4	0
80	FUNCTION OF THE LOWER URINARY TRACT IN MICE LACKING $\hat{1}\pm_{1d}$ -ADRENOCEPTOR. Journal of Urology, 2005, 174, 370-374.	0.4	74
81	EFFICACY AND SAFETY OF EXTENDED RELEASE OXYBUTYNIN FOR THE TREATMENT OF URGE INCONTINENCE: AN ANALYSIS OF DATA FROM 3 FLEXIBLE DOSING STUDIES. Journal of Urology, 2005, 174, 1301-1305.	0.4	30
82	COMBINATION TREATMENT WITH PROPIVERINE HYDROCHLORIDE PLUS DOXAZOSIN CONTROLLED RELEASE GASTROINTESTINAL THERAPEUTIC SYSTEM FORMULATION FOR OVERACTIVE BLADDER AND COEXISTING BENIGN PROSTATIC OBSTRUCTION: A PROSPECTIVE, RANDOMIZED, CONTROLLED MULTICENTER STUDY. Journal of Urology, 2005, 174, 1334-1338.	0.4	149
83	INCREASED WARNING TIME WITH DARIFENACIN: A NEW CONCEPT IN THE MANAGEMENT OF URINARY URGENCY. Journal of Urology, 2005, 173, 1214-1218.	0.4	66
84	Tolterodine for the treatment of overactive bladder: a review. Expert Opinion on Pharmacotherapy, 2005, 6, 653-666.	1.8	14
85	Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5â€‰mg. Current Medical Research and Opinion, 2005, 21, 71-80.	1.9	27
87	Pharmacological Management of Overactive Bladder. Pharmacoeconomics, 2005, 23, 995-1006.	3.3	16
88	Antimuscarinic agents: Implications and concerns in the management of overactive bladder in the elderly. Clinical Therapeutics, 2005, 27, 127-138.	2.5	85
89	Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: Urodynamic outcome and patient satisfaction. Urology, 2005, 66, 82-87.	1.0	81
90	Prevalence and impact on generic quality of life of urinary incontinence in Japanese working women: Assessment by ICI questionnaire and SF-36 Health Survey. Urology, 2005, 66, 88-93.	1.0	35
91	The role of corticotropin releasing factor and its antagonist, astressin, on micturition in the rat. Autonomic Neuroscience: Basic and Clinical, 2005, 123, 26-35.	2.8	75
92	Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health and Quality of Life Outcomes, 2005, 3, 47.	2.4	301
93	Treatment of overactive bladder syndrome and detrusor overactivity. Reviews in Gynaecological Practice, 2005, 5, 243-250.	0.1	3
94	Men's bladder health: urinary incontinence in the elderly (Part I). The Journal of Men's Health & Gender: the Official Journal of the International Society for Men's Health & Gender, 2005, 2, 31-37.	0.2	5
95	Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery. Expert Opinion on Drug Delivery, 2005, 2, 935-950.	5.0	31
96	Overactive Bladder in the Elderly. Drugs and Aging, 2005, 22, 1013-1028.	2.7	60

#	ARTICLE	IF	CITATIONS
97	ASSESSMENT OF COGNITIVE FUNCTION OF THE ELDERLY POPULATION: EFFECTS OF DARIFENACIN. Journal of Urology, 2005, 173, 493-498.	0.4	169
98	Nerve Growth Factor and Prostaglandins in the Urine of Female Patients With Overactive Bladder. Journal of Urology, 2006, 175, 1773-1776.	0.4	204
99	The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy. Expert Opinion on Pharmacotherapy, 2006, 7, 509-527.	1.8	7
100	The Physiological Function of the Urothelium – More than a Simple Barrier. Urologia Internationalis, 2006, 76, 289-295.	1.3	38
101	The emergence of new drugs for overactive bladder. Expert Opinion on Emerging Drugs, 2006, 11, 125-136.	2.4	1
102	Tolterodine: pharmacokinetics, efficacy and safety. Expert Review of Obstetrics and Gynecology, 2006, 1, 159-171.	0.4	0
103	Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice. European Urology Supplements, 2006, 5, 698-703.	0.1	8
104	Epidemiology of Stress, Urgency, and Mixed Incontinence: Where Do the Boundaries Cross?. European Urology Supplements, 2006, 5, 842-848.	0.1	8
106	The Prevalence of Urinary Incontinence Among Community Dwelling Men: Results From the National Health and Nutrition Examination Survey. Journal of Urology, 2006, 176, 2103-2108.	0.4	69
107	Urgency is the Core Symptom of Female Overactive Bladder Syndrome, as Demonstrated by a Statistical Analysis. Journal of Urology, 2006, 176, 636-640.	0.4	32
108	Sacral Nerve Stimulation for the Overactive Bladder. Urologic Clinics of North America, 2006, 33, 491-501.	1.8	11
110	Efficacy and Safety of a Neurokinin-1 Receptor Antagonist in Postmenopausal Women With Overactive Bladder With Urge Urinary Incontinence. Journal of Urology, 2006, 176, 2535-2540.	0.4	88
111	The Overactive Bladder: Epidemiology and Morbidity. Urologic Clinics of North America, 2006, 33, 433-438.	1.8	36
112	When to Use Antimuscarinics in Men Who Have Lower Urinary Tract Symptoms. Urologic Clinics of North America, 2006, 33, 531-537.	1.8	5
114	Overactive Bladder: A Better Understanding of Pathophysiology, Diagnosis and Management. Journal of Urology, 2006, 175, S5-10.	0.4	165
115	Is Nocturia Equally Common Among Men and Women? A Population Based Study in Finland. Journal of Urology, 2006, 175, 596-600.	0.4	128
116	Safety and Tolerability of Tolterodine for the Treatment of Overactive Bladder in Men With Bladder Outlet Obstruction. Journal of Urology, 2006, 175, 999-1004.	0.4	254
117	Pharmacological Management of Women with Mixed Urinary Incontinence. Drugs, 2006, 66, 591-606.	10.9	23

#	ARTICLE	IF	CITATIONS
118	Pharmacotherapy for Overactive Bladder. <i>Drugs</i> , 2006, 66, 1361-1370.	10.9	26
119	Cost implications of antimuscarinic drugs in the treatment of overactive bladder syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 539-544.	1.8	0
120	Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis. <i>Current Medical Research and Opinion</i> , 2006, 22, 41-48.	1.9	31
121	The Causes and Consequences of Overactive Bladder. <i>Journal of Women's Health</i> , 2006, 15, 251-260.	3.3	35
122	Overactive bladder and urinary incontinence: A multitherapy approach to treatment. <i>Sexuality, Reproduction & Menopause</i> , 2006, 4, 66-70.	1.0	1
123	Pathophysiology of Overactive Bladder. <i>American Journal of Medicine</i> , 2006, 119, 3-8.	1.5	541
124	Disruptive Effects of Overactive Bladder and Urge Urinary Incontinence in Younger Women. <i>American Journal of Medicine</i> , 2006, 119, 16-23.	1.5	46
125	Pharmacologic Management of Overactive Bladder: Practical Options for the Primary Care Physician. <i>American Journal of Medicine</i> , 2006, 119, 24-28.	1.5	54
126	Management of Overactive Bladder and Urge Urinary Incontinence in the Elderly Patient. <i>American Journal of Medicine</i> , 2006, 119, 29-36.	1.5	124
127	Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis. <i>American Journal of Geriatric Pharmacotherapy</i> , 2006, 4, 14-24.	3.0	133
128	Solifenacin succinate for the treatment of symptoms of overactive bladder. <i>Clinical Therapeutics</i> , 2006, 28, 1247-1272.	2.5	50
129	Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: The VESicare open-label trial (VOLT). <i>Clinical Therapeutics</i> , 2006, 28, 1935-1946.	2.5	65
130	Psychometric evaluation of the medical outcomes study-sleep scale in persons with overactive bladder. <i>Clinical Therapeutics</i> , 2006, 28, 2119-2132.	2.5	14
131	Major classes of sensory neurons to the urinary bladder. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2006, 126-127, 390-397.	2.8	63
132	Developing and validating a Chinese instrument to measure lower urinary tract symptoms among employed women in Taiwan. <i>Nursing Outlook</i> , 2006, 54, 353-361.	2.6	18
133	Translating overactive bladder questionnaires in 14 languages. <i>Urology</i> , 2006, 67, 536-540.	1.0	145
134	Patient-reported outcomes in overactive bladder: The influence of perception of condition and expectation for treatment benefit. <i>Urology</i> , 2006, 68, 29-37.	1.0	57
135	Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. <i>Urology</i> , 2006, 68, 328-332.	1.0	77

#	ARTICLE	IF	CITATIONS
136	Epidemiologic survey of lower urinary tract symptoms in Japan. <i>Urology</i> , 2006, 68, 560-564.	1.0	152
137	Effects of potassium channel modulators on human detrusor smooth muscle myogenic phasic contractile activity: Potential therapeutic targets for overactive bladder. <i>Urology</i> , 2006, 68, 442-448.	1.0	55
138	Effects of Bladder Training and/or Tolterodine in Female Patients with Overactive Bladder Syndrome: A Prospective, Randomized Study. <i>Journal of Korean Medical Science</i> , 2006, 21, 1060.	2.5	44
139	Trospium chloride: a different anticholinergic. <i>Expert Review of Obstetrics and Gynecology</i> , 2006, 1, 29-39.	0.4	1
140	Correlation Between the Overactive Bladder Questionnaire (OAB-q) and Urodynamic Data of Parkinson Disease Patients Affected by Neurogenic Detrusor Overactivity During Antimuscarinic Treatment. <i>Clinical Neuropharmacology</i> , 2006, 29, 220-229.	0.7	24
141	Urinary Incontinence and Diabetes. <i>Journal of Wound, Ostomy and Continence Nursing</i> , 2006, 33, 619-623.	1.0	16
142	Darifenacin: a selective M3 muscarinic receptor antagonist for the treatment of overactive bladder. <i>Therapy: Open Access in Clinical Medicine</i> , 2006, 3, 723-732.	0.2	3
143	Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. <i>BJU International</i> , 2006, 97, 96-100.	2.5	269
144	Medical visits among adults with symptoms commonly associated with an overactive bladder. <i>BJU International</i> , 2006, 97, 551-554.	2.5	5
145	Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. <i>BJU International</i> , 2006, 97, 1003-1006.	2.5	80
146	The impact of the overactive bladder on health-related utility and quality of life. <i>BJU International</i> , 2006, 97, 1267-1272.	2.5	54
147	Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. <i>BJU International</i> , 2006, 97, 1262-1266.	2.5	45
148	The global burden of female pelvic floor disorders. <i>BJU International</i> , 2006, 98, 1-5.	2.5	73
149	Neuromodulatory therapies in female pelvic medicine and reconstructive surgery: biological agents. <i>BJU International</i> , 2006, 98, 50-60.	2.5	12
150	Developments in pharmacological therapy for the overactive bladder. <i>BJU International</i> , 2006, 98, 78-87.	2.5	8
151	Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. <i>BJU International</i> , 2006, 98, 1025-1032.	2.5	56
152	Clinical efficacy of an α_1 -adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia. <i>International Journal of Urology</i> , 2006, 13, 15-20.	1.0	47
153	Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. <i>International Journal of Urology</i> , 2006, 13, 692-698.	1.0	55

#	ARTICLE	IF	CITATIONS
154	Overactive bladder: current understanding and future issues. BJOG: an International Journal of Obstetrics and Gynaecology, 2006, 113, 2-8.	2.3	5
155	Defining success in overactive bladder management: the importance of patient-focused outcomes. BJOG: an International Journal of Obstetrics and Gynaecology, 2006, 113, 9-18.	2.3	3
156	The contemporary pharmacological management of overactive bladder. BJOG: an International Journal of Obstetrics and Gynaecology, 2006, 113, 19-28.	2.3	5
157	Implant-Driven Tibial Nerve Stimulation in the Treatment of Refractory Overactive Bladder Syndrome: 12-Month Follow-up. Neuromodulation, 2006, 9, 163-171.	0.8	43
158	Neuromodulation in Intractable Interstitial Cystitis and Related Pelvic Pain Syndromes. Pain Medicine, 2006, 7, S166-S184.	1.9	32
159	Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. International Journal of Clinical Practice, 2006, 60, 745-751.	1.7	55
160	Overactive bladder made ridiculously simple?. International Journal of Clinical Practice, 2006, 60, 631-633.	1.7	4
161	Epidemiology, prescribing patterns and resource use associated with overactive bladder in UK primary care. International Journal of Clinical Practice, 2006, 60, 949-958.	1.7	28
162	Treatment-resistant detrusor overactivity - underlying pharmacology and potential mechanisms. International Journal of Clinical Practice, 2006, 60, 8-16.	1.7	31
163	Managing enlarged prostate in primary care. International Journal of Clinical Practice, 2006, 60, 1609-1615.	1.7	8
165	Common Problems of Urination in Nonpregnant Women: Causes, Current Management, and Prevention Strategies. Journal of Midwifery and Women's Health, 2006, 51, 159-173.	1.3	1
166	The impact of the overactive bladder syndrome on sexual function: A preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. American Journal of Obstetrics and Gynecology, 2006, 195, 1730-1735.	1.3	78
167	The puzzle of overactive bladder: controversies, inconsistencies, and insights. International Urogynecology Journal, 2006, 17, 650-658.	1.4	12
168	Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder. International Urogynecology Journal, 2006, 17, 502-511.	1.4	32
169	Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. International Urogynecology Journal, 2006, 17, 512-519.	1.4	39
171	Effects of gender, age and hypertension on β_2 -adrenergic receptor function in rat urinary bladder. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 373, 300-309.	3.0	56
173	Overactive bladder in the male patient: Epidemiology, etiology, evaluation, and treatment. Current Bladder Dysfunction Reports, 2006, 1, 52-60.	0.5	2
174	An updated review of quality-of-life questionnaires for urinary incontinence and overactive bladder: Which ones to use and why. Current Bladder Dysfunction Reports, 2006, 1, 71-80.	0.5	5

#	ARTICLE	IF	CITATIONS
175	The impact of detrusor overactivity on the management of stress urinary incontinence in women. <i>Current Urology Reports</i> , 2006, 7, 354-362.	2.2	15
176	Urinary incontinence: Economic burden and new choices in pharmaceutical treatment. <i>Advances in Therapy</i> , 2006, 23, 556-573.	2.9	40
177	The Validation of the Patient Perception of Bladder Condition (PPBC): A Single-Item Global Measure for Patients with Overactive Bladder. <i>European Urology</i> , 2006, 49, 1079-1086.	1.9	316
178	Overactive Bladder: Prevalence and Implications in Brazil. <i>European Urology</i> , 2006, 49, 1087-1092.	1.9	60
179	A Shifted Paradigm for the Further Understanding, Evaluation, and Treatment of Lower Urinary Tract Symptoms in Men: Focus on the Bladder. <i>European Urology</i> , 2006, 49, 651-659.	1.9	329
181	The Current and Future Burden and Cost of Overactive Bladder in Five European Countries. <i>European Urology</i> , 2006, 50, 1050-1057.	1.9	139
182	Population-Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC Study. <i>European Urology</i> , 2006, 50, 1306-1315.	1.9	2,119
183	Pharmacoeconomic Evaluation of Antimuscarinic Agents for the Treatment of Overactive Bladder. <i>Pharmacotherapy</i> , 2006, 26, 1694-1702.	2.6	55
184	Minimal clinically important change in urinary incontinence detected by a quality of life assessment tool in overactive bladder syndrome with urge incontinence. <i>Neurourology and Urodynamics</i> , 2006, 25, 228-235.	1.5	28
185	Effect of the potassium channel opener WAY-133537 on the overactive bladder of spinalized rats. <i>Neurourology and Urodynamics</i> , 2006, 25, 808-814.	1.5	8
186	Prevalence and risk factors of overactive bladder syndrome in Fuzhou Chinese women. <i>Neurourology and Urodynamics</i> , 2006, 25, 717-721.	1.5	55
188	Trospium chloride: over 20 years of clinical use. <i>Therapy: Open Access in Clinical Medicine</i> , 2006, 3, 215-226.	0.2	1
189	Trospium chloride: the European experience. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1373-1380.	1.8	7
190	Antimuscarinic Drugs for the Treatment of Female Urinary Incontinence. <i>Women's Health</i> , 2006, 2, 251-265.	1.5	1
191	Mechanisms of Disease: the role of nerve growth factor in the pathophysiology of bladder disorders. <i>Nature Reviews Urology</i> , 2006, 3, 101-110.	1.4	177
192	Perceptions and behaviours of women with bladder control problems. <i>Family Practice</i> , 2006, 23, 568-577.	1.9	51
193	Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 2357-2364.	1.0	8
194	Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 2421-2434.	1.8	17

#	ARTICLE	IF	CITATIONS
195	Current and emerging investigational medical therapies for the treatment of overactive bladder. Expert Opinion on Investigational Drugs, 2006, 15, 1017-1037.	4.1	21
196	Overactive Bladder Syndrome among Community-Dwelling Adults in Taiwan: Prevalence, Correlates, Perception, and Treatment Seeking. Urologia Internationalis, 2006, 77, 327-333.	1.3	53
197	EGF and HB-EGF modulate inward potassium current in human bladder urothelial cells from normal and interstitial cystitis patients. American Journal of Physiology - Cell Physiology, 2007, 292, C106-C114.	4.6	27
198	The Coexistence of the Fibromyalgia Syndrome and the Overactive Bladder Syndrome. Journal of Musculoskeletal Pain, 2007, 15, 31-37.	0.3	2
199	Development and validation of a short, easy-to-use questionnaire for diagnosing urinary incontinence and lower urinary tract symptoms in women: the Female Urinary Symptom Score. Primary Health Care Research and Development, 2007, 8, 243.	1.2	5
200	Evaluation of Sexual Function in Women with Overactive Bladder Syndrome. Urologia Internationalis, 2007, 78, 112-115.	1.3	22
201	New Options and Strategies for the Treatment of Urinary Incontinence. Journal of Pharmacy Practice, 2007, 20, 29-48.	1.0	1
202	Overactive bladder: an update. Current Opinion in Urology, 2007, 17, 231-236.	1.8	78
204	Assessment and Management of Urinary Incontinence in the Elderly Male. Nurse Practitioner, 2007, 32, 26-34.	0.3	8
205	Assessment and Management of Urinary Incontinence in the Elderly Male. Nurse Practitioner, 2007, 32, 34-35.	0.3	0
206	Randomized Trial of Oxybutynin Extended Versus Immediate Release for Women Aged 65 and Older with Overactive Bladder: Lessons Learned from Conducting a Trial. Journal of Obstetrics and Gynaecology Canada, 2007, 29, 726-732.	0.7	18
207	Association Between Urogenital Symptoms and Depression in Community-Dwelling Women Aged 20 to 70 Years. Urology, 2007, 69, 691-696.	1.0	34
208	Sacral Neuromodulation: Cost Considerations and Clinical Benefits. Urology, 2007, 70, 1069-1073.	1.0	44
211	Incontinence Related to Management of Benign Prostatic Hypertrophy. American Journal of Geriatric Pharmacotherapy, 2007, 5, 324-334.	3.0	15
212	A generic health-related quality of life instrument, the Medical Outcomes Study Short Form-36, in women with urinary incontinence. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2007, 130, 18-24.	1.1	18
213	Pelvic floor dysfunction and evidence-based physical therapy. , 2007, , 161-315.		0
215	New Data on Tolterodine: Do Recent Findings Dispel Questions About Treating Overactive Bladder in Men?. European Urology Supplements, 2007, 6, 10-16.	0.1	2
216	Outcomes in Overactive Bladder Treatment: Patient Perception—A Key to Success. European Urology Supplements, 2007, 6, 17-22.	0.1	5

#	ARTICLE	IF	CITATIONS
217	A Cross-Sectional, Population-Based, Multinational Study of the Prevalence of Overactive Bladder and Lower Urinary Tract Symptoms: Results from the EPIC Study. <i>European Urology Supplements</i> , 2007, 6, 4-9.	0.1	39
218	Long-Term Management of Overactive Bladder with Antimuscarinic Agents. <i>European Urology Supplements</i> , 2007, 6, 432-437.	0.1	12
219	Pelvic Floor Dysfunction in Aging Women. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2007, 46, 374-378.	1.3	30
220	Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study. <i>Current Medical Research and Opinion</i> , 2007, 23, 2697-2704.	1.9	32
221	Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 511-523.	1.8	24
222	Anticholinergic drugs versus other medications for overactive bladder syndrome in adults. <i>The Cochrane Library</i> , 2007, , CD003190.	2.8	32
224	Disease Burden of Overactive Bladder. <i>Pharmacoeconomics</i> , 2007, 25, 129-142.	3.3	22
225	Managing urinary incontinence in women depends on whether symptoms are associated with stress, urgency or both. <i>Drugs and Therapy Perspectives</i> , 2007, 23, 10-13.	0.6	0
226	Impact of overactive bladder on women in the United States: results of a national survey. <i>Current Medical Research and Opinion</i> , 2007, 23, 65-76.	1.9	103
227	Transdermal oxybutynin: a review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 435-439.	3.3	6
228	Darifenacin treatment of patients ≥ 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. <i>Current Medical Research and Opinion</i> , 2007, 23, 2347-2358.	1.9	86
229	Onset of efficacy of tolterodine extended release in patients with overactive bladder. <i>Current Medical Research and Opinion</i> , 2007, 23, 777-781.	1.9	16
230	Female urinary incontinence: A review. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2007, 49, 34-39.	0.6	2
231	Symptoms of Interstitial Cystitis, Painful Bladder Syndrome and Similar Diseases in Women: A Systematic Review. <i>Journal of Urology</i> , 2007, 177, 450-456.	0.4	190
235	Efficacy, Safety and Tolerability of Fesoterodine for Overactive Bladder Syndrome. <i>Journal of Urology</i> , 2007, 178, 2488-2494.	0.4	179
236	Safety and Tolerability of Sedation-Free Flexible Cystoscopy for Intradetrusor Botulinum Toxin-A Injection. <i>Journal of Urology</i> , 2007, 177, 1006-1010.	0.4	50
237	The Relative Importance of Health Related Quality of Life and Prescription Insurance Coverage in the Decision to Pharmacologically Manage Symptoms of Overactive Bladder. <i>Journal of Urology</i> , 2007, 178, 2532-2536.	0.4	18
239	The Challenge of the Overactive Bladder: From Laboratory to New Drugs. <i>EAU-EBU Update Series</i> , 2007, 5, 250-258.	0.6	2

#	ARTICLE	IF	CITATIONS
240	Botulinum toxin injections for adults with overactive bladder syndrome. , 2007, , CD005493.		43
242	Is the Prevalence of Overactive Bladder Overestimated? A Population-Based Study in Finland. PLoS ONE, 2007, 2, e195.	2.5	61
243	Lower Urinary Tract Disorders in Postmenopausal Women. , 2007, , 693-737.		4
244	The molecular basis of urgency: regional difference of vanilloid receptor expression in the human urinary bladder. Neurourology and Urodynamics, 2007, 26, 433-438.	1.5	72
245	The responsiveness of the OAB-q among OAB patient subgroups. Neurourology and Urodynamics, 2007, 26, 196-203.	1.5	34
246	Are there differences between women with urge predominant and stress predominant mixed urinary incontinence?. Neurourology and Urodynamics, 2007, 26, 204-207.	1.5	19
247	Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients. Neurourology and Urodynamics, 2007, 26, 190-195.	1.5	31
248	Correlations between the ICIQ-SF score and urodynamic findings. Neurourology and Urodynamics, 2007, 26, 492-494.	1.5	58
249	Intradetrusor injection of botulinum toxin in patients with idiopathic and neurogenic detrusor overactivity: Urodynamic outcome and patient satisfaction. Neurourology and Urodynamics, 2007, 26, 531-536.	1.5	34
250	Defining overactive bladder as hypersensitivity. Neurourology and Urodynamics, 2007, 26, 904-907.	1.5	69
251	Properties of the major classes of mechanoreceptors in the guinea pig bladder. Journal of Physiology, 2007, 585, 147-163.	2.9	81
252	The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU International, 2007, 99, 85-96.	2.5	108
253	Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU International, 2007, 99, 836-844.	2.5	92
254	Redefining response in overactive bladder syndrome. BJU International, 2007, 99, 101-106.	2.5	27
255	The overactive bladder syndrome: treating patients on an individual basis. BJU International, 2007, 99, 1-7.	2.5	11
256	Economic conditions and marriage quality of men with prostate cancer. BJU International, 2007, 99, 1391-1397.	2.5	13
257	Randomized, double-blind, placebo-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU International, 2007, 100, 579-587.	2.5	103
258	Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. BJU International, 2007, 100, 1007-1014.	2.5	27

#	ARTICLE	IF	CITATIONS
259	A population-based study of urinary symptoms and incontinence: the Canadian Urinary Bladder Survey. BJU International, 2008, 101, 52-58.	2.5	109
260	Muscarinic receptor antagonists for overactive bladder. BJU International, 2007, 100, 987-1006.	2.5	339
261	Lower urinary tract symptoms (LUTS) in people aged 50 or older consulting general practitioners. Geriatrics and Gerontology International, 2007, 7, 147-153.	1.5	12
262	Novel uses for antidiuresis. International Journal of Clinical Practice, 2007, 61, 32-36.	1.7	2
263	Nocturia in women. International Journal of Clinical Practice, 2007, 61, 23-31.	1.7	7
264	A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting. International Journal of Clinical Practice, 2007, 61, 1535-1546.	1.7	57
265	Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions. International Journal of Clinical Practice, 2008, 62, 27-38.	1.7	32
266	Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study). International Journal of Clinical Practice, 2007, 62, 191-196.	1.7	24
267	Comparative in vivo uroselectivity profiles of anticholinergics, tested in a novel anesthetized rabbit model. European Journal of Pharmacology, 2007, 572, 207-212.	3.5	4
268	Effects of antimuscarinics on voiding function after cerebral infarction in a rat model of overactive bladder. European Journal of Pharmacology, 2007, 577, 143-149.	3.5	4
269	Efficacy and Tolerability of Tolterodine Extended Release in Male and Female Patients with Overactive Bladder. European Urology, 2007, 51, 1054-1064.	1.9	55
270	Design and Validation of a New Screening Instrument for Lower Urinary Tract Dysfunction: The Bladder Control Self-Assessment Questionnaire (B-SAQ). European Urology, 2007, 52, 230-238.	1.9	47
271	The Economic Costs of Overactive Bladder in Germany. European Urology, 2007, 51, 1654-1663.	1.9	44
272	Evaluating the Impact of Overactive Bladder on Sexual Health in Women: What Is Relevant?. Journal of Sexual Medicine, 2007, 4, 124-136.	0.6	25
273	ORIGINAL RESEARCH—OUTCOMES ASSESSMENT: Overactive Bladder and Women's Sexual Health: What is the Impact?. Journal of Sexual Medicine, 2007, 4, 656-666.	0.6	90
274	Darifenacin: first M3 receptor antagonist for overactive bladder. The Prescriber, 2007, 18, 14-20.	0.3	0
275	A prospective assessment of overactive bladder symptoms in a cohort of elderly women who underwent transvaginal surgery for advanced pelvic organ prolapse. American Journal of Obstetrics and Gynecology, 2007, 197, 82.e1-82.e4.	1.3	77
276	Sacral nerve neuromodulation in patients with cardiac pacemakers. American Journal of Obstetrics and Gynecology, 2007, 197, 94.e1-94.e3.	1.3	9

#	ARTICLE	IF	CITATIONS
277	Impact of stress urinary incontinence and overactive bladder on micturition patterns and health-related quality of life. International Urogynecology Journal, 2007, 18, 65-71.	1.4	17
278	Quality of life in women with multiple sclerosis and overactive bladder syndrome. International Urogynecology Journal, 2007, 18, 189-194.	1.4	40
279	Current and future trends in the management of overactive bladder. International Urogynecology Journal, 2007, 18, 81-94.	1.4	15
280	Symptom change in women with overactive bladder after extracorporeal magnetic stimulation: a prospective trial. International Urogynecology Journal, 2007, 18, 875-880.	1.4	18
281	Prevalence of urinary incontinence in Korean women:an epidemiologic survey. International Urogynecology Journal, 2007, 18, 1309-1315.	1.4	37
282	Is there an association between depressive and urinary symptoms during and after pregnancy?. International Urogynecology Journal, 2007, 18, 1409-1415.	1.4	21
283	Evaluation and outcome measures in the treatment of female urinary stress incontinence: International Urogynecological Association (IUGA) guidelines for research and clinical practice. International Urogynecology Journal, 2008, 19, 5-33.	1.4	153
284	Cross-cultural differences for adapting overactive bladder symptoms: results of an epidemiologic survey in Korea. World Journal of Urology, 2007, 25, 505-511.	2.2	31
287	Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials. International Urology and Nephrology, 2007, 39, 1069-1077.	1.4	18
288	Sacral neuromodulation for the treatment of overactive bladder in men. Current Bladder Dysfunction Reports, 2007, 2, 117-123.	0.5	0
289	Antimuscarinics for the treatment of overactive bladder: A review of central nervous system effects. Current Bladder Dysfunction Reports, 2007, 2, 227-233.	0.5	2
290	Combination antimuscarinics and alpha-blockers for benign prostatic hyperplasia. Current Prostate Reports, 2007, 5, 71-77.	0.1	0
291	Male overactive bladder: The role of urodynamics and anticholinergics. Current Urology Reports, 2007, 8, 66-73.	2.2	6
292	How to choose the initial drug treatment for overactive bladder. Current Urology Reports, 2007, 8, 364-369.	2.2	9
293	Repeated botulinum toxin injection for idiopathic overactive bladder: Will chemodenervation become a long-term solution?. Current Urology Reports, 2007, 8, 419-424.	2.2	6
294	Antimuscarinics for the treatment of overactive bladder: A review of central nervous system effects. Current Urology Reports, 2007, 8, 441-447.	2.2	23
295	Predicting detrusor overactivity using a physician-based scoring system. International Urogynecology Journal, 2008, 19, 1223-1227.	1.4	8
296	Why do stress and urge incontinence co-occur much more often than expected?. International Urogynecology Journal, 2008, 19, 1429-1440.	1.4	31

#	ARTICLE	IF	CITATIONS
297	Anticholinergic drugs, bladder retraining and their combination for urge urinary incontinence: a pilot randomised trial. <i>International Urogynecology Journal</i> , 2008, 19, 1533-1543.	1.4	20
298	Does anticholinergic medication have a role in treating men with overactive bladder and benign prostatic hyperplasia?. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2008, 377, 491-501.	3.0	11
299	How to choose the initial drug treatment for overactive bladder. <i>Current Bladder Dysfunction Reports</i> , 2008, 3, 41-46.	0.5	0
300	Antimuscarinics for the treatment of overactive bladder: A review of central nervous system effects. <i>Current Bladder Dysfunction Reports</i> , 2008, 3, 161-167.	0.5	1
301	Anticholinergics in men: Does the evidence support combination therapy?. <i>Current Bladder Dysfunction Reports</i> , 2008, 3, 168-173.	0.5	1
302	Combination antimuscarinics and α -blockers for benign prostatic hyperplasia. <i>Current Urology Reports</i> , 2008, 9, 265-271.	2.2	5
303	The treatment of overactive bladder: A primary care provider's perspective. <i>Current Urology Reports</i> , 2008, 9, 428-432.	2.2	1
304	Development and validation of the overactive bladder satisfaction (OAB-S) questionnaire. <i>Neurourology and Urodynamics</i> , 2008, 27, 179-190.	1.5	53
305	Spontaneous activity of mouse detrusor smooth muscle and the effects of the urothelium. <i>Neurourology and Urodynamics</i> , 2008, 27, 79-87.	1.5	55
306	Urgency assessment in the evaluation of overactive bladder (OAB). <i>Neurourology and Urodynamics</i> , 2008, 27, 13-21.	1.5	57
307	Voiding urges perceived by patients with interstitial cystitis/painful bladder syndrome. <i>Neurourology and Urodynamics</i> , 2008, 27, 287-290.	1.5	24
308	Development of de novo urge incontinence in women post sling: The role of preoperative urodynamics in assessing the risk. <i>Neurourology and Urodynamics</i> , 2008, 27, 407-411.	1.5	36
309	Mixed urinary symptoms: What are the urodynamic findings?. <i>Neurourology and Urodynamics</i> , 2008, 27, 372-375.	1.5	45
310	Long-term benefits of darifenacin treatment for patient quality of life: Results from a 2-year extension study. <i>Neurourology and Urodynamics</i> , 2008, 27, 540-547.	1.5	20
311	Discovery of novel series of benzoic acid derivatives containing biphenyl ether moiety as potent and selective human β_3 -adrenergic receptor agonists: Part IV. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5037-5040.	2.2	7
312	It's just the worry about not being able to control it! A qualitative study of living with overactive bladder. <i>British Journal of Health Psychology</i> , 2008, 13, 343-359.	3.5	93
313	Intradetrusor botulinum toxin injections for overactive bladder. <i>Trends in Urology Gynaecology & Sexual Health</i> , 2008, 13, 27-28.	0.1	0
314	Validation of a real-time urodynamic measure of urinary sensation. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 198, 661.e1-661.e5.	1.3	25

#	ARTICLE	IF	CITATIONS
315	Reoperation for urinary incontinence. American Journal of Obstetrics and Gynecology, 2008, 199, 546.e1-546.e8.	1.3	33
316	Lower urinary tract symptoms in womenâ€”A common but neglected problem. Journal of the American Academy of Nurse Practitioners, 2008, 20, 311-318.	1.4	25
317	Diagnosis and treatment of lower urinary tract symptoms suggestive of overactive bladder and bladder outlet obstruction among men in general practice in the UK. International Journal of Clinical Practice, 2008, 62, 688-694.	1.7	32
318	Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine. International Journal of Clinical Practice, 2008, 62, 925-931.	1.7	20
319	Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. International Journal of Clinical Practice, 2008, 62, 1792-1800.	1.7	127
320	Long-term nitric oxide deficiency causes muscarinic supersensitivity and reduces IP_{3} -adrenoceptor-mediated relaxation, causing rat detrusor overactivity. British Journal of Pharmacology, 2008, 153, 1659-1668.	5.4	44
321	Survey Assessment of Continuation of and Satisfaction with Pharmacological Treatment for Urinary Incontinence. Value in Health, 2008, 11, 726-732.	0.3	27
322	A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology, 2008, 15, 809-815.	1.0	46
323	Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology, 2008, 15, 986-991.	1.0	43
324	Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, <i>in vitro</i> and <i>in vivo</i> . BJU International, 2008, 101, 1036-1042.	2.5	60
325	Understanding the elements of overactive bladder: questions raised by the EPIC study. BJU International, 2008, 101, 1381-1387.	2.5	102
326	The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU International, 2008, 101, 1388-1395.	2.5	700
327	Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU International, 2008, 102, 56-61.	2.5	59
328	Prospects and limitations of treatment with botulinum neurotoxin type A for patients with refractory idiopathic detrusor overactivity. BJU International, 2008, 102, 7-10.	2.5	11
329	Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU International, 2008, 102, 1120-1127.	2.5	128
330	Clinical management of lower urinary tract symptoms with combined medical therapy. BJU International, 2008, 102, 13-17.	2.5	11
331	Absolute bioavailability of imidafenacin after oral administration to healthy subjects. British Journal of Clinical Pharmacology, 2008, 65, 197-202.	2.4	31
332	Symptom Bother and Health Care-Seeking Behavior among Individuals with Overactive Bladder. European Urology, 2008, 53, 1029-1039.	1.9	126

#	ARTICLE	IF	CITATIONS
333	Lower Urinary Tract Symptoms Revisited: A Broader Clinical Perspective. <i>European Urology</i> , 2008, 54, 563-569.	1.9	184
334	The Motion: Antimuscarinics are the Mainstay of Therapy for Overactive Bladder. <i>European Urology</i> , 2008, 54, 226-230.	1.9	3
335	The Impact of Lower Urinary Tract Symptoms and Urinary Incontinence on Female Sexual Dysfunction Using a Validated Instrument. <i>Journal of Sexual Medicine</i> , 2008, 5, 1418-1423.	0.6	94
336	Overactive Bladder Is Associated with Erectile Dysfunction and Reduced Sexual Quality of Life in Men. <i>Journal of Sexual Medicine</i> , 2008, 5, 2904-2910.	0.6	71
337	Physiological and pathological regulation of the autonomic control of urinary bladder contractility. , 2008, 117, 297-312.		79
338	Cardiovascular Safety and Overall Tolerability of Solifenacin in Routine??Clinical Use. <i>Drug Safety</i> , 2008, 31, 505-514.	3.2	55
340	Evidence-Based Criteria for Pain of Interstitial Cystitis/Painful Bladder Syndrome in Women. <i>Urology</i> , 2008, 71, 444-448.	1.0	65
341	Trospium 60 mg Once Daily (QD) for Overactive Bladder Syndrome: Results from a Placebo-Controlled Interventional Study. <i>Urology</i> , 2008, 71, 449-454.	1.0	88
342	Tolterodine Extended Release Is Efficacious in Continent and Incontinent Subjects with Overactive Bladder. <i>Urology</i> , 2008, 72, 488-493.	1.0	11
344	Management of overactive bladder and lower urinary tract symptoms in men. <i>Current Bladder Dysfunction Reports</i> , 2008, 3, 117-122.	0.5	0
345	Gender differences in voluntary micturition control â€” An fMRI study. <i>NeuroImage</i> , 2008, 43, 183-191.	4.2	34
346	Deficits in Urological Knowledge Among Medical Students and Primary Care Providers: Potential for Impact on Urological Care. <i>Journal of Urology</i> , 2008, 180, 2140-2147.	0.4	22
348	Efficacy and Safety of Extended-Release Oxybutynin in Combination With Tamsulosin for Treatment of Lower Urinary Tract Symptoms in Men: Randomized, Double-Blind, Placebo-Controlled Study. <i>Mayo Clinic Proceedings</i> , 2008, 83, 1002-1010.	3.0	104
350	A Simple Validated Scale to Measure Urgency. <i>Journal of Urology</i> , 2008, 179, 1000-1005.	0.4	19
351	Voiding Pattern Analysis as a Surrogate for Cystometric Evaluation in Uroplakin II Knockout Mice. <i>Journal of Urology</i> , 2008, 179, 2046-2051.	0.4	19
352	Association of Pre-Existing Symptoms with Treatment Decisions among Newly Diagnosed Prostate Cancer Patients. <i>Patient</i> , 2008, 1, 189-200.	2.7	5
353	Prevalence of probable overactive bladder in a private obstetrics and gynecology group practice. <i>Current Medical Research and Opinion</i> , 2008, 24, 1083-1090.	1.9	13
354	Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms. <i>Current Medical Research and Opinion</i> , 2008, 24, 3513-3521.	1.9	32

#	ARTICLE	IF	CITATIONS
355	PATHOPHYSIOLOGY OF OVERACTIVE BLADDER. , 2008, , 204-212.		0
356	Urinary Incontinence in Women. Obstetrics and Gynecology, 2008, 111, 324-331.	2.4	237
357	Population Pharmacokinetic Analysis of a Novel Muscarinic Receptor Antagonist, Imidafenacin, in Healthy Volunteers and Overactive Bladder Patients. Drug Metabolism and Pharmacokinetics, 2008, 23, 456-463.	2.2	4
358	POSTERIOR TIBIAL NERVE STIMULATION FOR PELVIC FLOOR DYSFUNCTION. , 2008, , 277-283.		2
359	Association of overactive bladder and stress urinary incontinence in rats with pudendal nerve ligation injury. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2008, 294, R1510-R1516.	1.8	21
360	Effect of Itraconazole on the Pharmacokinetics of Imidafenacin in Healthy Subjects. Journal of Clinical Pharmacology, 2008, 48, 330-334.	2.0	11
361	Systematic Review: Randomized, Controlled Trials of Nonsurgical Treatments for Urinary Incontinence in Women. Annals of Internal Medicine, 2008, 148, 459.	3.9	218
362	No Effect of Imidafenacin, a Novel Antimuscarinic Drug, on Digoxin Pharmacokinetics in Healthy Subjects. Drug Metabolism and Pharmacokinetics, 2008, 23, 95-100.	2.2	6
363	Patient Tolerability of Botulinum Toxin Type A Injections Under Local Anesthesia Using a Rigid Cystoscope. Journal of Pelvic Medicine & Surgery, 2008, 14, 179-184.	0.1	3
364	Behavioral Therapies for Overactive Bladder. Journal of Wound, Ostomy and Continence Nursing, 2008, 35, 93-101.	1.0	44
365	Lower Urinary Tract Symptoms in Older Adults Undergoing Hip Arthroplasty. Journal of Wound, Ostomy and Continence Nursing, 2008, 35, 334-340.	1.0	5
366	Prevalence and Co-Occurrence of Pelvic Floor Disorders in Community-Dwelling Women. Obstetrics and Gynecology, 2008, 111, 678-685.	2.4	268
367	Discontinuation Rates of Anticholinergic Medications Used for the Treatment of Lower Urinary Tract Symptoms. Obstetrics and Gynecology, 2008, 112, 1311-1318.	2.4	110
368	Current management of overactive bladder. Current Opinion in Obstetrics and Gynecology, 2008, 20, 489-495.	2.0	14
369	Overactive Bladder Disease: The Urge for Better Therapies. Journal of Managed Care Pharmacy, 2008, 14, 381-386.	2.2	6
370	Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin. Patient Preference and Adherence, 2008, 2, 349.	1.8	3
371	CLINICAL DIAGNOSIS OF OVERACTIVE BLADDER. , 2008, , 197-203.		0
372	MIXED URINARY INCONTINENCE. , 2008, , 477-485.		3

#	ARTICLE	IF	CITATIONS
373	EPIDEMIOLOGY OF INCONTINENCE AND VOIDING DYSFUNCTION IN THE ELDERLY. , 2008, , 939-947.		0
374	NEUROMODULACIÓN PERIFÉRICA EN EL TRATAMIENTO DE LA INCONTINENCIA DE ORINA: EFECTO DE LA ESTIMULACIÓN TRANSCUTÁNEA DEL NERVO TIBIAL POSTERIOR SOBRE LA VEJIGA HIPERACTIVA. Revista Chilena De Obstetricia Y Ginecologia, 2008, 73, .	0.1	3
376	Here Is the Case for the Urge in Administrative Claims Database Research About Overactive Bladder Therapies. Journal of Managed Care Pharmacy, 2008, 14, 309-311.	2.2	2
377	A review of solifenacin in the treatment of urinary incontinence. Therapeutics and Clinical Risk Management, 2008, Volume 4, 117-128.	2.0	32
378	Micturition in Normal and Hypertensive Conscious Rat: Sex Difference in Cyclooxygenase Inhibition. Current Urology, 2008, 1, 134-140.	0.6	5
379	Oxybutynin extended release for the management of overactive bladder: a clinical review. Drug Design, Development and Therapy, 2009, 3, 151.	4.3	13
380	Role of fesoterodine in the treatment of overactive bladder. Research and Reports in Urology, 2009, Volume 2, 1-9.	1.0	2
381	Terminology of Lower Urinary Tract Symptoms. Helpful or Confusing ?. Scientific World Journal, The, 2009, 9, 17-22.	2.1	5
382	Use of Antimuscarinics in the Elderly. Scientific World Journal, The, 2009, 9, 459-465.	2.1	8
383	Fesoterodine for the treatment of urinary incontinence and overactive bladder. Therapeutics and Clinical Risk Management, 2009, 5, 869.	2.0	16
384	Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder. Expert Opinion on Pharmacotherapy, 2009, 10, 3103-3111.	1.8	39
385	Tolterodine extended-release for overactive bladder. Expert Opinion on Pharmacotherapy, 2009, 10, 2181-2194.	1.8	8
386	Effects of β 3-Adrenergic Receptor Activation on Rat Urinary Bladder Hyperactivity Induced by Ovariectomy. Journal of Pharmacology and Experimental Therapeutics, 2009, 330, 704-717.	2.5	39
387	Estimating the prevalence and economic burden of overactive bladder among Medicare beneficiaries prior to Medicare Part D coverage. Current Medical Research and Opinion, 2009, 25, 911-919.	1.9	23
388	The Role of P-Glycoprotein in Limiting Brain Penetration of the Peripherally Acting Anticholinergic Overactive Bladder Drug Trospium Chloride. Drug Metabolism and Disposition, 2009, 37, 1371-1374.	3.3	42
389	Behavioral Intervention versus Pharmacotherapy or Their Combinations in the Management of Overactive Bladder Dysfunction. Advances in Urology, 2009, 2009, 1-10.	1.3	11
390	Formulary Forum: Fesoterodine for the Treatment of Overactive Bladder. Annals of Pharmacotherapy, 2009, 43, 1992-2000.	1.9	8
391	Incidence of Overactive Bladder after Vaginal Hysterectomy and Associated Repairs for Pelvic Organ Prolapse. Gynecologic and Obstetric Investigation, 2009, 68, 65-70.	1.6	15

#	ARTICLE	IF	CITATIONS
392	Bladder-Relaxant Properties of the Novel Benzofuroindole Analogue LDD175. <i>Pharmacology</i> , 2009, 83, 367-378.	2.2	17
393	Do Pharmaceutical Marketing Activities Raise Prices? Evidence from Five Major Therapeutic Classes. <i>Journal of Public Policy and Marketing</i> , 2009, 28, 146-161.	3.4	29
394	Augmented bladder urothelial polyamine signaling and block of BK channel in the pathophysiology of overactive bladder syndrome. <i>American Journal of Physiology - Cell Physiology</i> , 2009, 297, C1445-C1451.	4.6	20
395	Evaluation of the Differences between the Urodynamic Findings of Neurogenic and Idiopathic Subtypes of Detrusor Overactivity. <i>Current Urology</i> , 2009, 3, 57-61.	0.6	0
396	Comparison of Receptor Binding Characteristics of Commonly Used Muscarinic Antagonists in Human Bladder Detrusor and Mucosa. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 328, 893-899.	2.5	43
397	Overactive bladder in males. <i>Therapeutic Advances in Urology</i> , 2009, 1, 209-221.	2.0	17
398	Increased Sexual Dysfunction in Men with Storage and Voiding Lower Urinary Tract Symptoms. <i>Journal of Sexual Medicine</i> , 2009, 6, 1103-1110.	0.6	34
399	Tolterodine Treatment Improves Storage Symptoms Suggestive of Overactive Bladder in Men Treated With β -Blockers. <i>European Urology</i> , 2009, 56, 534-543.	1.9	160
400	A Longitudinal Population-based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Women. <i>European Urology</i> , 2009, 55, 783-791.	1.9	141
401	Prevalence, Severity, and Symptom Bother of Lower Urinary Tract Symptoms among Men in the EPIC Study: Impact of Overactive Bladder. <i>European Urology</i> , 2009, 56, 14-20.	1.9	169
403	A Refocus on the Bladder as the Originator of Storage Lower Urinary Tract Symptoms: A Systematic Review of the Latest Literature. <i>European Urology</i> , 2009, 56, 810-820.	1.9	107
404	Preoperative opening detrusor pressure is predictive of detrusor overactivity following TVT in patients with preoperative mixed urinary incontinence. <i>Neurourology and Urodynamics</i> , 2009, 28, 82-85.	1.5	41
405	Urinary incontinence among institutionalized oldest old Chinese men in Taiwan. <i>Neurourology and Urodynamics</i> , 2009, 28, 335-338.	1.5	23
406	Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q). <i>Neurourology and Urodynamics</i> , 2009, 28, 416-422.	1.5	17
407	Mixed incontinence: Comparing definitions in women having stress incontinence surgery. <i>Neurourology and Urodynamics</i> , 2009, 28, 268-273.	1.5	44
408	Analysis of bladder diary with urinary perception to assess overactive bladder symptoms in community-dwelling women. <i>Neurourology and Urodynamics</i> , 2009, 28, 982-985.	1.5	16
409	“We have to stop again!” The impact of overactive bladder on family members. <i>Neurourology and Urodynamics</i> , 2009, 28, 969-975.	1.5	27
410	The psychometric validation of the OAB family impact measure (OAB-FIM). <i>Neurourology and Urodynamics</i> , 2010, 29, 359-369.	1.5	11

#	ARTICLE	IF	CITATIONS
411	Clinical and experimental aspects of Adreno-µmuscarinic synergy in the bladder base and prostate. Neurourology and Urodynamics, 2009, 28, 938-943.	1.5	11
412	Predictors of variability in urinary incontinence and overactive bladder symptoms. Neurourology and Urodynamics, 2010, 29, 328-335.	1.5	18
413	Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. Neurourology and Urodynamics, 2010, 29, 551-554.	1.5	22
414	Utility of Nanosized Microemulsion for Transdermal Delivery of Tolterodine Tartrate: Ex-Vivo Permeation and In-Vivo Pharmacokinetic Studies. Pharmaceutical Research, 2009, 26, 2446-2453.	3.5	36
415	Prevalence of the overactive bladder among Iranian women based on the International Continence Society definition: a population-based study. International Urology and Nephrology, 2009, 41, 35-45.	1.4	14
416	The importance of monitoring fluid intake during treatment of overactive bladder. Current Bladder Dysfunction Reports, 2009, 4, 98-105.	0.5	1
417	Measuring bladder sensation: A clinical and laboratory approach. Current Bladder Dysfunction Reports, 2009, 4, 155-159.	0.5	1
418	Overlap of voiding symptoms among common urologic conditions. Current Bladder Dysfunction Reports, 2009, 4, 176-180.	0.5	0
419	The importance of bladder wall thickness in the assessment of overactive bladder. Current Bladder Dysfunction Reports, 2009, 4, 220-224.	0.5	5
420	Algorithms for the management of overactive bladder. Current Urology Reports, 2009, 10, 352-361.	2.2	1
421	The association between overactive bladder and diuretic use in the elderly. Current Urology Reports, 2009, 10, 434-440.	2.2	22
422	Pharmacotherapy of urinary incontinence. International Urogynecology Journal, 2009, 20, 475-482.	1.4	11
423	Continued symptom improvement in sexually active women with overactive bladder and urgency urinary incontinence treated with tolterodine ER for 6 months. International Urogynecology Journal, 2009, 20, 381-385.	1.4	24
424	Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin. International Urogynecology Journal, 2009, 20, 667-675.	1.4	10
425	Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. International Urogynecology Journal, 2009, 20, 1431-1438.	1.4	19
426	Prevalence, treatment and known risk factors of urinary incontinence and overactive bladder in the non-institutionalized Portuguese population. International Urogynecology Journal, 2009, 20, 1481-1489.	1.4	29
427	Bladder pain syndrome/interstitial cystitis: a sense of urgency. World Journal of Urology, 2009, 27, 717-721.	2.2	25
428	Urgency as the cardinal symptom of overactive bladder: a critical analysis. World Journal of Urology, 2009, 27, 701-703.	2.2	5

#	ARTICLE	IF	CITATIONS
429	Perspectives on overactive bladder in the elderly population. World Journal of Urology, 2009, 27, 729-737.	2.2	11
430	Evaluation of drug-drug interactions with fesoterodine. European Journal of Clinical Pharmacology, 2009, 65, 551-560.	1.9	28
431	Prevalence, evaluation and management of overactive bladder in primary care. BMC Family Practice, 2009, 10, 8.	2.9	47
432	Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence. BMC Urology, 2009, 9, 18.	1.4	26
433	Effects of 17 β -oestradiol on rat detrusor smooth muscle contractility. Experimental Physiology, 2009, 94, 834-846.	2.0	11
434	Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. International Journal of Clinical Practice, 2009, 63, 560-567.	1.7	79
435	Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. International Journal of Clinical Practice, 2009, 63, 1177-1191.	1.7	166
436	Tolterodine extended release is well tolerated in older subjects. International Journal of Clinical Practice, 2009, 63, 1198-1204.	1.7	20
437	Urinary urgency - translating the evidence base into daily clinical practice. International Journal of Clinical Practice, 2009, 63, 1675-1682.	1.7	11
438	Nocturia: A non-specific but important symptom of urological disease. International Journal of Urology, 2009, 16, 249-256.	1.0	50
439	A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology, 2009, 16, 499-506.	1.0	76
440	The economic impact of overactive bladder syndrome in six Western countries. BJU International, 2009, 103, 202-209.	2.5	183
441	The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU International, 2009, 103, 4-11.	2.5	371
442	Implications of recent epidemiology studies for the clinical management of lower urinary tract symptoms. BJU International, 2009, 103, 48-57.	2.5	27
443	Introduction. BJU International, 2009, 103, 1-3.	2.5	0
444	Symptom severity and patient perceptions in overactive bladder: how are they related?. BJU International, 2009, 104, 968-972.	2.5	47
445	Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome. BJU International, 2009, 104, 960-967.	2.5	39
446	Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. BJU International, 2010, 106, 268-274.	2.5	58

#	ARTICLE	IF	CITATIONS
447	Discovery of Highly Potent and Selective Biphenylacetylsulfonamide-Based β_2 -Adrenergic Receptor Agonists and Evaluation of Physical Properties as Potential Overactive Bladder Therapies: Part 5. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 3063-3072.	6.4	10
448	Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. <i>Current Therapeutic Research</i> , 2009, 70, 405-420.	1.2	29
449	Prevalence and Associated Factors of Overactive Bladder in Korean Children 5-13 Years Old: A Nationwide Multicenter Study. <i>Urology</i> , 2009, 73, 63-67.	1.0	87
450	Burden of Illness Associated With Lower Urinary Tract Symptoms Including Overactive Bladder/Urinary Incontinence. <i>Urology</i> , 2009, 74, 34-38.	1.0	73
451	Nocturia and disturbed sleep in the elderly. <i>Sleep Medicine</i> , 2009, 10, 540-548.	1.6	221
452	Impact of solifenacin on quality of life, medical care use, work productivity, and health utility in the elderly: An exploratory subgroup analysis. <i>American Journal of Geriatric Pharmacotherapy</i> , 2009, 7, 373-382.	3.0	9
453	Diary and Patient-Reported Outcomes in Patients with Severe Overactive Bladder Switching from Tolterodine Extended Release 4 mg/day to Solifenacin Treatment. <i>Clinical Drug Investigation</i> , 2009, 29, 305-316.	2.2	17
454	Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. <i>Health and Quality of Life Outcomes</i> , 2009, 7, 13.	2.4	28
455	Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 615-626.	2.4	79
456	Solifenacin for overactive bladder in women unsuccessfully treated with immediate release oxybutynin: A pilot study. <i>Journal of Obstetrics and Gynaecology</i> , 2009, 29, 31-34.	0.9	9
457	Impact of Transdermal Oxybutynin on Work Productivity in Patients with Overactive Bladder. <i>Pharmacoeconomics</i> , 2009, 27, 329-339.	3.3	21
458	Urinary Flow Measurements Via Acoustic Signatures with Application to Telemedicine. , 2009, , .		6
459	The Influence of Psychiatric Comorbidities and Sexual Trauma on Lower Urinary Tract Symptoms in Female Veterans. <i>Journal of Urology</i> , 2009, 182, 2785-2790.	0.4	26
460	Bother Related to Bladder Control and Health Care Seeking Behavior in Adults in the United States. <i>Journal of Urology</i> , 2009, 181, 2591-2598.	0.4	61
461	Trospium Chloride Treatment of Overactive Bladder. <i>Annals of Pharmacotherapy</i> , 2009, 43, 283-295.	1.9	32
462	Urinary incontinence is associated with an increase in falls: a systematic review. <i>Australian Journal of Physiotherapy</i> , 2009, 55, 89-95.	0.9	166
463	Bladder Wall Thickness in Overactive Bladder: Does It Have a Role?. <i>European Urology Supplements</i> , 2009, 8, 769-771.	0.1	11
464	Preclinical compounds for the treatment of overactive bladder. <i>Expert Opinion on Therapeutic Patents</i> , 2009, 19, 107-117.	5.0	0

#	ARTICLE	IF	CITATIONS
465	Overactive Bladder in Female Patients with Chronic Diseases Visiting Primary Care Doctors: Effect of Age on Prevalence and Bothersomeness. LUTS: Lower Urinary Tract Symptoms, 2009, 1, 45-50.	1.3	3
466	Attenuation of Non-neuronal Adenosin Triphosphate Release from Human Bladder Mucosa by Antimuscarinic Agents. LUTS: Lower Urinary Tract Symptoms, 2009, 1, 88-92.	1.3	12
467	Does the Number of Previous Vaginal Deliveries Affect Overactive Bladder Symptoms and their Response to Treatment?. LUTS: Lower Urinary Tract Symptoms, 2009, 1, 82-87.	1.3	16
468	Efficacy and Safety of Oxybutynin Chloride Topical Gel for Overactive Bladder: A Randomized, Double-Blind, Placebo Controlled, Multicenter Study. Journal of Urology, 2009, 181, 1764-1772.	0.4	104
470	Talking to patients about bladder control problems. Nurse Practitioner, 2009, 34, 33-45.	0.3	7
471	Lower urinary tract symptoms in women. Current Opinion in Urology, 2009, 19, 337-341.	1.8	83
472	Epidural steroid injections in the management of a patient with spinal stenosis and urinary urgency. Nature Reviews Urology, 2009, 6, 113-115.	1.4	4
473	Promoting Continence and Managing Incontinence with People with Dementia Living at Home: One More Challenge for Integration. Journal of Integrated Care, 2009, 17, 15-25.	0.5	5
474	Urinary Tract Dysfunction in Neurological Disorders. Journal of Neuroscience Nursing, 2010, 42, E8-E23.	1.1	2
475	Lower urinary tract symptoms in women and quality of life. International Journal of Urological Nursing, 2010, 4, 97-105.	0.2	9
476	Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia. Current Opinion in Urology, 2010, 20, 43-48.	1.8	41
477	Contributors to Satisfaction With Combined Drug and Behavioral Therapy for Overactive Bladder in Subjects Dissatisfied With Prior Drug Treatment. Journal of Wound, Ostomy and Continence Nursing, 2010, 37, 199-205.	1.0	11
478	Efficacy of Solifenacin on Symptom Bother and Health-Related Quality of Life in Patients With Acute, Early Chronic, and Late Chronic Overactive Bladder. Female Pelvic Medicine and Reconstructive Surgery, 2010, 16, 320-326.	1.1	1
479	The Forefront for Novel Therapeutic Agents Based on the Pathophysiology of Lower Urinary Tract Dysfunction: Pathophysiology and Pharmacotherapy of Overactive Bladder. Journal of Pharmacological Sciences, 2010, 112, 128-134.	2.5	44
481	Análisis del síndrome de vejiga hiperactiva y de la incontinencia urinaria en mujeres laboralmente activas entre 25-64 años. Estudio EPICC. Actas Urológicas Españolas, 2010, 34, 618-624.	0.7	7
482	Loss-of-Function Mutations in HPSE2 Cause the Autosomal Recessive Urofacial Syndrome. American Journal of Human Genetics, 2010, 86, 957-962.	6.2	75
483	The pharmacokinetic profile of fesoterodine 8Âmg with daytime or nighttime dosing. European Journal of Clinical Pharmacology, 2010, 66, 171-176.	1.9	13
484	Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. International Urogynecology Journal, 2010, 21, 847-854.	1.4	11

#	ARTICLE	IF	CITATIONS
485	Urge incontinence: estimating environmental and obstetrical risk factors using an identical twin study. <i>International Urogynecology Journal</i> , 2010, 21, 939-946.	1.4	11
486	Parity is not associated with urgency with or without urinary incontinence. <i>International Urogynecology Journal</i> , 2010, 21, 1095-1102.	1.4	15
487	Pelvic organ prolapse quantification in women referred with overactive bladder. <i>International Urogynecology Journal</i> , 2010, 21, 1365-1369.	1.4	10
488	The effect of tolterodine 4 and 8Âmg on the heart rate variability in healthy subjects. <i>World Journal of Urology</i> , 2010, 28, 651-656.	2.2	24
489	Lower Urinary Tract Symptoms: Defining Syndromes in Urology. <i>Current Bladder Dysfunction Reports</i> , 2010, 5, 233-238.	0.5	1
490	Sacral Nerve Modulation in Overactive Bladder. <i>Current Urology Reports</i> , 2010, 11, 348-352.	2.2	9
491	Can We Predict if Overactive Bladder Symptoms Will Resolve After Sling Surgery in Women With Mixed Urinary Incontinence?. <i>Current Urology Reports</i> , 2010, 11, 328-337.	2.2	18
492	The Use of Botulinum Toxin A in Idiopathic Overactive Bladder Syndrome. <i>Current Urology Reports</i> , 2010, 11, 353-359.	2.2	8
493	Overactive Bladder and Mixed Incontinence. <i>Current Urology Reports</i> , 2010, 11, 385-392.	2.2	15
494	Complete Continence after Botulinum Neurotoxin Type A Injections for Refractory Idiopathic Detrusor Overactivity Incontinence: Patient-Reported Outcome at 4 Weeks. <i>European Urology</i> , 2010, 57, 891-896.	1.9	11
495	In Vitro Release of Adenosine Triphosphate from the Urothelium of Human Bladders with Detrusor Overactivity, Both Neurogenic and Idiopathic. <i>European Urology</i> , 2010, 57, 1087-1092.	1.9	72
496	A Comparison of the Frequencies of Medical Therapies for Overactive Bladder in Men and Women: Analysis of More Than 7.2 Million Aging Patients. <i>European Urology</i> , 2010, 57, 586-591.	1.9	39
497	Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms: A Longitudinal Population-Based Survey in Men Aged 45â€103 Years. <i>European Urology</i> , 2010, 58, 149-156.	1.9	128
498	Dynamic Progression of Overactive Bladder and Urinary Incontinence Symptoms: A Systematic Review. <i>European Urology</i> , 2010, 58, 532-543.	1.9	87
499	Effects of stimulation of muscarinic receptors on bladder afferent nerves in the in vitro bladderâ€pelvic afferent nerve preparation of the rat. <i>Brain Research</i> , 2010, 1361, 43-53.	2.2	23
501	Impact of convenience void in a bladder diary with urinary perception grade to assess overactive bladder symptoms: A communityâ€based study. <i>Neurourology and Urodynamics</i> , 2010, 29, 1286-1289.	1.5	5
502	Mixed incontinence: Current evidence and future perspectives. <i>Neurourology and Urodynamics</i> , 2010, 29, 618-622.	1.5	36
503	Urinary and Fecal Incontinence and Quality of Life in African Americans. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 1941-1945.	2.6	23

#	ARTICLE	IF	CITATIONS
504	AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder. <i>British Journal of Pharmacology</i> , 2010, 160, 1119-1127.	5.4	10
505	Do gender, age or lifestyle factors affect responses to antimuscarinic treatment in overactive bladder patients?. <i>International Journal of Clinical Practice</i> , 2010, 64, 1287-1293.	1.7	43
506	Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder. <i>International Journal of Clinical Practice</i> , 2010, 64, 1279-1286.	1.7	74
507	Women's toileting behaviour related to urinary elimination: concept analysis. <i>Journal of Advanced Nursing</i> , 2010, 66, 1874-1884.	3.3	45
508	Incontinence in women prisoners: an exploration of the issues. <i>Journal of Advanced Nursing</i> , 2010, 66, 1953-1967.	3.3	7
509	Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study. <i>BJU International</i> , 2010, 105, 1126-1135.	2.5	29
510	Predictors of discontinuing overactive bladder medications. <i>BJU International</i> , 2010, 105, 1283-1290.	2.5	42
511	Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity. <i>BJU International</i> , 2010, 105, 1268-1275.	2.5	54
512	Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α -blocker: effect of baseline prostate-specific antigen concentration. <i>BJU International</i> , 2010, 106, 1332-1338.	2.5	29
513	Urodynamic effects of solifenacin in untreated female patients with symptomatic overactive bladder. <i>International Journal of Urology</i> , 2010, 17, 796-800.	1.0	16
514	Muscarinic Receptor Antagonists, the Overactive Bladder and Efficacy against Urinary Urgency. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S4606.	0.4	4
515	Update on the management of overactive bladder: patient considerations and adherence. <i>Research and Reports in Urology</i> , 2010, Volume 3, 7-17.	1.0	0
516	Urinary incontinence after vaginal delivery or cesarean section. <i>Einstein (Sao Paulo, Brazil)</i> , 2010, 8, 192-196.	0.7	5
517	Prevalence of Overactive Bladder, its Under-Diagnosis, and Risk Factors in a Male Urologic Veterans Population. <i>International Journal of Medical Sciences</i> , 2010, 7, 391-394.	2.5	23
518	Quality of Life of Women with Urinary Incontinence: A Systematic Literature Review. <i>International Neurourology Journal</i> , 2010, 14, 133.	1.2	81
519	Effects of Oxybutynin Chloride Topical Gel on Health-Related Quality of Life in Adults with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled Study. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S5742.	0.4	1
520	Transdermal Oxybutynin: What Role in the Management of Overactive Bladder?. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S2608.	0.4	0
521	Social, economic, and health utility considerations in the treatment of overactive bladder. <i>Research and Reports in Urology</i> , 2010, Volume 2, 11-24.	1.0	25

#	ARTICLE	IF	CITATIONS
522	Oxybutynin topical gel in the treatment of overactive bladder. Research and Reports in Urology, 2010, Volume 2, 91-98.	1.0	1
523	Comparison of intravaginal electrical stimulation and tiroprium hydrochloride in women with overactive bladder syndrome: a randomized controlled study. Clinical Rehabilitation, 2010, 24, 342-351.	2.2	36
524	Treatment of Urinary Voiding Dysfunction Syndromes With Spinal Cord Stimulation. Clinical Medicine and Research, 2010, 8, 22-24.	0.8	9
525	Current Information on Sacral Neuromodulation and Botulinum Toxin Treatment for Refractory Idiopathic Overactive Bladder Syndrome: A Review. Urologia Internationalis, 2010, 84, 245-253.	1.3	40
526	Update on the management of overactive bladder: patient considerations and adherence. Open Access Journal of Urology, 2010, 3, 7.	0.3	6
527	Pharmacokinetics of Onceâ€¢Daily Tiroprium Chloride 60 mg Extended Release and Twiceâ€¢Daily Tiroprium Chloride 20 mg in Healthy Adults. Journal of Clinical Pharmacology, 2010, 50, 143-150.	2.0	16
528	The overactive bladder. Therapeutic Advances in Urology, 2010, 2, 147-155.	2.0	13
529	Managing Patients With â€¢Wetâ€¢ Overactive Bladder: Results of Pooled Studies Show Efficacy of Darifenacin as Measured by â€¢Dry Daysâ€¢. UroToday International Journal, 2010, 03, .	0.1	1
530	Efficacy and Safety of Tamsulosin With and Without Flavoxate in the Treatment of Symptomatic Benign Prostastic Hypoplasia: A Randomized, Single-Blind Study. UroToday International Journal, 2010, 03, .	0.1	0
531	BK channel activation by NS11021 decreases excitability and contractility of urinary bladder smooth muscle. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2010, 298, R378-R384.	1.8	48
532	Efficacy of fesoterodine over 24 hours in subjects with overactive bladder. Current Medical Research and Opinion, 2010, 26, 813-818.	1.9	5
533	Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder. Journal of Medical Economics, 2010, 13, 508-515.	2.1	11
534	Under Treatment of Overactive Bladder. Journal of Urology, 2010, 183, 1282-1283.	0.4	4
535	Detrusor Overactivity Persisting at Night and Preceding Nocturia in Patients With Overactive Bladder Syndrome: A Nocturnal Cystometrogram and Polysomnogram Study. Journal of Urology, 2010, 184, 623-628.	0.4	23
536	Efficacy and Adverse Effects of Solifenacin in the Treatment of Lower Urinary Tract Symptoms in Patients With Overactive Bladder. Urological Science, 2010, 21, 38-43.	0.6	4
537	Overactive Bladder Medication Adherence When Medication is Free to Patients. Journal of Urology, 2010, 183, 1077-1081.	0.4	83
538	Long-Term Durability of Percutaneous Tibial Nerve Stimulation for the Treatment of Overactive Bladder. Journal of Urology, 2010, 183, 234-240.	0.4	206
539	A Multicenter, Double-Blind, Randomized, Placebo Controlled Trial of a Neurokinin-1 Receptor Antagonist for Overactive Bladder. Journal of Urology, 2010, 184, 616-622.	0.4	58

#	ARTICLE	IF	CITATIONS
540	Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. <i>Current Medical Research and Opinion</i> , 2010, 26, 2277-2285.	1.9	14
541	Idiopathic Urgency Urinary Incontinence. <i>New England Journal of Medicine</i> , 2010, 363, 1156-1162.	27.0	70
542	Management of overactive bladder. <i>Nature Reviews Urology</i> , 2010, 7, 572-582.	3.8	44
543	Demographic distribution and prevalence of overactive bladder in Venezuela. <i>Actas Urológicas Españolas (English Edition)</i> , 2010, 34, 176-180.	0.2	6
544	Analysis of overactive bladder and urinary incontinence in males in the age range between 50 and 65 years. EPICC study. <i>Actas Urológicas Españolas (English Edition)</i> , 2010, 34, 543-548.	0.2	1
545	Analysis of overactive bladder and urinary incontinence in working women aged between 25 and 64 years. EPICC study. <i>Actas Urológicas Españolas (English Edition)</i> , 2010, 34, 618-624.	0.2	7
546	A noninvasive evaluation of autonomic nervous system dysfunction in women with an overactive bladder. <i>International Journal of Gynecology and Obstetrics</i> , 2010, 110, 12-17.	2.3	23
547	Overactive bladder. <i>Maturitas</i> , 2010, 66, 257-262.	2.4	23
548	Fesoterodine for overactive bladder: A review of the literature. <i>Current Therapeutic Research</i> , 2010, 71, 273-288.	1.2	7
549	The medical management of urinary incontinence. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2010, 152, 4-10.	2.8	25
550	Muscarinic acetylcholine receptor subtypes expressed by mouse bladder afferent neurons. <i>Neuroscience</i> , 2010, 168, 842-850.	2.3	41
551	Peripheral Blood Mononuclear Cell Gene Array Profiles in Patients With Overactive Bladder. <i>Urology</i> , 2010, 75, 896-901.	1.0	14
552	Economic Costs of Overactive Bladder in the United States. <i>Urology</i> , 2010, 75, 526-532.e18.	1.0	211
553	Impact on Quality of Life of Urinary Incontinence and Overactive Bladder: A Systematic Literature Review. <i>Urology</i> , 2010, 75, 491-500.	1.0	182
554	Efficacy and Tolerability of Fesoterodine in Men With Overactive Bladder: A Pooled Analysis of 2 Phase III Studies. <i>Urology</i> , 2010, 75, 1149-1155.	1.0	45
555	Randomized, Double-blind, Placebo-controlled Trial of Flexible-dose Fesoterodine in Subjects With Overactive Bladder. <i>Urology</i> , 2010, 75, 62-68.	1.0	86
556	Effect of the Amount of Hours Spent Studying on the Prevalence of Overactive Bladder in College Women. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2010, 2, 113-118.	1.3	1
557	Review of Neurologic Diseases for the Urologist. <i>Urologic Clinics of North America</i> , 2010, 37, 517-526.	1.8	30

#	ARTICLE	IF	CITATIONS
558	Solifenacin and Tolterodine are Equally Effective in the Treatment of Overactive Bladder Symptoms. Journal of the Formosan Medical Association, 2010, 109, 702-708.	1.7	23
559	Development, Validation and Testing of an Epidemiological Case Definition of Interstitial Cystitis/Painful Bladder Syndrome. Journal of Urology, 2010, 183, 1848-1852.	0.4	90
560	Vulnerable Elderly Patients and Overactive Bladder Syndrome. Drugs and Aging, 2010, 27, 697-713.	2.7	34
561	Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms. Current Medical Research and Opinion, 2011, 27, 921-930.	1.9	19
562	Tolerability of solifenacin and oxybutynin immediate release in older (>65 years) and younger (≤65) Tj ETQq0 0 0 rgBT /Overlock 10 Current Medical Research and Opinion, 2011, 27, 375-382.	1.9	33
563	Establishing the Content Validity of the King's Health Questionnaire in Men and Women with Overactive Bladder in the US. Patient, 2011, 4, 177-187.	2.7	20
564	Clinical symptoms and videourodynamic findings of detrusor overactivity in women. Urological Science, 2011, 22, 116-119.	0.6	4
565	Pharmacotherapy of overactive bladder: epidemiology and pathophysiology of overactive bladder. Expert Opinion on Pharmacotherapy, 2011, 12, 1017-1027.	1.8	15
566	The Association of Adiposity and Overactive Bladder Appears to Differ by Gender: Results From the Boston Area Community Health Survey. Journal of Urology, 2011, 185, 955-963.	0.4	60
567	Assessment of reasons for overactive bladder treatment change. Actas Urológicas Españolas (English) Tj ETQq1 1 0.784314 rgBT /Ov 0.2	0.2	14
568	Psychometric Evaluation of Brief Patient-reported Outcome Measures of Overactive Bladder: The ICIQ-SF, SAC, SATS, SATT, and TBS. Health Outcomes Research in Medicine, 2011, 2, e61-e69.	0.6	1
569	Adverse Event Assessment of Antimuscarinics for Treating Overactive Bladder: A Network Meta-Analytic Approach. PLoS ONE, 2011, 6, e16718.	2.5	119
570	Pharmacokinetics of Oxybutynin Chloride Topical Gel. Clinical Drug Investigation, 2011, 31, 559-571.	2.2	18
571	Functional electrical stimulation as a neuroprosthetic methodology for enabling closed-loop urinary incontinence treatment. , 2011, , .		8
572	Les traitements oraux. , 2011, , 257-268.		0
574	Quality of life and urinary incontinence in women. Maturitas, 2011, 68, 137-142.	2.4	62
575	Urodynamic Profile of Diabetic Patients With Lower Urinary Tract Symptoms: Association of Diabetic Cystopathy With Autonomic and Peripheral Neuropathy. Urology, 2011, 77, 699-705.	1.0	70
576	Change in International Prostate Symptom Storage Subscore After Long-term Medical Therapy in BPH Patients: Finasteride and Alpha-blocker Combination Therapy in Men With Moderate-to-severe LUTS/BPH in Korea. Urology, 2011, 77, 171-176.	1.0	9

#	ARTICLE	IF	CITATIONS
577	Safety and Efficacy of Once-Daily Trosipium Chloride Extended-release in Male Patients With Overactive Bladder. <i>Urology</i> , 2011, 77, 24-29.	1.0	11
578	National Community Prevalence of Overactive Bladder in the United States Stratified by Sex and Age. <i>Urology</i> , 2011, 77, 1081-1087.	1.0	289
579	Alterations in Expression of HIF-1 α , HIF-2 α , and VEGF by Idiopathic Overactive Bladder Urothelial Cells During Stretch Suggest Role for Hypoxia. <i>Urology</i> , 2011, 77, 1266.e7-1266.e11.	1.0	13
580	Prevalence of Overactive Bladder and Associated Risk Factors in 1359 Patients With Type 2 Diabetes. <i>Urology</i> , 2011, 78, 1040-1045.	1.0	93
581	Survey of Overactive Bladder Symptoms Influencing Bother Before and After Treatment With Tamsulosin Hydrochloride in Japanese Patients With Benign Prostatic Hyperplasia. <i>Urology</i> , 2011, 78, 1058-1062.	1.0	12
582	The Effects of Acute and Chronic Psychological Stress on Bladder Function in a Rodent Model. <i>Urology</i> , 2011, 78, 967.e1-967.e7.	1.0	92
583	Promise of Urinary Nerve Growth Factor for Assessment of Overactive Bladder Syndrome. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2011, 3, 2-9.	1.3	9
584	Efficacy, Safety and Tolerability of Fesoterodine in Asian Patients with Overactive Bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2011, 3, 43-50.	1.3	23
585	Urinary Incontinence in Women. <i>Medical Clinics of North America</i> , 2011, 95, 101-109.	2.5	32
586	Efficacy of Solifenacin on Nocturia in Japanese Patients With Overactive Bladder: Impact on Sleep Evaluated by Bladder Diary. <i>Journal of Urology</i> , 2011, 186, 170-174.	0.4	45
587	Reevaluating the Health-Related Quality of Life Impact and the Economic Burden of Urgency Urinary Incontinence. <i>European Urology Supplements</i> , 2011, 10, 3-7.	0.1	0
588	Fesoterodine: Individualised Treatment of Urgency Urinary Incontinence Across Patient Groups. <i>European Urology Supplements</i> , 2011, 10, 14-22.	0.1	6
589	OAB Update: Focus on Trosipium. <i>Clinical Medicine Insights Urology</i> , 2011, 5, CMU.S5068.	0.4	0
590	Overactive bladder syndrome in the ageing population. <i>Urogynaecologia International Journal</i> , 2011, 25, 12.	0.2	0
591	Characterization of overactive bladder in women in a primary care setting. <i>Research and Reports in Urology</i> , 0, Volume 3, 29-34.	1.0	0
592	Development of oxybutynin chloride topical gel for overactive bladder. <i>Research and Reports in Urology</i> , 0, Volume 3, 35-42.	1.0	1
593	Prevalence of urinary incontinence and other lower tract urinary symptoms in patients with uterine myomas. <i>Urogynaecologia International Journal</i> , 2011, 25, 18.	0.2	0
594	Overactive Bladder: Pathophysiology, Diagnostics, and Therapies. <i>Advances in Urology</i> , 2011, 2011, 1-1.	1.3	5

#	ARTICLE	IF	CITATIONS
595	Urinary incontinence in the aging female: etiology, pathophysiology and treatment options. Aging Health, 2011, 7, 79-88.	0.3	6
596	Overactive Bladder and Hyperlipidemia. Female Pelvic Medicine and Reconstructive Surgery, 2011, 17, 76-79.	1.1	3
597	Posterior Tibial Nerve Stimulation in Patients Who Have Failed Anticholinergic Therapy. Female Pelvic Medicine and Reconstructive Surgery, 2011, 17, 74-75.	1.1	7
598	Update on the treatment of overactive bladder. Current Opinion in Urology, 2011, 21, 286-290.	1.8	22
599	Tricyclic Antidepressants. Psychopharm Review: Timely Reports in Psychopharmacology and Device-based Therapies, 2011, 46, 17-23.	0.1	0
600	Tricyclic Antidepressants. Psychopharm Review: Timely Reports in Psychopharmacology and Device-based Therapies, 2011, 46, 24-25.	0.1	0
601	Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. Menopause, 2011, 18, 962-966.	2.0	66
602	Efficacy of Solifenacin on Overactive Bladder Symptoms, Symptom Bother, and Other Patient-Reported Outcomes in Subjects With or Without Incontinence. Female Pelvic Medicine and Reconstructive Surgery, 2011, 17, 24-29.	1.1	2
603	Patient Preferences for Different Severities of and Treatments for Overactive Bladder. Female Pelvic Medicine and Reconstructive Surgery, 2011, 17, 184-189.	1.1	31
604	The prevalence of chronic constipation and faecal incontinence among men and women with symptoms of overactive bladder. BJU International, 2011, 107, 254-261.	2.5	89
605	Patient-Optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study. BJU International, 2011, 107, 603-611.	2.5	19
606	Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder. BJU International, 2011, 108, 558-564.	2.5	65
607	Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU International, 2011, 108, 1132-1138.	2.5	790
608	The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS. BJU International, 2011, 108, 1459-1471.	2.5	210
609	Risk factors for overactive bladder in the elderly population: A community-based study with face-to-face interview. International Journal of Urology, 2011, 18, 212-218.	1.0	37
610	Impact of robot-assisted radical prostatectomy on health-related quality of life in patients with lower urinary tract symptoms. International Journal of Urology, 2011, 18, 297-303.	1.0	5
611	Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. Journal of Obstetrics and Gynaecology Research, 2011, 37, 1084-1091.	1.3	31
612	Systematic Review and Meta-Analysis: Do Clinical Trials Testing Antimuscarinic Agents for Overactive Bladder Adequately Measure Central Nervous System Adverse Events?. Journal of the American Geriatrics Society, 2011, 59, 1332-1339.	2.6	53

#	ARTICLE	IF	CITATIONS
613	Prevalence and Effect on Health-Related Quality of Life of Overactive Bladder in Older Americans: Results from the Epidemiology of Lower Urinary Tract Symptoms Study. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 1465-1470.	2.6	131
614	Behavioral Versus Drug Treatment for Overactive Bladder in Men: The Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 2209-2216.	2.6	86
615	Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. <i>International Journal of Clinical Practice</i> , 2011, 65, 211-218.	1.7	7
616	Validation of a 3-item OAB awareness tool. <i>International Journal of Clinical Practice</i> , 2011, 65, 219-224.	1.7	30
617	Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. <i>International Journal of Clinical Practice</i> , 2011, 65, 487-507.	1.7	80
618	Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. <i>International Journal of Clinical Practice</i> , 2011, 65, 567-585.	1.7	228
619	Symptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: a randomised, multicentre trial. <i>International Journal of Clinical Practice</i> , 2011, 65, 997-1004.	1.7	34
620	Large conductance Ca ²⁺ -activated K ⁺ channel activation with NS1619 decreases myogenic and neurogenic contractions of rat detrusor smooth muscle. <i>European Journal of Pharmacology</i> , 2011, 670, 252-259.	3.5	36
621	The Prevalence of Clinically Meaningful Overactive Bladder: Bother and Quality of Life Results from the Population-Based FINNO Study. <i>European Urology</i> , 2011, 59, 629-636.	1.9	88
622	Genetic Influences Are Important for Most But Not All Lower Urinary Tract Symptoms: A Population-Based Survey in a Cohort of Adult Swedish Twins. <i>European Urology</i> , 2011, 59, 1032-1038.	1.9	53
624	Overactive Bladder Drugs and Constipation: A Meta-Analysis of Randomized, Placebo-Controlled Trials. <i>Digestive Diseases and Sciences</i> , 2011, 56, 7-18.	2.3	58
625	A classification study of human \hat{I}^2 3-adrenergic receptor agonists using BCUT descriptors. <i>Molecular Diversity</i> , 2011, 15, 877-887.	3.9	9
626	Anticholinergic therapy: do the patients take the pills prescribed?. <i>Archives of Gynecology and Obstetrics</i> , 2011, 284, 663-666.	1.7	21
627	Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: results of Korean EPIC study. <i>World Journal of Urology</i> , 2011, 29, 185-190.	2.2	152
628	Prevalence of painful bladder syndrome/interstitial cystitis-like symptoms in women: a population-based study in Korea. <i>World Journal of Urology</i> , 2011, 29, 103-108.	2.2	27
631	Is a dipstick test sufficient to exclude urinary tract infection in women with overactive bladder?. <i>International Urogynecology Journal</i> , 2011, 22, 229-232.	1.4	28
632	Women's perspective of botulinum toxin treatment for overactive bladder symptoms. <i>International Urogynecology Journal</i> , 2011, 22, 425-431.	1.4	8
633	The psychometric validation of a 1-week recall period for the OAB-q. <i>International Urogynecology Journal</i> , 2011, 22, 1555-1563.	1.4	22

#	ARTICLE	IF	CITATIONS
634	Time-to-effect with darifenacin in overactive bladder: a pooled analysis. International Urogynecology Journal, 2011, 22, 1573-1580.	1.4	6
635	Future Directions in Overactive Bladder Treatment. Current Bladder Dysfunction Reports, 2011, 6, 45-50.	0.5	2
636	Clinical Differences Between Solifenacin and Tolterodine. Current Bladder Dysfunction Reports, 2011, 6, 1-6.	0.5	0
637	Conservative Management and Behavioral Modifications for Overactive Bladder. Current Bladder Dysfunction Reports, 2011, 6, 13-19.	0.5	0
638	Topical Pharmacotherapy for Overactive Bladder. Current Bladder Dysfunction Reports, 2011, 6, 20-24.	0.5	1
639	Update on Neuromodulation. Current Bladder Dysfunction Reports, 2011, 6, 135-141.	0.5	0
640	Antimuscarinic Drugs: Review of the Cognitive Impact When Used to Treat Overactive Bladder in Elderly Patients. Current Urology Reports, 2011, 12, 351-357.	2.2	74
641	Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: A decision-tree model. BMC Urology, 2011, 11, 9.	1.4	28
642	Mixed incontinence: Comparing definitions in non-surgical patients. Neurourology and Urodynamics, 2011, 30, 47-51.	1.5	27
643	The role of urgency, frequency, and nocturia in defining overactive bladder adaptive behavior. Neurourology and Urodynamics, 2011, 30, 406-411.	1.5	9
644	Which single-item measures of overactive bladder symptom treatment correlate best with patient satisfaction?. Neurourology and Urodynamics, 2011, 30, 510-514.	1.5	11
645	Elevation of serum C-reactive protein in patients with OAB and IC/BPS implies chronic inflammation in the urinary bladder. Neurourology and Urodynamics, 2011, 30, 417-420.	1.5	85
646	Once-daily trospium chloride 60-mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms. Neurourology and Urodynamics, 2011, 30, 1214-1219.	1.5	18
647	Epidemiology and healthcare utilization of neurogenic bladder patients in a us claims database. Neurourology and Urodynamics, 2011, 30, 395-401.	1.5	208
648	Women's experience with severe overactive bladder symptoms and treatment: Insight revealed from patient focus groups. Neurourology and Urodynamics, 2011, 30, 1295-1299.	1.5	54
649	Validation of the urinary sensation scale (USS). Neurourology and Urodynamics, 2011, 30, 360-365.	1.5	39
650	Once-daily administration of trospium chloride extended release provides 24-hr coverage of nocturnal and diurnal symptoms of overactive bladder: An integrated analysis of two phase III trials. Neurourology and Urodynamics, 2011, 30, 563-567.	1.5	9
651	Falls risk reduction and treatment of overactive bladder symptoms with antimuscarinic agents: A scoping review. Neurourology and Urodynamics, 2011, 30, 490-494.	1.5	13

#	ARTICLE	IF	CITATIONS
652	Urgency severity scale could predict urodynamic detrusor overactivity in patients with overactive bladder syndrome. <i>Neurourology and Urodynamics</i> , 2011, 30, 1300-1304.	1.5	39
653	Prevalence, risk factors, and impact on health related quality of life of overactive bladder in China. <i>Neurourology and Urodynamics</i> , 2011, 30, 1448-1455.	1.5	91
654	The natural history of the overactive bladder syndrome in females: A long-term analysis of a health screening project. <i>Neurourology and Urodynamics</i> , 2011, 30, 1437-1441.	1.5	25
655	Evaluation of drug efflux transporter liabilities of darifenacin in cell culture models of the blood-brain and blood-ocular barriers. <i>Neurourology and Urodynamics</i> , 2011, 30, 1633-1638.	1.5	15
656	Botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: Lack of anticholinergic efficacy versus intolerability. <i>Neurourology and Urodynamics</i> , 2011, 30, 1538-1540.	1.5	33
657	Efficacy and Tolerability of Solifenacin in Patients Aged ≥ 65 Years with Overactive Bladder: Post-Hoc Analysis of 2 Open-Label Studies. <i>Postgraduate Medicine</i> , 2011, 123, 94-104.	2.0	12
658	The pharmacotherapy of overactive bladder. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1003-1005.	1.8	11
659	Characterization of overactive bladder in women in a primary care setting. <i>Open Access Journal of Urology</i> , 2011, 3, 29.	0.3	5
660	Development of oxybutynin chloride topical gel for overactive bladder. <i>Open Access Journal of Urology</i> , 2011, 3, 35.	0.3	2
661	Effect of baseline symptom severity on continence improvement mediated by oxybutynin chloride topical gel. <i>Open Access Journal of Urology</i> , 2011, 3, 145.	0.3	3
662	Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST) <i>Tj ETQq0 0 0 rgBTL3 Overlook 110 Tf 50</i>	0.3	0
663	Role of KIT-Positive Interstitial Cells of Cajal in the Urinary Bladder and Possible Therapeutic Target for Overactive Bladder. <i>Advances in Urology</i> , 2011, 2011, 1-7.	1.3	29
664	Peripheral blood mononuclear cell gene array profiles in female patients with involuntary bladder contractions. <i>Advances in Genomics and Genetics</i> , 2011, , 3.	0.8	0
665	Initial combined treatment with anticholinergics and α_1 -blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. <i>Prostate Cancer and Prostatic Diseases</i> , 2011, 14, 320-325.	3.9	41
666	Patient experience with darifenacin - results of a short-term community-based survey in managing overactive bladder. <i>Current Medical Research and Opinion</i> , 2011, 27, 431-437.	1.9	2
667	Les incontinences urinaires de l'homme. , 2011, , .		0
669	Urinary Incontinence, Overactive Bladder, and Enuresis in the Spanish Population: An Epidemiologic, Multicenter, and National Study. <i>UroToday International Journal</i> , 2011, 04, .	0.1	0
670	Intradetrusor botulinum toxin type A in refractory overactive bladder: A potential future treatment. <i>International Journal of Applied & Basic Medical Research</i> , 2011, 1, 67.	0.5	1

#	ARTICLE	IF	CITATIONS
671	Suppression of human detrusor smooth muscle excitability and contractility via pharmacological activation of large conductance Ca^{2+} -activated K^{+} channels. American Journal of Physiology - Cell Physiology, 2012, 302, C1632-C1641.	4.6	47
672	Nonselective Blocking of the Sympathetic Nervous System Decreases Detrusor Overactivity in Spontaneously Hypertensive Rats. International Journal of Molecular Sciences, 2012, 13, 5048-5059.	4.1	4
673	Sacral neuromodulation and refractory overactive bladder: an emerging tool for an old problem. Therapeutic Advances in Urology, 2012, 4, 179-185.	2.0	18
674	Inhibition of bladder overactivity by a combination of tibial neuromodulation and tramadol treatment in cats. American Journal of Physiology - Renal Physiology, 2012, 302, F1576-F1582.	2.7	19
676	Prevalence and Risk Factors Associated with Overactive Bladder. UroToday International Journal, 2012, 05, .	0.1	2
678	Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder. Current Opinion in Obstetrics and Gynecology, 2012, 24, 331-336.	2.0	9
680	Medical Treatment of Overactive Bladder: An Overview. Current Clinical Pharmacology, 2012, 7, 229-239.	0.6	7
681	The management of overactive bladder syndrome. BMJ, The, 2012, 344, e2365-e2365.	6.0	49
682	Contemporary Management of Overactive Bladder. Postgraduate Medicine, 2012, 124, 104-116.	2.0	2
683	Treatment of Overactive Bladder Symptoms beyond Antimuscarinics: Current and Future Therapies. Postgraduate Medicine, 2012, 124, 16-27.	2.0	8
685	The Effect of Robot-Assisted Laparoscopic Prostatectomy on Nocturia. Journal of Endourology, 2012, 26, 861-865.	2.1	6
686	Oxybutynin gel for the treatment of overactive bladder. Expert Opinion on Pharmacotherapy, 2012, 13, 1337-1343.	1.8	4
687	A comparison study of two lower urinary tract symptoms screening tools in clinical practice: The B-SAQ and OAB-V8 questionnaires. Journal of Obstetrics and Gynaecology, 2012, 32, 666-671.	0.9	18
688	Beliefs About Medications as a Predictor of Treatment Adherence in Women with Urinary Incontinence. Journal of Women's Health, 2012, 21, 440-446.	3.3	15
689	Management of refractory overactive bladder. Expert Review of Obstetrics and Gynecology, 2012, 7, 605-613.	0.4	2
690	SK but not IK channels regulate human detrusor smooth muscle spontaneous and nerve-evoked contractions. American Journal of Physiology - Renal Physiology, 2012, 303, F559-F568.	2.7	37
691	Vascular incontinence: incontinence in the elderly due to ischemic white matter changes. Neurology International, 2012, 4, 13.	2.8	50
692	Clinical utility of transdermal delivery of oxybutynin gel via a metered-dose pump in the management of overactive bladder. Research and Reports in Urology, 2012, 4, 57.	1.0	3

#	ARTICLE	IF	CITATIONS
693	Treatments for Overactive Bladder: Focus on Pharmacotherapy. Journal of Obstetrics and Gynaecology Canada, 2012, 34, 1092-1101.	0.7	31
695	Neuroprotection of green tea catechins on surgical menopause-induced overactive bladder in a rat model. Menopause, 2012, 19, 346-354.	2.0	19
696	Near-infrared spectroscopy of the detrusor during urodynamics with simultaneous ultrasound measurements of bladder dimensions and position. Biomedical Spectroscopy and Imaging, 2012, 1, 137-145.	1.2	9
697	The Evolution of Wireless near Infrared Spectroscopy Applications in Urology and Rationale for Clinical Use. Journal of Near Infrared Spectroscopy, 2012, 20, 57-73.	1.5	15
698	Clinical trials and overactive bladder: lessons learned. Clinical Investigation, 2012, 2, 689-705.	0.0	0
699	Muscarinic Agonists and Antagonists: Effects on the Urinary Bladder. Handbook of Experimental Pharmacology, 2012, , 375-400.	1.8	37
700	Anticholinergics for Overactive Bladder Therapy: Central Nervous System Effects. CNS Neuroscience and Therapeutics, 2012, 18, 167-174.	3.9	95
701	The Association between Severity of Atherosclerosis and Lower Urinary Tract Function in Male Patients with Lower Urinary Tract Symptoms. LUTS: Lower Urinary Tract Symptoms, 2012, 4, 9-13.	1.3	24
702	Quality of Life in Patients with Overactive Bladder. Clinical Drug Investigation, 2012, 32, 523-532.	2.2	22
703	Effect of Anticholinergic Use for the Treatment of Overactive Bladder on Cognitive Function in Postmenopausal Women. Clinical Drug Investigation, 2012, 32, 697-705.	2.2	23
704	Fesoterodine in randomised clinical trials: an updated systematic clinical review of efficacy and safety. International Urogynecology Journal, 2012, 23, 1337-1344.	1.4	5
705	The efficacy of posterior tibial nerve stimulation for the treatment of overactive bladder in women: a systematic review. International Urogynecology Journal, 2012, 23, 1591-1597.	1.4	34
706	Associations between subjective overactive bladder symptoms and objective parameters on bladder diary and filling cystometry. International Urogynecology Journal, 2012, 23, 1619-1624.	1.4	15
707	The prevalence of detrusor overactivity amongst patients with symptoms of overactive bladder: a retrospective cohort study. International Urogynecology Journal, 2012, 23, 1577-1580.	1.4	13
708	A Multicenter, Double-blind, Randomized, Placebo-controlled Trial of the β ³ -Adrenoceptor Agonist Solabegron for Overactive Bladder. European Urology, 2012, 62, 834-840.	1.9	96
709	Efficacy and Adverse Events of Antimuscarinics for Treating Overactive Bladder: Network Meta-analyses. European Urology, 2012, 62, 1040-1060.	1.9	143
710	An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15â€‰mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: results of the STOP study. Current Medical Research and Opinion, 2012, 28, 1369-1379.	1.9	11
711	Metabolic Syndrome in Female Patients With Overactive Bladder. Urology, 2012, 79, 72-75.	1.0	68

#	ARTICLE	IF	CITATIONS
712	Racial Differences in the Prevalence of Overactive Bladder in the United States From the Epidemiology of LUTS (EpiLUTS) Study. <i>Urology</i> , 2012, 79, 95-101.	1.0	78
713	Phase IIb, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Determine Effects of Elocalcitol in Women With Overactive Bladder and Idiopathic Detrusor Overactivity. <i>Urology</i> , 2012, 80, 48-54.	1.0	43
714	Effect of Bothersome Overactive Bladder Symptoms on Health-related Quality of Life, Anxiety, Depression, and Treatment Seeking in the United States: Results From EpiLUTS. <i>Urology</i> , 2012, 80, 90-96.	1.0	217
715	Risk Factors for New-onset Overactive Bladder in Older Subjects: Results of the Fujiwara-Kyo Study. <i>Urology</i> , 2012, 80, 71-76.	1.0	39
716	Anticholinergic Therapy vs. OnabotulinumtoxinA for Urgency Urinary Incontinence. <i>New England Journal of Medicine</i> , 2012, 367, 1803-1813.	27.0	199
717	Effective and clinically meaningful non-hormonal hot flash therapies. <i>Maturitas</i> , 2012, 72, 6-12.	2.4	29
718	Anticholinergic versus botulinum toxin A comparison trial for the treatment of bothersome urge urinary incontinence: ABC trial. <i>Contemporary Clinical Trials</i> , 2012, 33, 184-196.	1.8	30
719	Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study. <i>BMC Urology</i> , 2012, 12, 19.	1.4	17
720	Content validity and test-retest reliability of patient perception of intensity of urgency scale (PPIUS) for overactive bladder. <i>BMC Urology</i> , 2012, 12, 26.	1.4	38
721	Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder. <i>Journal of Medical Economics</i> , 2012, 15, 35-44.	2.1	19
722	Comparative persistence and adherence to overactive bladder medications in patients with and without diabetes. <i>International Journal of Clinical Practice</i> , 2012, 66, 1042-1051.	1.7	17
725	Descriptive epidemiological study of the diagnosis of detrusor overactivity in urodynamic units in Spain. <i>Actas Urológicas Españolas (English Edition)</i> , 2012, 36, 21-28.	0.2	0
726	Pharmacokinetic Properties of Mirabegron, a β_3 -Adrenoceptor Agonist: Results From Two Phase I, Randomized, Multiple-Dose Studies in Healthy Young and Elderly Men and Women. <i>Clinical Therapeutics</i> , 2012, 34, 2144-2160.	2.5	83
727	Antimuscarinic therapy “what is new?”. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2012, 9, e21-e25.	0.5	1
728	The prevalence of probable overactive bladder, associated risk factors and its effect on quality of life among Turkish midwifery students. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2012, 164, 105-109.	1.1	15
729	Do lower urinary tract symptoms (LUTS) predispose the individuals to more admissions in Taiwanese women? “A preliminary report. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2012, 51, 402-404.	1.3	3
730	Population Based Study of Long-Term Rates of Surgery for Urinary Incontinence After Radical Prostatectomy for Prostate Cancer. <i>Journal of Urology</i> , 2012, 188, 502-506.	0.4	86
731	How Dry is “œOAB-Dry”? Perspectives from Patients and Physician Experts. <i>Journal of Urology</i> , 2012, 188, 1811-1815.	0.4	15

#	ARTICLE	IF	CITATIONS
732	Antimuscarinic Treatment in Overactive Bladder. <i>Drugs and Aging</i> , 2012, 29, 539-548.	2.7	30
733	Bloodâ€“Brain Barrier Permeation and Efflux Exclusion of Anticholinergics Used in the Treatment of Overactive Bladder. <i>Drugs and Aging</i> , 2012, 29, 259-273.	2.7	88
734	Long-Term Safety, Tolerability and Efficacy of Fesoterodine in Subjects with Overactive Bladder Symptoms Stratified by Age. <i>Drugs and Aging</i> , 2012, 29, 119-131.	2.7	33
735	Interstitial Cystitis and the Overlap With Overactive Bladder. <i>Current Urology Reports</i> , 2012, 13, 319-326.	2.2	27
736	Percutaneous Tibial Nerve Stimulation: A Clinically and Cost Effective Addition to the Overactive Bladder Algorithm of Care. <i>Current Urology Reports</i> , 2012, 13, 327-334.	2.2	71
737	Nocturia. , 2012, , .		9
738	Muscarinic Receptors. <i>Handbook of Experimental Pharmacology</i> , 2012, , .	1.8	12
739	Overactive Bladder in Clinical Practice. , 2012, , .		6
740	Diagnosis and Treatment of Overactive Bladder. , 0, , .		0
741	â€œVascular Incontinenceâ€•and Normal-Pressure Hydrocephalus: Two Commonsources of Elderly Incontinence with Brain Etiologies. <i>Current Drug Therapy</i> , 2012, 7, 67-76.	0.3	8
742	A comparative analisys of pelvic floor muscle strength in women with stress and urge urinary incontinence. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2012, 38, 661-666.	1.5	15
743	Survey on the Prevalence of Overactive Bladder in Healthy Korean Postmenopausal Women. <i>The Journal of Korean Society of Menopause</i> , 2012, 18, 60.	0.6	5
744	Clinical Efficacy in the Treatment of Overactive Bladder Refractory to Anticholinergics by Posterior Tibial Nerve Stimulation. <i>Korean Journal of Urology</i> , 2012, 53, 483.	1.2	10
745	Overactive bladder, differential diagnosis, and clinical utility of fesoterodine. <i>International Journal of General Medicine</i> , 2012, 5, 943.	1.8	3
746	Detrusor overactivity in diabetic and non-diabetic patients: is there a difference?. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2012, 38, 652-660.	1.5	10
747	Analysis of the Risk Factors for Overactive Bladder on the Basis of a Survey in the Community. <i>Korean Journal of Urology</i> , 2012, 53, 541.	1.2	18
748	Overactive bladder in men: initial assessment. <i>Trends in Urology & Men's Health</i> , 2012, 3, 7-12.	0.4	1
749	The effect of rectal distension on bladder function in patients with overactive bladder. <i>Neurourology and Urodynamics</i> , 2012, 31, 541-543.	1.5	11

#	ARTICLE	IF	CITATIONS
750	Predictors of care seeking in women with urinary incontinence. <i>Neurourology and Urodynamics</i> , 2012, 31, 470-474.	1.5	32
751	Detrusor overactivity leak point pressure in women with urgency incontinence. <i>International Urogynecology Journal</i> , 2012, 23, 443-446.	1.4	5
752	Pelvic floor muscle training for urgency urinary incontinence in women: a systematic review. <i>International Urogynecology Journal</i> , 2012, 23, 687-697.	1.4	29
753	Pathophysiology of overactive bladder. <i>International Urogynecology Journal</i> , 2012, 23, 975-982.	1.4	78
754	A systematic review of clinical studies of electrical stimulation for treatment of lower urinary tract dysfunction. <i>International Urogynecology Journal</i> , 2012, 23, 993-1005.	1.4	43
755	Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment. <i>World Journal of Urology</i> , 2012, 30, 367-373.	2.2	10
756	Urinary urgency: a review of its assessment as the key symptom of the overactive bladder syndrome. <i>World Journal of Urology</i> , 2012, 30, 385-392.	2.2	50
758	The assessment of quality of life in female Turkish patients with overactive bladder. <i>International Journal of Nursing Practice</i> , 2012, 18, 20-27.	1.7	5
759	Prescription pattern of oxybutynin ER in patients with overactive bladder in real life practice: a multicentre, open-label, prospective observational study. <i>International Journal of Clinical Practice</i> , 2012, 66, 132-138.	1.7	7
760	Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 206, 168.e1-168.e6.	1.3	19
761	OnabotulinumtoxinA Improves Health-Related Quality of Life in Patients With Urinary Incontinence Due to Idiopathic Overactive Bladder: A 36-Week, Double-Blind, Placebo-Controlled, Randomized, Dose-Ranging Trial. <i>European Urology</i> , 2012, 62, 148-157.	1.9	70
762	Patient-reported goal achievement after antimuscarinic treatment in patients with overactive bladder symptoms. <i>International Journal of Clinical Practice</i> , 2012, 66, 663-670.	1.7	10
763	The Presence of Overactive Bladder Wet Increased the Risk and Severity of Erectile Dysfunction in Men with Type 2 Diabetes. <i>Journal of Sexual Medicine</i> , 2012, 9, 1913-1922.	0.6	23
764	Outcome Measurement of Overactive Bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2012, 4, 62-66.	1.3	0
765	Low-Dose Anticholinergic Combination Therapy in Male Benign Prostatic Hyperplasia Patients with Overactive Bladder Symptoms. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2012, 4, 102-109.	1.3	1
766	Tension-free vaginal tape procedure without preoperative urodynamic examination: Long-term outcome. <i>International Journal of Urology</i> , 2012, 19, 1003-1009.	1.0	11
767	Comparisons of pelvic floor muscle performance, anxiety, quality of life and life stress in women with dry overactive bladder compared with asymptomatic women. <i>BJU International</i> , 2012, 109, 1685-1689.	2.5	28
768	Association of overactive bladder and C-reactive protein levels. Results from the Boston Area Community Health (BACH) Survey. <i>BJU International</i> , 2012, 110, 401-407.	2.5	32

#	ARTICLE	IF	CITATIONS
769	Diagnosis and medical treatment of lower urinary tract symptoms in adult men: applying specialist guidelines in clinical practice. BJU International, 2012, 110, 710-718.	2.5	29
770	Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU International, 2012, 110, 1767-1774.	2.5	286
771	Overactive bladder in Taiwanese women: Re-analysis of epidemiological database of community from 1999 to 2001. Neurourology and Urodynamics, 2012, 31, 56-59.	1.5	23
772	Biomarkers in Overactive Bladder. Current Bladder Dysfunction Reports, 2012, 7, 33-39.	0.5	1
773	Is There a Role for Stem Cell Therapy for Overactive Bladder?. Current Bladder Dysfunction Reports, 2012, 7, 14-18.	0.5	0
774	Biofeedback Treatment for Overactive Bladder. Current Bladder Dysfunction Reports, 2012, 7, 7-13.	0.5	5
775	Interstitial Cystitis and the Overlap with Overactive Bladder. Current Bladder Dysfunction Reports, 2012, 7, 1-6.	0.5	1
776	Nocturia – disturbed sleep: a review. International Urogynecology Journal, 2012, 23, 255-267.	1.4	18
777	Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure?. International Urogynecology Journal, 2012, 23, 179-192.	1.4	17
778	Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study. Neurourology and Urodynamics, 2013, 32, 24-29.	1.5	69
779	The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: Results from OAB-POLL. Neurourology and Urodynamics, 2013, 32, 230-237.	1.5	191
780	Impact of cough and urinary incontinence on quality of life in women and men with chronic obstructive pulmonary disease. Journal of Clinical Nursing, 2013, 22, 97-105.	3.0	24
781	Influence of comorbidities in idiopathic normal pressure hydrocephalus – research and clinical care. A report of the ISHCSF task force on comorbidities in INPH. Fluids and Barriers of the CNS, 2013, 10, 22.	5.0	167
782	Urinary Incontinence: Diagnosis and Treatment in the Elderly. Current Translational Geriatrics and Experimental Gerontology Reports, 2013, 2, 66-75.	0.7	12
783	Assessment of female prevalence of overactive bladder (OAB) in Barcelona using a self-administered screening questionnaire: the Cuestionario de Autoevaluaci3n del Control de la Vejiga (CACV). International Urogynecology Journal, 2013, 24, 1559-1566.	1.4	16
784	Predicting self-perceived antimuscarinic therapy effectiveness on overactive bladder symptoms using the Overactive Bladder 8-Question Awareness Tool. International Urogynecology Journal, 2013, 24, 573-581.	1.4	7
785	Oxybutynin: past, present, and future. International Urogynecology Journal, 2013, 24, 595-604.	1.4	30
786	Comparison of diary-derived bladder and sleep measurements across OAB individuals, primary insomniacs, and healthy controls. International Urogynecology Journal, 2013, 24, 501-508.	1.4	6

#	ARTICLE	IF	CITATIONS
787	Drugs for the treatment of overactive bladder syndrome: present and future (A Review). Pharmaceutical Chemistry Journal, 2013, 46, 699-706.	0.8	2
788	Anticholinergic therapy for overactive bladder: A nicotinic modality?. Medical Hypotheses, 2013, 81, 456-458.	1.5	2
789	Understanding Clinic Options for Overactive Bladder. Current Urology Reports, 2013, 14, 541-548.	2.2	21
791	Mixed Incontinence: How Best to Manage It?. Current Bladder Dysfunction Reports, 2013, 8, 7-12.	0.5	9
792	Objective Evaluation of Overactive Bladder: Which Surveys Should I Use?. Current Bladder Dysfunction Reports, 2013, 8, 45-50.	0.5	18
793	Obesity and the Overactive Bladder. Current Bladder Dysfunction Reports, 2013, 8, 62-68.	0.5	6
794	A Population-based survey of lower urinary tract symptoms (LUTS) and symptom-specific bother: results from the Brazilian LUTS epidemiology study (BLUES). World Journal of Urology, 2013, 31, 1451-1458.	2.2	34
795	Effect of Concomitant Administration of Trosipium Chloride Extended Release on the Steady-State Pharmacokinetics of Metformin in Healthy Adults. Clinical Drug Investigation, 2013, 33, 123-131.	2.2	13
796	Neuromodulation for overactive bladder. Nature Reviews Urology, 2013, 10, 513-521.	3.8	64
797	Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder. BJU International, 2013, 112, 373-385.	2.5	34
798	Relationship between overactive bladder and irritable bowel syndrome: a large-scale internet survey in <sc>Japan using the overactive bladder symptom score and Rome <sc>III criteria. BJU International, 2013, 111, 647-652.	2.5	52
799	OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial. European Urology, 2013, 64, 249-256.	1.9	327
800	Healthcare-seeking Prevalence of Lower Urinary Tract Symptoms Among National Health Insurance Enrollees in Taiwan, 2000-2009. Urology, 2013, 81, 61-65.	1.0	20
801	Tratamiento farmacológico de los síntomas del tracto urinario inferior en el hombre: aplicación de las recomendaciones en la práctica clínica. Actas Urológicas Españolas, 2013, 37, 330-337.	0.7	6
802	Mapping EQ-5D Utility Scores from the Incontinence Quality of Life Questionnaire among Patients with Neurogenic and Idiopathic Overactive Bladder. Value in Health, 2013, 16, 394-402.	0.3	29
803	Short Pelvic Floor Electromyographic Lag Time: A Novel Noninvasive Approach to Document Detrusor Overactivity in Children with Lower Urinary Tract Symptoms. Journal of Urology, 2013, 189, 2282-2286.	0.4	30
804	Electrical and Mechanical Office-based Neuromodulation. Urologic Clinics of North America, 2013, 40, 581-589.	1.8	7
805	Re: The Prevalence of Clinically Meaningful Overactive Bladder: Bother and Quality of Life Results from the Population-Based FINNO Study. Journal of Urology, 2013, 189, 611-612.	0.4	0

#	ARTICLE	IF	CITATIONS
806	Correlation between age and overactive bladder symptoms in young women in Brazil. <i>Actas Urológicas Españolas (English Edition)</i> , 2013, 37, 156-161.	0.2	2
807	Pharmacological treatment of lower urinary tract symptoms in men: Implementation of recommendations in clinical practice. <i>Actas Urológicas Españolas (English Edition)</i> , 2013, 37, 330-337.	0.2	4
808	The Impact of OAB on Physical Activity in the United States: Results from OAB-POLL. <i>Urology</i> , 2013, 82, 799-806.	1.0	30
811	Study of the Population Pharmacokinetic Characteristics of Once-Daily Trosipium Chloride 60mg Extended-Release Capsules in Patients with Overactive Bladder and in Healthy Subjects. <i>Clinical Drug Investigation</i> , 2013, 33, 133-141.	2.2	6
812	Prospective study of prevalence of overactive bladder symptoms and childbearing in women of reproductive age. <i>Journal of Obstetrics and Gynaecology Research</i> , 2013, 39, 1324-1329.	1.3	6
813	Bladder health across the life course. <i>International Journal of Clinical Practice</i> , 2013, 67, 397-406.	1.7	18
814	Propiverine. <i>Clinical Drug Investigation</i> , 2013, 33, 71-91.	2.2	36
815	Clinical and urodynamic differences among women with overactive bladder according to the presence of detrusor overactivity. <i>International Urogynecology Journal</i> , 2013, 24, 255-261.	1.4	21
816	Changes in urinary nerve growth factor and prostaglandin E2 in women with overactive bladder after anticholinergics. <i>International Urogynecology Journal</i> , 2013, 24, 325-330.	1.4	31
817	Treatment of overactive bladder: what is on the horizon?. <i>International Urogynecology Journal</i> , 2013, 24, 5-13.	1.4	21
818	Development and validation of the Chinese Overactive Bladder Symptom Score for assessing overactive bladder syndrome in a RESORT study. <i>Journal of the Formosan Medical Association</i> , 2013, 112, 276-282.	1.7	27
819	Improving Patient Knowledge about Sacral Nerve Stimulation Using a Patient Based Educational Video. <i>Journal of Urology</i> , 2013, 190, 1300-1305.	0.4	9
820	Randomised, Multicentre, Placebo-controlled, Double-blind Crossover Study Investigating the Effect of Solifenacin and Oxybutynin in Elderly People with Mild Cognitive Impairment: The SENIOR Study. <i>European Urology</i> , 2013, 64, 74-81.	1.9	113
821	Osteopathic manipulative treatment (OMT) for lower urinary tract symptoms (LUTS) in women. <i>Journal of Bodywork and Movement Therapies</i> , 2013, 17, 11-18.	1.2	29
822	OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial. <i>Journal of Urology</i> , 2013, 189, 2186-2193.	0.4	347
823	Percutaneous Tibial Nerve Stimulation for the Long-Term Treatment of Overactive Bladder: 3-Year Results of the STEP Study. <i>Journal of Urology</i> , 2013, 189, 2194-2201.	0.4	173
824	Dimensions of Sensation Assessed in Urinary Urgency: A Systematic Review. <i>Journal of Urology</i> , 2013, 190, 1165-1172.	0.4	10
825	A level set based algorithm to reconstruct the urinary bladder from multiple views. <i>Medical Engineering and Physics</i> , 2013, 35, 1819-1824.	1.7	8

#	ARTICLE	IF	CITATIONS
826	Reduction in the volume of water for ingesting orally disintegrating tablets of solifenacin (Vesicare®) Tj ETQq0 0 0 rgBT /Overlock 10 T Journal of Pharmaceutics, 2013, 446, 1-5.	5.2	8
827	Bladder contractility is modulated by Kv7 channels in pig detrusor. European Journal of Pharmacology, 2013, 715, 312-320.	3.5	25
829	Role of Opioid and Metabotropic Glutamate 5 Receptors in Pudendal Inhibition of Bladder Overactivity in Cats. Journal of Urology, 2013, 189, 1574-1579.	0.4	43
830	The importance of cystoscopy and bladder biopsy in women with refractory overactive bladder: the urogynaecologist's point of view?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2013, 169, 408-411.	1.1	6
831	Clinical and urodynamic effects of tolterodine in women with an overactive bladder. Taiwanese Journal of Obstetrics and Gynecology, 2013, 52, 381-384.	1.3	3
832	1606 FUNCTIONAL PLASTICITY OF AUTONOMIC PELVIC GANGLIA IN RAT MODELS OF OVERACTIVE BLADDER. Journal of Urology, 2013, 189, .	0.4	0
833	Nocturia: current concepts and future perspectives. Acta Physiologica, 2013, 207, 53-65.	3.8	20
834	Comorbidities associated with bladder dysfunction. International Journal of Clinical Practice, 2013, 67, 105-113.	1.7	18
835	Sex Differences in the Physiology and Pharmacology of the Lower Urinary Tract. Current Urology, 2013, 6, 179-188.	0.6	35
836	Health-related quality of life and economic impact of urinary incontinence due to detrusor overactivity associated with a neurologic condition: a systematic review. Health and Quality of Life Outcomes, 2013, 11, 13.	2.4	60
837	The Convergence of Medicine and Neurotoxins: A Focus on Botulinum Toxin Type A and Its Application in Aesthetic Medicineâ€”A Global, Evidence-Based Botulinum Toxin Consensus Education Initiative. Dermatologic Surgery, 2013, 39, 493-509.	0.8	47
838	Solifenacin Succinate versus Percutaneous Tibial Nerve Stimulation in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Crossover Study. Gynecologic and Obstetric Investigation, 2013, 75, 230-234.	1.6	37
839	Capsaicin and the Urinary Bladder. , 2013, , 67-87.		0
840	Inhibitory control task is decreased in vascular incontinence patients. Clinical Autonomic Research, 2013, 23, 85-89.	2.5	25
841	Primer of Geriatric Urology. , 2013, , .		1
842	Management of OAB in Those Over Age 65. Current Urology Reports, 2013, 14, 379-385.	2.2	41
843	Association between occupational stress and risk of overactive bladder and other lower urinary tract symptoms: A crossâ€”sectional study of female nurses in China. Neurourology and Urodynamics, 2013, 32, 254-260.	1.5	42
844	Effects of percutaneous tibial nerve stimulation on adult patients with overactive bladder syndrome: A systematic review. Neurourology and Urodynamics, 2013, 32, 206-214.	1.5	55

#	ARTICLE	IF	CITATIONS
846	Understanding the effects on HR-QoL of treatment for overactive bladder: a detailed analysis of EQ-5D clinical trial data for mirabegron. <i>Journal of Medical Economics</i> , 2013, 16, 866-876.	2.1	9
847	Cardiovascular effects of antimuscarinic agents in overactive bladder. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 815-827.	2.4	25
848	Control of urinary bladder smooth muscle excitability by the TRPM4 channel modulator 9-phenanthrol. <i>Channels</i> , 2013, 7, 537-540.	2.8	19
849	Involvement of 5-HT ₃ receptors in pudendal inhibition of bladder overactivity in cats. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 305, F663-F671.	2.7	27
850	Intradetrusor Injection of Botulinum Toxin for the Management of Refractory Overactive Bladder Syndrome. <i>Surgical Innovation</i> , 2013, 20, 351-355.	0.9	1
851	A Noninvasive Bladder Sensory Test Supports a Role for Dysmenorrhea Increasing Bladder Noxious Mechanosensitivity. <i>Clinical Journal of Pain</i> , 2013, 29, 883-890.	1.9	32
852	The management of overactive bladder syndrome: a review of the European Association of Urology Guidelines. <i>Clinical Practice (London, England)</i> , 2013, 10, 593-606.	0.1	3
853	New developments in the diagnosis and management of overactive bladder. <i>Clinical Practice (London, England)</i> , 2013, 10, 593-606.	0.1	3
854	Experience with imidafenacin in the management of overactive bladder disorder. <i>Therapeutic Advances in Urology</i> , 2013, 5, 43-58.	2.0	12
855	Flexible-Dose Fesoterodine in Elderly Adults with Overactive Bladder: Results of the Randomized, Double-Blind, Placebo-Controlled Study of Fesoterodine in an Aging Population Trial. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 185-193.	2.6	95
856	Systematic review of the relationship between bladder and bowel function: implications for patient management. <i>International Journal of Clinical Practice</i> , 2013, 67, 205-216.	1.7	64
857	Sacral neuromodulation effects on periurethral sensation and urethral sphincter activity. <i>Neurourology and Urodynamics</i> , 2013, 32, 476-479.	1.5	6
858	Overactive bladder mediated by accelerated Ca ²⁺ influx mode of Na ⁺ /Ca ²⁺ exchanger in smooth muscle. <i>American Journal of Physiology - Cell Physiology</i> , 2013, 305, C299-C308.	4.6	18
859	The association between the self-perception period of overactive bladder symptoms and overactive bladder symptom scores in a non-treated population and related sociodemographic and lifestyle factors. <i>International Journal of Clinical Practice</i> , 2013, 67, 795-800.	1.7	8
860	Evaluation of fesoterodine fumarate for the treatment of an overactive bladder. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 1659-1666.	3.3	8
861	Burden of overactive bladder symptom on quality of life in stroke patients. <i>Neurourology and Urodynamics</i> , 2013, 32, 428-434.	1.5	18
862	Biomechanics of the Human Urinary Bladder. , 2013, , .		7
863	Comorbidities and personal burden of urgency urinary incontinence: a systematic review. <i>International Journal of Clinical Practice</i> , 2013, 67, 1015-1033.	1.7	129

#	ARTICLE	IF	CITATIONS
864	Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. <i>International Journal of Clinical Practice</i> , 2013, 67, 619-632.	1.7	186
865	Health-related quality of life in people with overactive bladder symptoms: reliability and validity of the traditional Chinese version of the Kings' Health Questionnaire. <i>International Journal of Urological Nursing</i> , 2013, 7, 154-160.	0.2	1
866	Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (<sc>SUNRISE</sc>). <i>BJU International</i> , 2013, 111, 804-810.	2.5	31
868	Efficacy of Botulinum Toxin A Intradetrusor Injections for Non-neurogenic Urinary Urge Incontinence: A Randomized Double-Blind Controlled Trial. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2013, 35, 53-60.	0.7	12
869	Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain. <i>BMC Urology</i> , 2013, 13, 51.	1.4	10
870	Debilitating Lower Urinary Tract Symptoms in the Post-Renal Transplant Population Can Be Predicted Pretransplantation. <i>Transplantation</i> , 2013, 95, 589-594.	1.0	12
871	Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency. <i>Research and Reports in Urology</i> , 2013, 5, 147.	1.0	5
872	Use of the SF-36 quality of life scale to assess the effect of pelvic floor muscle exercise on aging males who received transurethral prostate surgery. <i>Clinical Interventions in Aging</i> , 2013, 8, 667.	2.9	7
873	Influence of Type of Nocturia and Lower Urinary Tract Symptoms on Therapeutic Outcome in Women Treated With Desmopressin. <i>Korean Journal of Urology</i> , 2013, 54, 95.	1.2	13
874	Symptom Bother, Physical and Mental Stress, and Health-related Quality of Life in Women with Overactive Bladder Syndrome. <i>Korean Journal of Women Health Nursing</i> , 2013, 19, 295.	0.8	6
875	Efficacy and safety of propiverine and terazosine combination for one year in male patients with luts and detrusor overactivity. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2013, 39, 513-518.	1.5	5
876	Neurogenic Detrusor Overactivity Is Associated with Decreased Expression and Function of the Large Conductance Voltage- and Ca ²⁺ -Activated K ⁺ Channels. <i>PLoS ONE</i> , 2013, 8, e68052.	2.5	45
877	Validation of transcutaneous NIRS monitoring of bladder hemodynamics and oxygenation using a rabbit model. <i>Biomedical Spectroscopy and Imaging</i> , 2013, 2, 91-99.	1.2	3
878	Pathogens in Urine from a Female Patient with Overactive Bladder Syndrome Detected by Culture-independent High Throughput Sequencing: A Case Report. <i>Open Microbiology Journal</i> , 2014, 8, 148-153.	0.7	18
879	Overactive bladder in the vulnerable elderly. <i>Research and Reports in Urology</i> , 2014, 6, 131.	1.0	26
880	OnabotulinumtoxinA for the treatment of overactive bladder. <i>Research and Reports in Urology</i> , 2014, 6, 79.	1.0	20
881	Persistence and Adherence with Urinary Antispasmodic Medications Among Employees and the Impact of Adherence on Costs and Absenteeism. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 1047-1056.	2.2	16
882	The evolution of near infrared spectroscopy in urology. <i>Biomedical Spectroscopy and Imaging</i> , 2014, 3, 311-344.	1.2	10

#	ARTICLE	IF	CITATIONS
883	Management of Stress Urinary Incontinence in Females with Diabetic Mellitus (Type 2). Journal of Diabetes & Metabolism, 2014, 05, .	0.2	2
884	Gender Differences in Coping Strategies for Troublesome Lower Urinary Tract Symptoms Prior to Seeking Treatment. Journal of General Practice (Los Angeles, Calif), 2014, 02, .	0.1	0
885	The Prevalence of Lower Urinary Tract Symptoms in Korean Men Aged 40 Years or Older: A Population-Based Survey. International Neurourology Journal, 2014, 18, 126.	1.2	32
886	Defining response and non-response to treatment in patients with overactive bladder: a systematic review. Current Medical Research and Opinion, 2014, 30, 509-526.	1.9	19
887	The Role of Mirabegron in Overactive Bladder: A Systematic Review and Meta-Analysis. Urologia Internationalis, 2014, 93, 326-337.	1.3	39
888	Management of Overactive Bladder Refractory to Medical Therapy. Current Bladder Dysfunction Reports, 2014, 9, 336-340.	0.5	1
889	Mixed Incontinence: What Takes Precedence in Its Management?. Current Urology Reports, 2014, 15, 461.	2.2	10
890	Intradetrusor onabotulinumtoxinA for overactive bladder. Expert Opinion on Biological Therapy, 2014, 14, 721-727.	3.1	4
891	Neural Control of the Lower Urinary Tract. , 2015, 5, 327-396.		337
892	Onabotulinum Toxin A: A Therapeutic Option for Refractory Neurogenic Detrusor Overactivity and Idiopathic Overactive Bladder. Urologic Nursing, 2014, 34, 165.	0.1	4
893	Optimizing individual treatment outcomes in men with lower urinary tract symptoms using storage subscale score/total International Prostate Symptom Score (IPSS) as a new IPSS ratio. Turkish Journal of Medical Sciences, 2014, 44, 1124-1129.	0.9	0
894	Assessment of treatment-seeking behavior and healthcare utilization in an international cohort of subjects with overactive bladder. Current Medical Research and Opinion, 2014, 30, 1557-1564.	1.9	11
895	Urinary incontinence in women. BMJ, The, 2014, 349, g4531-g4531.	6.0	156
896	The prevalence and risk factors of OAB in middle-aged and old people in China. Neurourology and Urodynamics, 2014, 33, 387-391.	1.5	35
897	Examining mechanisms of brain control of bladder function with resting state functional connectivity MRI. Neurourology and Urodynamics, 2014, 33, 493-501.	1.5	30
898	Combination of foot stimulation and tolterodine treatment eliminates bladder overactivity in cats. Neurourology and Urodynamics, 2014, 33, 1266-1271.	1.5	5
899	Phase III, randomised, double-blind, placebo-controlled study of the β_3 -adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with 2.5 overactive bladder. BJU International, 2014, 113, 951-960.		122
900	Botulinum Toxin A Intradetrusor Injection for Treating Neurogenic Detrusor Overactivity, A Single Centre Experience. LUTS: Lower Urinary Tract Symptoms, 2014, 6, 162-166.	1.3	0

#	ARTICLE	IF	CITATIONS
901	Validation of the bladder control self-assessment questionnaire (<sc>B</sc>-<sc>SAQ</sc>) in men. BJU International, 2014, 113, 783-788.	2.5	17
902	Olmesartan ameliorates urinary dysfunction in the spontaneously hypertensive rat via recovering bladder blood flow and decreasing oxidative stress. Neurourology and Urodynamics, 2014, 33, 350-357.	1.5	15
903	Editorial Comment to Prevalence of lower urinary tract symptoms, overactive bladder and urinary incontinence in western <sc>T</sc>-<sc>urkey: Results of a population-based survey. International Journal of Urology, 2014, 21, 1034-1034.	1.0	0
904	The Patient Voice: Incorporating Patient-Focused Assessment Into Needs Assessment, Gap Analysis, and Content Focus of Continuing Professional Development Programs. Journal of Continuing Education in the Health Professions, 2014, 34, S34-S35.	1.3	3
905	Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in <sc>J</sc>-<sc>apanese patients with overactive bladder: A randomized double-blind trial. International Journal of Urology, 2014, 21, 586-593.	1.0	32
906	How much improvement is needed for a real difference of lower urinary tract symptoms after long-term combination therapy for benign prostatic hyperplasia. International Journal of Clinical Practice, 2014, 68, 1081-1086.	1.7	2
907	Medical Therapy in Overactive Bladder of the Elderly. Current Bladder Dysfunction Reports, 2014, 9, 326-335.	0.5	1
908	Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms. BJU International, 2014, 113, 696-703.	2.5	29
909	Prevalence of lower urinary tract symptoms, overactive bladder and urinary incontinence in western <sc>T</sc>-<sc>urkey: Results of a population-based survey. International Journal of Urology, 2014, 21, 1027-1033.	1.0	32
910	Exploring Sex and Gender Differences in Sleep Health: A Society for Women's Health Research Report. Journal of Women's Health, 2014, 23, 553-562.	3.3	319
911	Is overactive bladder a brain disease? The pathophysiological role of cerebral white matter in the elderly. International Journal of Urology, 2014, 21, 33-38.	1.0	63
912	Safety and tolerability of the β_3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial. International Journal of Clinical Practice, 2014, 68, 972-985.	1.7	70
913	Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder. BJU International, 2014, 113, 484-491.	2.5	83
914	Clinical safety, tolerability and efficacy of combination tolterodine/pilocarpine in patients with overactive bladder. International Journal of Clinical Practice, 2014, 68, 986-994.	1.7	18
915	Acupuncture versus Solifenacin for Treatment of Overactive Bladder and Its Correlation with Urine Nerve Growth Factor Levels: A Randomized, Placebo-Controlled Clinical Trial. Urologia Internationalis, 2014, 93, 437-443.	1.3	27
916	Chapter 1: The conditions of neurogenic detrusor overactivity and overactive bladder. Neurourology and Urodynamics, 2014, 33, S2-5.	1.5	41
917	Female Mixed Urinary Incontinence. JAMA - Journal of the American Medical Association, 2014, 311, 2007.	7.4	44
918	Comparison of Mindfulness-Based Stress Reduction Versus Yoga on Urinary Urge Incontinence. Female Pelvic Medicine and Reconstructive Surgery, 2014, 20, 141-146.	1.1	93

#	ARTICLE	IF	CITATIONS
919	Cues to Urinary Urgency and Urge Incontinence. Journal of Wound, Ostomy and Continence Nursing, 2014, 41, 259-267.	1.0	14
920	The role of electrical stimulation techniques in the management of the male patient with urgency incontinence. Current Opinion in Urology, 2014, 24, 560-565.	1.8	2
921	Association of Depression and Anxiety in Underserved Women With and Without Urinary Incontinence. Female Pelvic Medicine and Reconstructive Surgery, 2014, 20, 349-353.	1.1	14
922	Urinary incontinence. Menopause, 2014, 21, 399-402.	2.0	14
923	The efficacy and tolerability of the $\hat{1}^{23}$ -adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients. Age and Ageing, 2014, 43, 666-675.	1.6	99
924	Featured paper Postmenopausal overactive bladder. Przegląd Menopauzalny, 2014, 6, 313-329.	1.3	10
925	Epidemiology of Lower Urinary Tract Symptoms: Emphasis on the Status in Korea. Korean Journal of Urology, 2014, 55, 300.	1.2	14
926	Podium Presentations. Female Pelvic Medicine and Reconstructive Surgery, 2014, 20, S1-S40.	1.1	3
927	Economic Burden of Urge Urinary Incontinence in the Workplace. Journal of Occupational and Environmental Medicine, 2014, 56, 266-269.	1.7	8
928	Global Prevalence and Economic Burden of Urgency Urinary Incontinence: A Systematic Review. European Urology, 2014, 65, 79-95.	1.9	306
929	Developing and Validating the International Consultation on Incontinence Questionnaire Bladder Diary. European Urology, 2014, 66, 294-300.	1.9	123
930	The Refractory Overactive Bladder: Sacral NEuromodulation vs. BoTulinum Toxin Assessment: ROSETTA trial. Contemporary Clinical Trials, 2014, 37, 272-283.	1.8	42
931	Consenso experto sobre la evidencia científica disponible acerca del uso de toxina botulínica en vejiga hiperactiva. Actas Urológicas Españolas, 2014, 38, 209-216.	0.7	7
932	Modulation of nerve-evoked contractions by $\hat{1}^{23}$ -adrenoceptor agonism in human and rat isolated urinary bladder. Pharmacological Research, 2014, 80, 14-20.	7.1	32
933	Incontinence: Do We Speak the Same Language?. European Urology, 2014, 65, 96-98.	1.9	0
934	La severidad de la vejiga hiperactiva modifica la carga asistencial y la productividad laboral. Actas Urológicas Españolas, 2014, 38, 249-256.	0.7	11
935	Urinary brain-derived neurotrophic factor: a potential biomarker for objective diagnosis of overactive bladder. International Urology and Nephrology, 2014, 46, 341-347.	1.4	46
936	Urinary Symptoms as a Prodrome of Bladder Pain Syndrome/Interstitial Cystitis. Urology, 2014, 83, 1035-1040.	1.0	15

#	ARTICLE	IF	CITATIONS
937	Economics of Overactive Bladder. <i>Current Bladder Dysfunction Reports</i> , 2014, 9, 52-57.	0.5	1
938	Reasons for dissatisfaction ten years after TVT procedure. <i>International Urogynecology Journal</i> , 2014, 25, 213-217.	1.4	9
939	Onset of action of the Î²3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder. <i>World Journal of Urology</i> , 2014, 32, 1565-1572.	2.2	26
940	Anticholinergic medication use for female overactive bladder in the ambulatory setting in the United States. <i>International Urogynecology Journal</i> , 2014, 25, 479-484.	1.4	23
941	Expert consensus on scientific evidence available on the use of botulinum toxin in overactive bladder. <i>Actas Urológicas Españolas (English Edition)</i> , 2014, 38, 209-216.	0.2	1
943	Sacral Neuromodulation for Refractory Overactive Bladder, Interstitial Cystitis, and Painful Bladder Syndrome. <i>Neurosurgery Clinics of North America</i> , 2014, 25, 33-46.	1.7	35
944	Urine Is Not Sterile: Use of Enhanced Urine Culture Techniques To Detect Resident Bacterial Flora in the Adult Female Bladder. <i>Journal of Clinical Microbiology</i> , 2014, 52, 871-876.	3.9	676
945	OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder. <i>International Journal of Clinical Practice</i> , 2014, 68, 1246-1256.	1.7	56
946	Prevalence of Overactive Bladder and Stress Urinary Incontinence in Women Who Have Sex with Women: An Internet-Based Survey. <i>Journal of Women's Health</i> , 2014, 23, 935-940.	3.3	4
948	The coexistence of interstitial cystitis and overactive bladder in a patient with lower urinary tract symptoms. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2014, 53, 263-266.	1.3	4
950	Phase II drugs that target cholinergic receptors for the treatment of overactive bladder. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1365-1374.	4.1	10
951	You are what you eat: The impact of diet on overactive bladder and lower urinary tract symptoms. <i>Maturitas</i> , 2014, 79, 8-13.	2.4	21
952	Autonomic dysfunction and arterial stiffness in female overactive bladder patients and antimuscarinics related effects. <i>Maturitas</i> , 2014, 79, 65-69.	2.4	20
953	Urodynamics in the Evaluation of Female LUTS. <i>Urologic Clinics of North America</i> , 2014, 41, 429-438.	1.8	13
954	Characteristics of TRK-130 (Naltalimide), a Novel Opioid Ligand, as a New Therapeutic Agent for Overactive Bladder. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 350, 543-551.	2.5	13
955	Mapping of Incontinence Quality of Life (I-QOL) scores to Assessment of Quality of Life 8D (AQoL-8D) utilities in patients with idiopathic overactive bladder. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 133.	2.4	13
956	The âœbotheraâœ of urinary incontinence. <i>International Urogynecology Journal</i> , 2014, 25, 947-951.	1.4	12
957	Antimuscarinic use among individuals with urinary incontinence who reside in long-term care facilities. <i>International Urology and Nephrology</i> , 2014, 46, 285-296.	1.4	1

#	ARTICLE	IF	CITATIONS
958	Impact of urinary incontinence on health-related quality of life, daily activities, and healthcare resource utilization in patients with neurogenic detrusor overactivity. <i>BMC Neurology</i> , 2014, 14, 74.	1.8	44
959	Yoga: A Biobehavioral Approach to Reduce Symptom Distress in Women with Urge Urinary Incontinence. <i>Journal of Alternative and Complementary Medicine</i> , 2014, 20, 737-742.	2.1	11
960	Solifenacin Is Able to Improve the Irritative Symptoms After Transurethral Resection of Bladder Tumors. <i>Urology</i> , 2014, 84, 117-121.	1.0	28
961	Overactive Bladder and Mental Health Symptoms in Recently Deployed Female Veterans. <i>Journal of Urology</i> , 2014, 191, 1327-1332.	0.4	44
962	A Novel Implantation Technique for Pudendal Nerve Stimulation for Treatment of Overactive Bladder and Urgency Incontinence. <i>Journal of Minimally Invasive Gynecology</i> , 2014, 21, 888-892.	0.6	20
963	The effect of hyperactive bladder severity on healthcare utilization and labor productivity. <i>Actas Urológicas Españolas (English Edition)</i> , 2014, 38, 249-256.	0.2	4
964	A Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of Oxybutynin Vaginal Ring for Alleviation of Overactive Bladder Symptoms in Women. <i>Journal of Urology</i> , 2014, 191, 1014-1021.	0.4	19
965	Frequency of bedwetting among primary school children in Benha city, Egypt. <i>Egyptian Journal of Medical Human Genetics</i> , 2014, 15, 287-292.	1.0	12
966	The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment. <i>Journal of the Formosan Medical Association</i> , 2014, 113, 506-512.	1.7	19
967	Trospium chloride for overactive bladder may induce central nervous system adverse events. <i>European Geriatric Medicine</i> , 2014, 5, 220-224.	2.8	4
968	Economic Burden of Urgency Urinary Incontinence in the United States: A Systematic Review. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 130-140.	2.2	202
969	Association of statin use with storage lower urinary tract symptoms (LUTS): data mining of prescription database. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2014, 52, 762-769.	0.6	13
970	Pharmacologic Management of Bladder Dysfunction in Adult Women. <i>JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing</i> , 2014, 43, 253-263.	0.5	1
971	Beta-3 adrenergic receptor agonist for adult with overactive bladder. <i>The Cochrane Library</i> , 0, , .	2.8	1
972	Impact of onabotulinumtoxinA on quality of life and practical aspects of daily living: A pooled analysis of two randomized controlled trials. <i>International Journal of Urology</i> , 2015, 22, 1131-1137.	1.0	7
973	Brain-bladder control network: The unsolved 21st century urological mystery. <i>International Journal of Urology</i> , 2015, 22, 342-348.	1.0	48
978	Safety and efficacy of mirabegron as add-on therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (<sc>MILAI</sc> study). <i>BJU International</i> , 2015, 116, 612-622.	2.5	84
979	Impact of urinary incontinence on female sexual health in women during midlife. <i>Women's Midlife Health</i> , 2015, 1, 6.	1.5	17

#	ARTICLE	IF	CITATIONS
980	Validation of a self-administered instrument to measure adherence to anticholinergic drugs in women with overactive bladder. <i>Neurourology and Urodynamics</i> , 2015, 34, 424-428.	1.5	11
981	Characterization of symptom bother and health-related quality of life in Japanese female patients with overactive bladder. <i>Neurourology and Urodynamics</i> , 2015, 34, 730-735.	1.5	10
983	Telemetric monitoring of bladder function in female Göttingen minipigs. <i>BJU International</i> , 2015, 116, 823-832.	2.5	9
984	New evidence in the treatment of overactive bladder. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015, 27, 366-372.	2.0	8
985	Pelvic Floor Physical Therapy as Primary Treatment of Pelvic Floor Disorders With Urinary Urgency and Frequency-Predominant Symptoms. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2015, 21, 252-256.	1.1	17
986	Formal Synthesis of Fesoterodine by Acid-Facilitated Aromatic Alkylation. <i>Bulletin of the Korean Chemical Society</i> , 2015, 36, 2885-2889.	1.9	3
987	Economic evaluation of sacral neuromodulation in overactive bladder: A Canadian perspective. <i>Canadian Urological Association Journal</i> , 2015, 9, 242.	0.6	23
988	Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada. <i>Canadian Urological Association Journal</i> , 2015, 9, 343.	0.6	94
989	Evaluation of female overactive bladder using urodynamics: relationship with female voiding dysfunction. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2015, 41, 722-728.	1.5	15
990	Overactive bladder. <i>F1000Research</i> , 2015, 4, 1406.	1.6	12
991	Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review. <i>BMJ, The</i> , 2015, 351, h4679.	6.0	31
992	Association between Menopausal Symptoms and Overactive Bladder: A Cross-Sectional Questionnaire Survey in China. <i>PLoS ONE</i> , 2015, 10, e0139599.	2.5	14
993	Treating Urge Incontinence in Older Women: A Cost-Effective Investment in Quality-Adjusted Life-Years (QALY). <i>Journal of Geriatrics</i> , 2015, 2015, 1-7.	0.2	2
994	Comparison of solifenacin and fesoterodine in treatment of overactive bladder. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2015, 36, 1181-1185.	1.1	10
995	Lower urinary tract dysfunction in patients with brain lesions. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2015, 130, 269-287.	1.8	62
996	Redefining the Autonomic Nerve Distribution of the Bladder Using 3-Dimensional Image Reconstruction. <i>Journal of Urology</i> , 2015, 194, 1661-1667.	0.4	34
997	Solabegron: a potential future addition to the β_3 adrenoceptor agonist armamentarium for the management of overactive bladder. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 413-419.	4.1	5
998	Effect of Hormonal Changes on Voiding in the Elderly Woman. <i>Current Bladder Dysfunction Reports</i> , 2015, 10, 362-369.	0.5	1

#	ARTICLE	IF	CITATIONS
999	Neural control of micturition in humans: a working model. <i>Nature Reviews Urology</i> , 2015, 12, 695-705.	3.8	115
1000	Predictors of persistence of preoperative urgency incontinence in women following pelvic organ prolapse repair. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2015, 54, 682-685.	1.3	7
1001	Outcomes of Sacral Neuromodulation for Overactive Bladder in Octogenarian Females. <i>Urology Practice</i> , 2015, 2, 22-25.	0.5	2
1003	Review of the Efficacy and Safety of Fesoterodine for Treating Overactive Bladder and Urgency Urinary Incontinence in Elderly Patients. <i>Drugs and Aging</i> , 2015, 32, 103-125.	2.7	16
1004	The interaction of stress and urgency urinary incontinence and its effect on quality of life. <i>International Urogynecology Journal</i> , 2015, 26, 269-276.	1.4	18
1005	Flavoxate in urogynecology: an old drug revisited. <i>International Urogynecology Journal</i> , 2015, 26, 959-966.	1.4	2
1006	Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis. <i>International Urology and Nephrology</i> , 2015, 47, 457-464.	1.4	23
1007	The potential role of stem cells in the treatment of urinary incontinence. <i>Therapeutic Advances in Urology</i> , 2015, 7, 22-40.	2.0	51
1008	Affective symptoms and the overactive bladder – A systematic review. <i>Journal of Psychosomatic Research</i> , 2015, 78, 95-108.	2.6	114
1009	How to define a refractory idiopathic overactive bladder?. <i>Neurourology and Urodynamics</i> , 2015, 34, 2-11.	1.5	25
1010	Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: A randomized, double-blind, placebo-controlled study. <i>Neurourology and Urodynamics</i> , 2015, 34, 37-43.	1.5	23
1011	Influence of antimuscarinic therapy on cognitive functions and quality of life in geriatric patients treated for overactive bladder. <i>Aging and Mental Health</i> , 2015, 19, 217-223.	2.8	23
1012	Effect of anticholinergics on the overactive bladder and bowel domain of the electronic personal assessment questionnaire (ePAQ). <i>International Urogynecology Journal</i> , 2015, 26, 533-537.	1.4	7
1013	Outcome after conservative management for mixed urinary incontinence. <i>Journal of Obstetrics and Gynaecology Research</i> , 2015, 41, 269-276.	1.3	5
1014	Diet Modification for Overactive Bladder: an Evidence-Based Review. <i>Current Bladder Dysfunction Reports</i> , 2015, 10, 25-30.	0.5	4
1015	Complementary Alternative Medicine and Therapies for Overactive Bladder Symptoms: Is There Evidence for Benefit?. <i>Current Bladder Dysfunction Reports</i> , 2015, 10, 20-24.	0.5	1
1016	Lower Limb Nerve Supply. , 2015, , 101-177.		4
1018	Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials. <i>Urological Science</i> , 2015, 26, 41-48.	0.6	6

#	ARTICLE	IF	CITATIONS
1020	The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials. <i>Quality of Life Research</i> , 2015, 24, 1719-1727.	3.1	18
1021	Bladder dysfunction and quality of life for people with multiple sclerosis. <i>Disability and Rehabilitation</i> , 2015, 37, 2350-2358.	1.8	33
1022	The Relationship between Acidic Urinary pH and Overactive Bladder; Alkalization of Urine Improves the Symptoms of Overactive Bladder. <i>Urologia Internationalis</i> , 2015, 95, 223-226.	1.3	10
1024	Treatment of Overactive Bladder in the Elderly Female: The Case for Trosipium, Oxybutynin, Fesoterodine and Darifenacin. <i>Drugs and Aging</i> , 2015, 32, 809-819.	2.7	20
1025	Psychosomatic Aspects of Urinary Incontinence in Women. <i>Geburtshilfe Und Frauenheilkunde</i> , 2015, 75, 165-169.	1.8	15
1026	Drug Therapy for an Overactive Bladder. <i>Women's Health</i> , 2015, 11, 445-448.	1.5	0
1027	Micturition in Göttingen minipigs: first reference in vivo data for urological research and review of literature. <i>Laboratory Animals</i> , 2015, 49, 336-344.	1.0	9
1028	Impact of overactive bladder on quality of life and resource use: results from Korean Burden of Incontinence Study (KOBIS). <i>Health and Quality of Life Outcomes</i> , 2015, 13, 89.	2.4	22
1029	An overactive bladder symptom and health-related quality of life short-form: Validation of the OAB-q SF. <i>Neurourology and Urodynamics</i> , 2015, 34, 255-263.	1.5	116
1030	Improving Outcomes in Patients With Refractory Idiopathic and Neurogenic Detrusor Overactivity: Management Strategies. <i>Archives of Physical Medicine and Rehabilitation</i> , 2015, 96, S341-S357.e1.	0.9	0
1031	The safety and efficiency of onabotulinumtoxinA for the treatment of overactive bladder: a systematic review and meta-analysis. <i>International Urology and Nephrology</i> , 2015, 47, 1779-1788.	1.4	22
1032	Safety considerations for synthetic sling surgery. <i>Nature Reviews Urology</i> , 2015, 12, 481-509.	3.8	78
1033	Early investigational β_3 adreno-receptor agonists for the management of the overactive bladder syndrome. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1299-1306.	4.1	13
1034	Clinical Pathways of Third-Line Treatment of Overactive Bladder in the Elderly. <i>Current Bladder Dysfunction Reports</i> , 2015, 10, 381-390.	0.5	0
1035	The relationship between irritable bowel syndrome, functional dyspepsia, chronic fatigue and overactive bladder syndrome: a controlled study 6 years after acute gastrointestinal infection. <i>BMC Gastroenterology</i> , 2015, 15, 66.	2.0	30
1036	Acupuncture for overactive bladder in female adult: a randomized controlled trial. <i>World Journal of Urology</i> , 2015, 33, 1303-1308.	2.2	32
1037	Systemic Atherosclerosis Causes Detrusor Overactivity: Functional and Morphological Changes in Hyperlipoproteinemic apoE ^{0/0} LDLR ^{0/0} Mice. <i>Journal of Urology</i> , 2015, 193, 345-351.	0.4	17
1038	The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: A systematic review and meta-analysis. <i>Neurourology and Urodynamics</i> , 2015, 34, 413-419.	1.5	38

#	ARTICLE	IF	CITATIONS
1039	Therapeutic Modulation of Urinary Bladder Function: Multiple Targets at Multiple Levels. Annual Review of Pharmacology and Toxicology, 2015, 55, 269-287.	9.4	21
1040	Development and psychometric evaluation of the urgency questionnaire for evaluating severity and health-related quality of life impact of urinary urgency in overactive bladder. International Urogynecology Journal, 2015, 26, 373-382.	1.4	10
1041	Health Resource Utilization and Cost for Patients with Incontinent Overactive Bladder Treated with Anticholinergics. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 406-413.	0.9	22
1042	Prevalence and Risk Factors of Urinary Incontinence and its Impact on the Quality of Life and Treatment Seeking Behavior among Malaysian Women: A Review. Journal of Women's Health Care, 2016, 05, .	0.2	2
1043	Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 1072-1084.	0.9	9
1044	An observational study of effect on quality of life in perimenopausal females suffering from urinary incontinence. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2016, , 448-451.	0.1	0
1045	Review of the epidemiology of overactive bladder. Research and Reports in Urology, 2016, 8, 71.	1.0	87
1046	Evaluation and management of overactive bladder: strategies for optimizing care. Research and Reports in Urology, 2016, Volume 8, 113-122.	1.0	39
1047	Overactive bladder “ 18 years “ part I. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2016, 42, 188-198.	1.5	18
1048	Cost-effectiveness analysis of fesoterodine flexible dose in newly diagnosed patients with overactive bladder in routine clinical practice in Spain. ClinicoEconomics and Outcomes Research, 2016, Volume 8, 541-550.	1.9	1
1049	Botulinum toxin A for the Treatment of Overactive Bladder. Toxins, 2016, 8, 59.	3.4	39
1050	Persistence and compliance with medication management in the treatment of overactive bladder. Investigative and Clinical Urology, 2016, 57, 84.	2.0	60
1051	Does the Urinary Microbiome Play a Role in Urgency Urinary Incontinence and Its Severity?. Frontiers in Cellular and Infection Microbiology, 2016, 6, 78.	3.9	224
1052	Testing and Treating Women after Unsuccessful Conservative Treatments for Overactive Bladder or Mixed Urinary Incontinence: A Model-Based Economic Evaluation Based on the BUS Study. PLoS ONE, 2016, 11, e0160351.	2.5	6
1053	Sacral neuromodulation in overactive bladder: a review and current perspectives. Research and Reports in Urology, 2016, Volume 8, 193-199.	1.0	33
1054	Optimum Dose of Once-a-Daily Oxybutynin Patch in Japanese Patients with Overactive Bladder: A Randomized Double-blind Trial Versus Placebo. LUTS: Lower Urinary Tract Symptoms, 2016, 8, 150-158.	1.3	4
1055	Cholinergic Antagonists Combined with Electrical Stimulation or Bladder Training Treatments for Overactive Bladder in Female Adults: A Meta-Analysis of Randomized Controlled Trials. Clinical Drug Investigation, 2016, 36, 801-808.	2.2	6
1056	Underactive bladder in women. Current Opinion in Urology, 2016, 26, 309-314.	1.8	7

#	ARTICLE	IF	CITATIONS
1057	Comparison of the overactive bladder symptom score and the overactive bladder symptom score derived from the bladder diaries. <i>Neurourology and Urodynamics</i> , 2016, 35, 349-353.	1.5	8
1058	Abnormal functional connectivity in women with urgency urinary incontinence: Can we predict disease presence and severity in individual women using Rsâ€cMRI/. <i>Neurourology and Urodynamics</i> , 2016, 35, 564-573.	1.5	28
1059	Original Research: Combined model of bladder detrusor smooth muscle and interstitial cells. <i>Experimental Biology and Medicine</i> , 2016, 241, 1853-1864.	2.4	4
1060	What is the role of combination drug therapy in the treatment of overactive bladder? ICI-RS 2014. <i>Neurourology and Urodynamics</i> , 2016, 35, 288-292.	1.5	6
1061	Do we need to know more about the effects of hormones on lower urinary tract dysfunction? ICI-RS 2014. <i>Neurourology and Urodynamics</i> , 2016, 35, 299-303.	1.5	33
1062	Traitements visant la vessie hyperactive : Accent sur la pharmacothÃ©rapie. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2016, 38, S158-S170.	0.7	0
1063	The Effectiveness of Anticholinergic Therapy for Overactive Bladders: Systematic Review and Meta-Analysis. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2016, 38, 564-575.	0.8	4
1064	Electrical Stimulation of the Spinal Dorsal Root Inhibits Reflex Bladder Contraction and External Urethra Sphincter Activity: Is This How Sacral Neuromodulation Works?. <i>Urologia Internationalis</i> , 2016, 96, 360-366.	1.3	6
1065	EstimulaciÃ³n transcutÃ¡nea del nervio tibial posterior versus darifenacina para el tratamiento de vejiga hiperactiva refractaria en mujeres. <i>Revista Mexicana De Urologia</i> , 2016, 76, 3-9.	0.0	3
1066	Impact of daily number of urgency urinary incontinence episodes on overactive bladder patient reported outcomes. <i>Actas UrolÃ³gicas EspaÃ±olas (English Edition)</i> , 2016, 40, 173-182.	0.2	4
1067	Real-World Patterns of Care for the Overactive Bladder Syndrome in the United States. <i>Urology</i> , 2016, 87, 64-69.	1.0	23
1068	An animal model of detrusor overactivity induced by depression. <i>Journal of Pharmacological and Toxicological Methods</i> , 2016, 80, 19-25.	0.7	4
1069	Mapping of the OAB-SF Questionnaire onto EQ-5D in Spanish Patients with Overactive Bladder. <i>Clinical Drug Investigation</i> , 2016, 36, 267-279.	2.2	6
1070	Impact of Caffeine on Overactive Bladder Symptoms. <i>Current Bladder Dysfunction Reports</i> , 2016, 11, 1-7.	0.5	2
1071	Real-world characteristics of elderly patients with overactive bladder in the United States. <i>Current Medical Research and Opinion</i> , 2016, 32, 1997-2005.	1.9	32
1072	Antimuscarinic Medication Use in Elderly Patients with Overactive Bladder. <i>Drugs and Aging</i> , 2016, 33, 755-763.	2.7	11
1073	Acupuncture for the treatment of overactive bladder: A protocol for systematic review and meta-analysis of randomized controlled trials. <i>European Journal of Integrative Medicine</i> , 2016, 8, 875-878.	1.7	0
1075	Voiding dysfunction in older women with overactive bladder symptoms: A comparison of urodynamic parameters between women with normal and elevated postâ€void residual urine. <i>Neurourology and Urodynamics</i> , 2016, 35, 95-99.	1.5	13

#	ARTICLE	IF	CITATIONS
1076	Pregnancy outcomes following exposure to onabotulinumtoxinA. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 179-187.	1.9	68
1077	Potential benefits of diagnosis and treatment on health outcomes among elderly people with symptoms of overactive bladder. <i>International Journal of Clinical Practice</i> , 2016, 70, 66-81.	1.7	5
1078	The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with β_1 -adrenergic receptor blocker monotherapy: prospective analysis of elderly men. <i>BMC Urology</i> , 2016, 16, 45.	1.4	24
1079	Multicenter Analysis of Urinary Urgency and Urge Incontinence in Patients with Anterior Urethral Stricture Disease before and after Urethroplasty. <i>Journal of Urology</i> , 2016, 196, 1700-1705.	0.4	14
1080	Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study. <i>Urologia Internationalis</i> , 2016, 97, 325-329.	1.3	16
1081	Methods for a multicenter randomized trial for mixed urinary incontinence: rationale and patient-centeredness of the ESTEEM trial. <i>International Urogynecology Journal</i> , 2016, 27, 1479-1490.	1.4	20
1082	In-Depth Characterization and Validation of Human Urine Metabolomes Reveal Novel Metabolic Signatures of Lower Urinary Tract Symptoms. <i>Scientific Reports</i> , 2016, 6, 30869.	3.3	31
1083	Overactive bladder in women. <i>Nursing Standard (Royal College of Nursing (Great Britain): 1987)</i> , 2016, 31, 52-63.	0.1	4
1084	The Prevalence of Overactive Bladder Syndrome and Urinary Incontinence in a Turkish Women Population; Associated Risk Factors and Effect on Quality of Life. <i>Urologia</i> , 2016, 83, 93-98.	0.7	11
1085	The relationship between depression and overactive bladder/urinary incontinence symptoms in the clinical OAB population. <i>BMC Urology</i> , 2016, 16, 60.	1.4	69
1086	Cost-Effectiveness Analysis of Anticholinergics Versus Botox for Urgency Urinary Incontinence. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2016, 22, 311-316.	1.1	11
1087	Positive association of female overactive bladder symptoms and estrogen deprivation. <i>Medicine (United States)</i> , 2016, 95, e4107.	1.0	18
1088	Reproductive Health Management for the Care of Women Veterans. <i>Obstetrics and Gynecology</i> , 2016, 127, 383-392.	2.4	20
1089	Fourteen-day administration of corticosterone may induce detrusor overactivity symptoms. <i>International Urogynecology Journal</i> , 2016, 27, 1713-1721.	1.4	16
1090	Antidepressant Use and Incident Urinary Incontinence: A Literature Review. <i>The Consultant Pharmacist</i> , 2016, 31, 151-160.	0.4	6
1091	Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives. <i>Journal of Medical Economics</i> , 2016, 19, 1135-1143.	2.1	23
1093	Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bladder (CONTROL) study. <i>International Urology and Nephrology</i> , 2016, 48, 1029-1036.	1.4	37
1094	The Burden of Overactive Bladder on US Public Health. <i>Current Bladder Dysfunction Reports</i> , 2016, 11, 8-13.	0.5	93

#	ARTICLE	IF	CITATIONS
1095	Is self-reported adherence associated with clinical outcomes in women treated with anticholinergic medication for overactive bladder?. <i>Neurourology and Urodynamics</i> , 2016, 35, 738-742.	1.5	13
1096	Clinical validation of the Bladder Health Survey for urinary incontinence in a population sample of women. <i>International Urogynecology Journal</i> , 2016, 27, 453-461.	1.4	3
1097	Use of Botulinum Toxin in Urologic Diseases. <i>Urology</i> , 2016, 91, 21-32.	1.0	16
1098	Akt activation correlates with the tumor aggressiveness in Tunisian patients with bladder cancer. <i>Tumor Biology</i> , 2016, 37, 7873-7879.	1.8	4
1099	Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). <i>European Urology</i> , 2016, 70, 136-145.	1.9	140
1100	Patient and physician preferences for oral pharmacotherapy for overactive bladder: two discrete choice experiments. <i>Current Medical Research and Opinion</i> , 2016, 32, 787-796.	1.9	14
1101	The psychological impact of overactive bladder: A systematic review. <i>Journal of Health Psychology</i> , 2016, 21, 69-81.	2.3	76
1102	Conjoint Urological Society of Australia and New Zealand (<scp>USANZ</scp>) and Urogynaecological Society of Australasia (<scp>UGSA</scp>) Guidelines on the management of adult non-neurogenic overactive bladder. <i>BJU International</i> , 2016, 117, 34-47.	2.5	28
1103	Impacto del número de episodios diarios de incontinencia de urgencia en los resultados descritos por el paciente con vejiga hiperactiva. <i>Actas Urológicas Españolas</i> , 2016, 40, 173-182.	0.7	8
1104	The role of local estrogen therapy in the management of pelvic floor disorders. <i>Climacteric</i> , 2016, 19, 162-171.	2.4	18
1105	Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. <i>Current Medical Research and Opinion</i> , 2016, 32, 621-638.	1.9	58
1106	The efficacy and tolerability of mirabegron, a β_3 adrenoceptor agonist, in patients with symptoms of overactive bladder. <i>Therapeutic Advances in Urology</i> , 2016, 8, 38-46.	2.0	21
1107	Nonantimuscarinic treatment for overactive bladder: a systematic review. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 34-57.	1.3	49
1108	Subjective Assessment of the Overactive Pelvic Floor. , 2016, , 131-150.		0
1109	Basal and stress-activated hypothalamic pituitary adrenal axis function in postmenopausal women with overactive bladder. <i>International Urogynecology Journal</i> , 2016, 27, 1383-1391.	1.4	20
1110	Discovery of 5-Chloro-1-(5-chloro-2-(methylsulfonyl)benzyl)-2-imino-1,2-dihydropyridine-3-carboxamide (TAK-259) as a Novel, Selective, and Orally Active β_3 Adrenoceptor Antagonist with Antiurinary Frequency Effects: Reducing Human Ether-a-go-go-Related Gene (hERG) Liabilities. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 2989-3002.	6.4	7
1111	LC-MS/TOF, LC-MSn and H/D Exchange Studies on Solifenacin Succinate Targeted to Characterize its Forced Degradation Products. <i>Chromatographia</i> , 2016, 79, 159-168.	1.3	13
1112	Delivery methods for drugs used in the treatment of overactive bladder. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 361-371.	5.0	2

#	ARTICLE	IF	CITATIONS
1113	Transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients. A prospective randomized trial. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2016, 196, 6-10.	1.1	45
1114	Cardiovascular Safety of β_3 -adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome. <i>European Urology</i> , 2016, 69, 311-323.	1.9	80
1115	The Overactive Pelvic Floor. , 2016, , .		6
1116	Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 7-13.	3.9	61
1117	Urinary nerve growth factor and a variable solifenacin dosage in patients with an overactive bladder. <i>International Urogynecology Journal</i> , 2016, 27, 275-280.	1.4	9
1118	Overactive bladder in adults with sickle cell disease. <i>Neurourology and Urodynamics</i> , 2016, 35, 642-646.	1.5	8
1119	Results of a randomized, double-blind, active-controlled clinical trial with propiverine extended release 30 mg in patients with overactive bladder. <i>BJU International</i> , 2017, 119, 148-157.	2.5	4
1120	Clinical characteristics, beliefs, and coping strategies among older patients with overactive bladder. <i>Neurourology and Urodynamics</i> , 2017, 36, 774-779.	1.5	13
1121	Is overactive bladder a nervous or bladder disorder? Autonomic imaging in patients with overactive bladder via dynamic pupillometry. <i>World Journal of Urology</i> , 2017, 35, 467-472.	2.2	17
1122	Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study). <i>Neurourology and Urodynamics</i> , 2017, 36, 1097-1103.	1.5	11
1123	Continuous urethral pressure measurements; measurement techniques; pressure variations; clinical interpretations; and clinical relevance. A Systematic Literature Analysis. <i>Neurourology and Urodynamics</i> , 2017, 36, 51-56.	1.5	6
1124	Solifenacin in the Elderly: Results of an Observational Study Measuring Efficacy, Tolerability and Cognitive Effects. <i>Urologia Internationalis</i> , 2017, 98, 350-357.	1.3	17
1125	Pathophysiology of Overactive Bladder: Current Understanding. <i>Current Bladder Dysfunction Reports</i> , 2017, 12, 74-79.	0.5	9
1126	Cognitive Effects of Anticholinergics in the Geriatric Patient Population: Safety and Treatment Considerations. <i>Current Bladder Dysfunction Reports</i> , 2017, 12, 104-111.	0.5	1
1127	Central control of micturition in women: Brain-bladder pathways in continence and urgency urinary incontinence. <i>Clinical Anatomy</i> , 2017, 30, 373-384.	2.7	25
1128	Indirect treatment comparison (ITC) of medical therapies for an overactive bladder. <i>Neurourology and Urodynamics</i> , 2017, 36, 1824-1831.	1.5	5
1129	The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Na ⁺ ve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial. <i>Journal of Urology</i> , 2017, 198, 167-175.	0.4	27
1130	Antimuscarinic Use in Females With Overactive Bladder Syndrome Increases the Risk of Depressive Disorder: A 3-Year Follow-up Study. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 1064-1070.	2.0	5

#	ARTICLE	IF	CITATIONS
1131	The Evidence for Female Pelvic Medicine Interventions. <i>Current Bladder Dysfunction Reports</i> , 2017, 12, 8-14.	0.5	2
1132	Current treatment of pelvic organ prolapse correlated with chronic pelvic pain, bladder and bowel dysfunction. <i>Current Opinion in Urology</i> , 2017, 27, 274-281.	1.8	27
1133	Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE). <i>International Journal of Clinical Practice</i> , 2017, 71, e12944.	1.7	19
1134	Prevalence of overactive bladder and its impact on quality of life in 1025 patients with type 2 diabetes in mainland China. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1254-1258.	2.3	11
1135	Overactive Bladder Is Strongly Associated With Frailty in Older Individuals. <i>Urology</i> , 2017, 106, 26-31.	1.0	47
1136	Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents. <i>Neurourology and Urodynamics</i> , 2017, 36, 2123-2131.	1.5	21
1137	Inhibition of the CRF1 receptor influences the activity of antidepressant drugs in the forced swim test in rats. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2017, 390, 769-774.	3.0	7
1138	Glutamatergic Mechanisms Involved in Bladder Overactivity and Pudendal Neuromodulation in Cats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 362, 53-58.	2.5	12
1139	Does physician specialty affect persistence to pharmacotherapy among patients with overactive bladder syndrome?. <i>International Urogynecology Journal</i> , 2017, 28, 409-415.	1.4	5
1140	Patient Satisfaction on Overactive Bladder Treatment. <i>Current Bladder Dysfunction Reports</i> , 2017, 12, 58-65.	0.5	1
1141	Long-Term Treatment with OnabotulinumtoxinA Results in Consistent, Durable Improvements in Health Related Quality of Life in Patients with Overactive Bladder. <i>Journal of Urology</i> , 2017, 198, 897-904.	0.4	19
1142	The Beneficial Effect of Fesoterodine, a Competitive Muscarinic Receptor Antagonist on Erectile Dysfunction in Streptozotocin-induced Diabetic Rats. <i>Urology</i> , 2017, 107, 271.e1-271.e7.	1.0	3
1143	Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada. <i>Journal of Medical Economics</i> , 2017, 20, 614-622.	2.1	10
1144	Clinical epidemiological insights into urinary incontinence. <i>International Urogynecology Journal</i> , 2017, 28, 687-696.	1.4	85
1145	Toileting behavior and urinary tract symptoms among younger women. <i>International Urogynecology Journal</i> , 2017, 28, 1677-1684.	1.4	16
1146	Prevalence and Possible Risk Factors for Urinary Incontinence: A Cohort Study in the City of Izmir. <i>Urologia Internationalis</i> , 2017, 99, 84-90.	1.3	24
1147	Effect of a Bicyclic Pyrimidine Derivative (KRP-103), a Novel Selective Tachykinin NK1 Receptor Antagonist, on Bladder Function in Guinea Pigs. <i>Drug Research</i> , 2017, 67, 302-307.	1.7	2
1148	Functional urological disorders: a sensitized defence response in the bladder-gut-brain axis. <i>Nature Reviews Urology</i> , 2017, 14, 153-163.	3.8	74

#	ARTICLE	IF	CITATIONS
1149	Critical evaluation of the overactive bladder and urgency urinary incontinence association with obstructive sleep apnea syndrome in a relatively young adult male population. <i>Neurourology and Urodynamics</i> , 2017, 36, 1804-1808.	1.5	12
1150	Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 131-151.	3.1	32
1151	OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial. <i>Journal of Urology</i> , 2017, 197, S216-S223.	0.4	133
1152	Persistence in the treatment of overactive bladder syndrome (OAB) with mirabegron in a multicenter clinical study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 210, 247-250.	1.1	10
1153	Urinary incontinence is associated with the development of peptic ulcers in adult women. <i>Medicine (United States)</i> , 2017, 96, e8266.	1.0	6
1154	Development of a core set of outcome measures for OAB treatment. <i>International Urogynecology Journal</i> , 2017, 28, 1785-1793.	1.4	18
1155	Impact of primary nocturnal enuresis on the quality of life in Egyptian mothers. <i>Middle East Current Psychiatry</i> , 2017, 24, 191-198.	1.2	1
1156	The impact of age, gender and severity of overactive bladder wet on quality of life, productivity, treatment patterns and satisfaction. <i>Journal of Clinical Urology</i> , 2017, 10, 513-522.	0.1	2
1157	Urinary Metabolic Phenotyping of Women with Lower Urinary Tract Symptoms. <i>Journal of Proteome Research</i> , 2017, 16, 4208-4216.	3.7	13
1158	AUGS Consensus Statement: Association of Anticholinergic Medication Use and Cognition in Women With Overactive Bladder. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2017, 23, 177-178.	1.1	32
1159	Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndrome. <i>Therapeutic Advances in Urology</i> , 2017, 9, 163-177.	2.0	2
1160	Prevalencia de la incontinencia urinaria y su relación con el sedentarismo en España. <i>Actas Urológicas Españolas</i> , 2017, 41, 624-630.	0.7	9
1161	Effects of tai chi on symptoms and quality of life in women with overactive bladder symptoms: A non-randomized clinical trial. <i>European Journal of Integrative Medicine</i> , 2017, 12, 189-195.	1.7	2
1162	Preliminary experience and possible predictors of successful mirabegron treatment for overactive bladder. <i>Urological Science</i> , 2017, 28, 162-165.	0.6	3
1163	Prevalence of Lower Urinary Tract Symptoms in China, Taiwan, and South Korea: Results from a Cross-Sectional, Population-Based Study. <i>Advances in Therapy</i> , 2017, 34, 1953-1965.	2.9	82
1164	Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms. <i>Current Medical Research and Opinion</i> , 2017, 33, 1731-1736.	1.9	3
1165	Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies. <i>Therapeutic Advances in Urology</i> , 2017, 9, 137-154.	2.0	43
1166	De novo overactive bladder following midurethral sling procedures: a systematic review of the literature and meta-analysis. <i>International Urogynecology Journal</i> , 2017, 28, 1631-1638.	1.4	28

#	ARTICLE	IF	CITATIONS
1167	Risk Factors for Infection Following Third-line Therapy for Overactive Bladder. <i>Current Bladder Dysfunction Reports</i> , 2017, 12, 268-272.	0.5	1
1168	Association Between Irritable Bowel Syndrome and Overactive Bladder: A Research Survey. <i>Urology</i> , 2017, 109, 88-93.	1.0	5
1169	Sleep Disturbance and Fatigue Are Associated With More Severe Urinary Incontinence and Overactive Bladder Symptoms. <i>Urology</i> , 2017, 109, 67-73.	1.0	51
1170	Prevalence and predictors of overactive bladder in nonpregnant nulliparous women below 65 years of age. <i>International Urogynecology Journal</i> , 2018, 29, 531-537.	1.4	3
1171	Are patients with bladder oversensitivity different from those with urodynamically proven detrusor overactivity in female overactive bladder syndrome?. <i>Journal of the Chinese Medical Association</i> , 2017, 80, 644-650.	1.4	20
1172	Movement-Related Urinary Urgency: A Theoretical Framework and Retrospective, Cross-sectional Study. <i>Journal of Women's Health Physical Therapy</i> , 2017, 41, 83-90.	0.8	4
1173	OAB without an overactive bladder in the acute prostaglandin E2 rat model. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 313, F1169-F1177.	2.7	16
1174	Using Advanced Imaging Including MRI to Detect Voiding Dysfunction in Neurogenic Bladder and Fowler Syndrome. <i>Current Bladder Dysfunction Reports</i> , 2017, 12, 321-327.	0.5	0
1175	Inhibition of salivary secretion by tolterodine transdermal patch. <i>Archives of Pharmacal Research</i> , 2017, 40, 1455-1463.	6.3	2
1176	Prevalence of urinary incontinence and its relation with sedentarism in Spain. <i>Actas Urológicas Españolas (English Edition)</i> , 2017, 41, 624-630.	0.2	1
1177	Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial. <i>Patient</i> , 2017, 10, 677-686.	2.7	8
1178	Real-Time Changes in Brain Activity during Sacral Neuromodulation for Overactive Bladder. <i>Journal of Urology</i> , 2017, 198, 1379-1385.	0.4	52
1179	Percutaneous Tibial Nerve Stimulation Therapy for Overactive Bladder Syndrome: Clinical Effectiveness, Urodynamic, and Durability Evaluation. <i>Urology</i> , 2017, 108, 52-58.	1.0	23
1180	CE. <i>American Journal of Nursing</i> , 2017, 117, 34-41.	0.4	2
1181	Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK. <i>PharmacoEconomics - Open</i> , 2017, 1, 25-36.	1.8	11
1182	Lumbosacral spinal segmental contributions to tibial and pudendal neuromodulation of bladder overactivity in cats. <i>Neurourology and Urodynamics</i> , 2017, 36, 1496-1502.	1.5	8
1183	Urothelial ATP signaling: what is its role in bladder sensation?. <i>Neurourology and Urodynamics</i> , 2017, 36, 966-972.	1.5	22
1184	Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?. <i>International Urogynecology Journal</i> , 2017, 28, 477-488.	1.4	14

#	ARTICLE	IF	CITATIONS
1185	Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment. <i>Neurourology and Urodynamics</i> , 2017, 36, 1377-1381.	1.5	18
1187	A community-based epidemiological survey of overactive bladder and voiding dysfunction in female Taiwanese residents aged 40 years and above. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2017, 56, 811-814.	1.3	2
1188	Adherence to antimuscarinics in children with overactive bladder. <i>Paediatrics and Child Health</i> , 2017, 22, 255-258.	0.6	8
1189	Effect of Trosipium Chloride on Cognitive Function in Women Aged 50 and Older: A Randomized Trial. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2017, 23, 118-123.	1.1	30
1190	Prevalence of overactive bladder symptoms and urinary incontinence in a tertiary care hospital in Egypt. <i>International Journal of Reproduction, Contraception, Obstetrics and Gynecology</i> , 2017, 6, 2132.	0.1	4
1191	Vitamin D and Female Reproduction. , 0, , .		0
1192	CUA guideline on adult overactive bladder. <i>Canadian Urological Association Journal</i> , 2017, 11, 142.	0.6	105
1193	Urinary Microbiome and Psychological Factors in Women with Overactive Bladder. <i>Frontiers in Cellular and Infection Microbiology</i> , 2017, 7, 488.	3.9	79
1194	The effect of extended release tolterodine used for overactive bladder treatment on female sexual function. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2017, 43, 713-720.	1.5	13
1195	Patient-reported quality of life recovery curves after robotic prostatectomy are similar across body mass index categories. <i>Investigative and Clinical Urology</i> , 2017, 58, 331.	2.0	5
1196	Urogynecological conditions associated with overactive bladder symptoms in women. <i>Canadian Urological Association Journal</i> , 2017, 11, 83.	0.6	6
1197	Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis. <i>PLoS ONE</i> , 2017, 12, e0169248.	2.5	24
1198	Macrovascular Complications and Prevalence of Urgency Incontinence in Japanese Patients with Type 2 Diabetes Mellitus: The Dogo Study. <i>Internal Medicine</i> , 2017, 56, 889-893.	0.7	4
1199	Urinary Incontinence in the Spanish Elderly: Prevalence and Risk Factors. <i>Journal of Novel Physiotherapies</i> , 2017, 07, .	0.1	0
1200	Schooling impacts on the overactive bladder diagnosis in women. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2017, 43, 1129-1135.	1.5	0
1201	Î² 3 -AR Agonists for the Treatment of Overactive Bladder. , 2017, , 714-737.		1
1202	Correlation between overactive bladder symptom score and neuropsychological parameters in Alzheimerâ€™s disease patients with lower urinary tract symptom. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2017, 43, 256-263.	1.5	9
1203	The influence of menopause on urinary incontinence in the women of the community: a cross-sectional study from North India. <i>International Journal of Reproduction, Contraception, Obstetrics and Gynecology</i> , 2017, 6, 911.	0.1	6

#	ARTICLE	IF	CITATIONS
1204	Primary Nonadherence to Overactive Bladder Medications in an Integrated Managed Care Health Care System. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 484-493.	0.9	7
1205	A randomized, multicenter, controlled study, comparing efficacy and safety of a new complementary and alternative medicine (CAM) versus Solifenacin Succinate in women with overactive bladder syndrome. <i>Archivio Italiano Di Urologia Andrologia</i> , 2017, 89, 296.	0.8	9
1206	The Influence of Tetrodotoxin (TTX) on the Distribution and Chemical Coding of Caudal Mesenteric Ganglion (CaMG) Neurons Supplying the Porcine Urinary Bladder. <i>Marine Drugs</i> , 2017, 15, 101.	4.6	4
1207	Impact of Overactive Bladder Step Therapy Policies on Medication Utilization and Expenditures Among Treated Medicare Members. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 27-37.	0.9	7
1208	Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada. <i>Canadian Urological Association Journal</i> , 2017, 11, 123.	0.6	10
1209	Prevalence of female urinary incontinence in the state of Roraima, Brazil. <i>Urogynaecologia International Journal</i> , 2017, 30, .	0.2	0
1210	Vascular risk factors for male and female urgency urinary incontinence at age 68 years from a British birth cohort study. <i>BJU International</i> , 2018, 122, 118-125.	2.5	14
1211	Clean intermittent catheterization rates after initial and subsequent treatments with onabotulinumtoxinA for non-neurogenic overactive bladder in real-world clinical settings. <i>Current Medical Research and Opinion</i> , 2018, 34, 1771-1776.	1.9	12
1212	No Increased Risk of Fracture in Patients Receiving Antimuscarinics for Overactive Bladder Syndrome: A Retrospective Cohort Study. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 727-732.	2.0	9
1213	The economic burden of overactive bladder (OAB) and its effects on the costs associated with other chronic, age-related comorbidities in the United States. <i>Neurourology and Urodynamics</i> , 2018, 37, 1641-1649.	1.5	40
1214	Is it Safe to Reduce Water Intake in the Overactive Bladder Population? A Systematic Review. <i>Journal of Urology</i> , 2018, 200, 375-381.	0.4	8
1215	Clinical features of, and association of bladder ultrasound and uroflowmetry with, overactive bladder recovery period in children. <i>Pediatrics International</i> , 2018, 60, 569-575.	0.5	5
1216	Effects of Bladder Training and Pelvic Floor Muscle Training in Female Patients with Overactive Bladder Syndrome: A Randomized Controlled Trial. <i>Urologia Internationalis</i> , 2018, 100, 420-427.	1.3	22
1217	Risk factors of overactive bladder syndrome and its relation to sexual function in menopausal women. <i>Urologia</i> , 2018, 85, 10-14.	0.7	16
1218	Selective bladder denervation for overactive bladder (<i>OAB</i>) syndrome: From concept to healing outcomes using the ovine model. <i>Neurourology and Urodynamics</i> , 2018, 37, 2097-2105.	1.5	13
1219	Efficacy of pelvic floor muscle training in women with overactive bladder syndrome: a systematic review. <i>International Urogynecology Journal</i> , 2018, 29, 1565-1573.	1.4	27
1220	Adult and Pediatric Neuromodulation. , 2018, , .		2
1221	Does vaginal estriol make urodynamic changes in women with overactive bladder syndrome and genitourinary syndrome of menopause?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 222, 75-79.	1.1	12

#	ARTICLE	IF	CITATIONS
1222	Vibegron, a Novel Potent and Selective β_3 -Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study. <i>European Urology</i> , 2018, 73, 783-790.	1.9	100
1223	Long-Term Outcomes of Laser Prostatectomy for Storage Symptoms: Comparison of Serial 5-Year Followup Data between High Performance System Photoselective Vaporization and Holmium Laser Enucleation of the Prostate. <i>Journal of Urology</i> , 2018, 199, 1591-1599.	0.4	9
1224	Proteomic Analysis of Urothelium of Rats with Detrusor Overactivity Induced by Bladder Outlet Obstruction. <i>Molecular and Cellular Proteomics</i> , 2018, 17, 948-960.	3.8	8
1225	Measurement properties of tools used to assess depression in adults with and without autism spectrum conditions: A systematic review. <i>Autism Research</i> , 2018, 11, 738-754.	3.8	98
1226	Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: A retrospective analysis. <i>Journal of Obstetrics and Gynaecology Research</i> , 2018, 44, 524-531.	1.3	7
1227	No. 283-Treatments for Overactive Bladder: Focus on Pharmacotherapy. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2018, 40, e22-e32.	0.7	8
1228	No 283-Traitements visant la vessie hyperactive : Accent sur la pharmacoth�rapie. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2018, 40, e33-e44.	0.7	0
1229	Female Voiding Dysfunction and Urinary Incontinence. <i>Medical Clinics of North America</i> , 2018, 102, 313-324.	2.5	9
1230	The economic burden of overactive bladder in the United States: A systematic literature review. <i>Neurourology and Urodynamics</i> , 2018, 37, 1241-1249.	1.5	42
1231	Impact of New Medications and \$4 Generic Programs on Overactive Bladder Treatment Among Older Adults in the United States, 2000�2015. <i>Medical Care</i> , 2018, 56, 162-170.	2.4	12
1232	Prognostic Value of Soluble Death Receptor Ligands in Patients with Transitional Cell Carcinoma of Bladder. <i>Urologia Internationalis</i> , 2018, 100, 476-484.	1.3	4
1233	Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis. <i>European Urology</i> , 2018, 74, 324-333.	1.9	151
1234	Overactive Bladder Syndrome: Evaluation and Management. <i>Current Urology</i> , 2018, 11, 117-125.	0.6	79
1235	Does transition of urinary incontinence from one subtype to another represent progression of the disease?. <i>International Urogynecology Journal</i> , 2018, 29, 1179-1185.	1.4	9
1236	Adenomyosis and urinary system symptoms. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 224, 74-76.	1.1	1
1237	Prevalence of lower urinary tract symptoms and social determinants in primary care users in Brazil. <i>International Urogynecology Journal</i> , 2018, 29, 1825-1832.	1.4	3
1238	Does sex matter? A matched pairs analysis of neuromodulation outcomes in women and men. <i>International Urology and Nephrology</i> , 2018, 50, 825-832.	1.4	9
1239	Long�term Persistence with Mirabegron versus Solifenacin in Women with Overactive Bladder: Prospective, Randomized Trial. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2018, 10, 148-152.	1.3	29

#	ARTICLE	IF	CITATIONS
1240	Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the United States. <i>Neurourology and Urodynamics</i> , 2018, 37, 213-222.	1.5	10
1241	Efficacy and safety of onabotulinumtoxinA injection in patients with refractory overactive bladder: First multicentric study in Turkish population. <i>Neurourology and Urodynamics</i> , 2018, 37, 263-268.	1.5	2
1242	Severe depression and anxiety in women with overactive bladder. <i>Neurourology and Urodynamics</i> , 2018, 37, 223-228.	1.5	42
1243	A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments. <i>Neurourology and Urodynamics</i> , 2018, 37, 177-185.	1.5	5
1244	Comorbidity between idiopathic overactive bladder and chronic migraine. <i>Cephalalgia</i> , 2018, 38, 581-584.	3.9	2
1245	The effectiveness of transcutaneous tibial nerve stimulation (TTNS) for adults with overactive bladder syndrome: A systematic review. <i>Neurourology and Urodynamics</i> , 2018, 37, 528-541.	1.5	71
1246	Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. <i>Neurourology and Urodynamics</i> , 2018, 37, 394-406.	1.5	33
1247	The aging bladder insights from animal models. <i>Asian Journal of Urology</i> , 2018, 5, 135-140.	1.2	21
1248	Refractory urgency urinary incontinence treatment in women: impact of age on outcomes and complications. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 218, 111.e1-111.e9.	1.3	27
1249	Inflammatory Urinary Cytokine Expression and Quality of Life in Patients With Overactive Bladder. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2018, 24, 449-453.	1.1	12
1251	Association between Metabolic Syndrome and Serum Nerve Growth Factor Levels in Women with Overactive Bladder. <i>Gynecologic and Obstetric Investigation</i> , 2018, 83, 140-144.	1.6	6
1252	Evaluation of overactive bladder and nocturia as a risk factor for hip fracture in climacteric women: a matched pair case control study. <i>Journal of Obstetrics and Gynaecology</i> , 2018, 38, 252-256.	0.9	4
1253	Assessment of overactive bladder symptoms among women with successful pessary placement. <i>International Urogynecology Journal</i> , 2018, 29, 571-577.	1.4	8
1254	A novel leadless, miniature implantable Tibial Nerve Neuromodulation System for the management of overactive bladder complaints. <i>Neurourology and Urodynamics</i> , 2018, 37, 1060-1067.	1.5	34
1255	Use of Third Line Therapy for Overactive Bladder in a Practice with Multiple Subspecialty Providers—Are We Doing Enough?. <i>Journal of Urology</i> , 2018, 199, 779-784.	0.4	37
1256	Cross-Sectional Epidemiological Analysis of the Nagahama Study for Correlates of Overactive Bladder: Genetic and Environmental Considerations. <i>Journal of Urology</i> , 2018, 199, 774-778.	0.4	17
1257	Real-World Retention Rates After Intravesical OnabotulinumtoxinA for Idiopathic Overactive Bladder. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2018, 24, 404-407.	1.1	13
1258	The prevalence of lower urinary tract symptoms (LUTS) in Brazil: Results from the epidemiology of LUTS (Brazil LUTS) study. <i>Neurourology and Urodynamics</i> , 2018, 37, 1356-1364.	1.5	60

#	ARTICLE	IF	CITATIONS
1259	The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2018, 36, 305-317.	2.2	22
1260	Pelvic floor disorders in women with gynecologic malignancy. <i>Current Opinion in Obstetrics and Gynecology</i> , 2018, 30, 446-450.	2.0	5
1261	A new paradigm for functional urology. <i>Canadian Urological Association Journal</i> , 2018, 13, 208.	0.6	0
1262	The Overactive Bladder Symptom Score, International Prostate Symptom Score—Storage Subscore, and Urgency Severity Score in Patients With Overactive Bladder and Hypersensitive Bladder: Which Scoring System is Best?. <i>International Neurourology Journal</i> , 2018, 22, 99-106.	1.2	29
1264	Weight Loss and Overactive Bladder. <i>Current Bladder Dysfunction Reports</i> , 2018, 13, 262-266.	0.5	0
1265	Device-Measured Sedentary Behavior Patterns in Office-Based University Employees. <i>Journal of Occupational and Environmental Medicine</i> , 2018, 60, 1150-1157.	1.7	19
1266	Onabotulinumtoxin-A improves health status and urinary symptoms in subjects with refractory overactive bladder: Real-life experience. <i>Urologia</i> , 2018, 85, 163-168.	0.7	2
1267	Nociceptin/Orphanin FQ and Urinary Bladder. <i>Handbook of Experimental Pharmacology</i> , 2018, 254, 347-365.	1.8	8
1268	Short-term results of the efficacy of percutaneous tibial nerve stimulation on urinary symptoms and its financial cost. <i>Journal of the Turkish German Gynecology Association</i> , 2018, 19, 7-10.	0.6	2
1269	The relationship between lower urinary tract symptoms and irritable bowel syndrome: a meta-analysis of cross-sectional studies. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2018, 70, 386-392.	3.9	7
1270	Impact of overactive bladder on retrograde ejaculation. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2018, 44, 972-980.	1.5	2
1272	The LURN Research Network Neuroimaging and Sensory Testing (NIST) Study: Design, protocols, and operations. <i>Contemporary Clinical Trials</i> , 2018, 74, 76-87.	1.8	7
1273	Urinary Urgency in the Elderly. <i>Gerontology</i> , 2018, 64, 541-550.	2.8	8
1274	Randomized controlled trial of belladonna and opiate suppository during intravesical onabotulinum toxin A—injection. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 488.e1-488.e7.	1.3	5
1275	Recurrent Urinary Tract Infections in Females and the Overlap with Overactive Bladder. <i>Current Urology Reports</i> , 2018, 19, 94.	2.2	20
1276	A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain. <i>BMC Urology</i> , 2018, 18, 76.	1.4	12
1277	What Is the Role of Additional Pharmacotherapy and Neuromodulation in Patients with Marginal Benefit from Botulinum Toxin Injection?. <i>Current Urology Reports</i> , 2018, 19, 91.	2.2	3
1278	Can Intradetrusor OnabotulinumtoxinA Injections Alter Heart Function in Patients with Cardiac Arrhythmia?. <i>Journal of Clinical Medicine</i> , 2018, 7, 263.	2.4	0

#	ARTICLE	IF	CITATIONS
1279	Validation of the urgency questionnaire in Portuguese: A new instrument to assess overactive bladder syndrome. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2018, 44, 338-347.	1.5	5
1280	The Prevention of Lower Urinary Tract Symptoms (PLUS) in girls and women: Developing a conceptual framework for a prevention research agenda. Neurourology and Urodynamics, 2018, 37, 2951-2964.	1.5	46
1281	Risk factors and factors affecting the severity of overactive bladder symptoms in Korean women who use public health centers. Obstetrics and Gynecology Science, 2018, 61, 404.	1.6	11
1282	Lower Urinary Tract Symptoms in Subjects with Subclinical Cerebral White Matter Lesions. Journal of Aging Research, 2018, 2018, 1-5.	0.9	6
1283	Refractory hyperactive bladder treated with sacral neuromodulator: case report and literature review. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2018, 7, 2937.	0.1	0
1284	A Novel Research Definition of Bladder Health in Women and Girls: Implications for Research and Public Health Promotion. Journal of Women's Health, 2018, 27, 974-981.	3.3	94
1285	A Prospective, non-interventional Registry Study of Patients initiating a Course of drug Therapy for overactive bladder (PERSPECTIVE): Rationale, design, and methodology. Contemporary Clinical Trials, 2018, 70, 83-87.	1.8	5
1286	Safety and therapeutic efficacy of mirabegron 25 mg in older patients with overactive bladder and multiple comorbidities. Geriatrics and Gerontology International, 2018, 18, 1330-1333.	1.5	13
1287	Should radical prostatectomy be encouraged at any age? A critical non-systematic review. Minerva Urology and Nephrology, 2018, 70, 42-52.	2.5	8
1288	The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study. BMC Urology, 2018, 18, 61.	1.4	12
1289	Knowledge and attitude for overactive bladder care among women: development and measurement. BMC Urology, 2018, 18, 56.	1.4	3
1291	The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy. Therapeutic Advances in Urology, 2018, 10, 243-256.	2.0	9
1292	Measuring urinary 8-hydroxy-2'-deoxyguanosine and malondialdehyde levels in women with overactive bladder. Investigative and Clinical Urology, 2018, 59, 252.	2.0	13
1293	Neuronal Activation in the Periaqueductal Gray Matter Upon Electrical Stimulation of the Bladder. Frontiers in Cellular Neuroscience, 2018, 12, 133.	3.7	13
1294	Office Management of Female Pelvic Floor Dysfunction. , 2018, , 195-212.		0
1295	Effectiveness and safety of acupuncture for elderly overactive bladder population in Hong Kong: study protocol for a randomized controlled trial. Trials, 2018, 19, 376.	1.6	9
1296	Antepartum urinary tract infection and postpartum depression in Taiwan – a nationwide population-based study. BMC Pregnancy and Childbirth, 2018, 18, 79.	2.4	5
1297	Long-term safety and efficacy of the novel β_3 -adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: A phase III prospective study. International Journal of Urology, 2018, 25, 668-675.	1.0	31

#	ARTICLE	IF	CITATIONS
1298	Characterizing the transcutaneous electrical recruitment of lower leg afferents in healthy adults: implications for non-invasive treatment of overactive bladder. <i>BMC Urology</i> , 2018, 18, 10.	1.4	7
1299	Insight Into the Central Control of Overactive Bladder Symptoms by Functional Brain Imaging. <i>Current Bladder Dysfunction Reports</i> , 2018, 13, 31-37.	0.5	3
1300	Review of Economic Value Drivers of the Treatment of Overactive Bladder. <i>Pharmacoeconomics</i> , 2018, 36, 1083-1092.	3.3	8
1301	Metabolomic Analysis of Overactive Bladder in Male Patients: Identification of Potential Metabolite Biomarkers. <i>Urology</i> , 2018, 118, 158-163.	1.0	8
1302	Urox containing concentrated extracts of <i>Crataeva nurvala</i> stem bark, <i>Equisetum arvense</i> stem and <i>Lindera aggregata</i> root, in the treatment of symptoms of overactive bladder and urinary incontinence: a phase 2, randomised, double-blind placebo controlled trial. <i>BMC Complementary and Alternative Medicine</i> , 2018, 18, 42.	3.7	12
1303	The Non-neurogenic Overactive Bladder: an Update. <i>Current Obstetrics and Gynecology Reports</i> , 2018, 7, 139-145.	0.8	1
1304	Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2018, 44, 102-108.	1.5	22
1305	Does Urodynamics Impact the Outcomes of Third-line Therapy of Refractory OAB (or Refractory) Tj ETQq1 1 0.784314 rgBT /Qoverlock 10	0.5	0
1306	Troubleshooting Interstim Sacral Neuromodulation Generators to Recover Function. <i>Current Urology Reports</i> , 2018, 19, 86.	2.2	17
1307	The Direct and Indirect Costs Associated With Overactive Bladder Within a Commercially-Insured Population in the United States. <i>Journal of Occupational and Environmental Medicine</i> , 2018, 60, 847-852.	1.7	6
1308	Current Therapeutic Strategies in Clinical Urology. <i>Molecular Pharmaceutics</i> , 2018, 15, 3010-3019.	4.6	6
1309	Objective and subjective improvement in children with idiopathic detrusor overactivity after intravesical botulinum toxin injection: A preliminary report. <i>Journal of Pediatric Surgery</i> , 2019, 54, 595-599.	1.6	11
1310	Health and functional status, health events, use of healthcare services and costs associated with overactive bladder among the medically complex vulnerable elderly in the US. <i>International Journal of Clinical Practice</i> , 2019, 73, e13207.	1.7	4
1311	Impact of sex, androgens, and prostate size on C57BL/6J mouse urinary physiology: functional assessment. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, F996-F1009.	2.7	13
1312	Urodynamic profile in the Department of Urology, Cipto Mangunkusumo Hospital Between 2010 and 2015. <i>Medical Journal of Indonesia</i> , 2019, 28, 146-53.	0.5	1
1314	Cucurbita pepo "Rhus aromatica" Humulus lupulus Combination Reduces Overactive Bladder Symptoms in Women " A Noninterventional Study. <i>Planta Medica</i> , 2019, 85, 1044-1053.	1.3	2
1315	Management of Overactive Bladder in the Young Man. <i>Current Bladder Dysfunction Reports</i> , 2019, 14, 205-213.	0.5	0
1316	Quality of life in patients aged 65 years and older with overactive bladder treated with mirabegron across eight European countries: Secondary analysis of <sc>BELIEVE</sc>. <i>International Journal of Urology</i> , 2019, 26, 890-896.	1.0	11

#	ARTICLE	IF	CITATIONS
1317	The management of overactive bladder symptom complex. The Prescriber, 2019, 30, 19-25.	0.3	1
1318	Clinical outcomes of percutaneous tibial nerve stimulation in elderly patients with overactive bladder. Arab Journal of Urology Arab Association of Urology, 2019, 17, 10-13.	1.5	6
1319	Turkish validation of the overactive bladder symptom score (OABSS) and evaluation of mirabegron treatment response. International Urogynecology Journal, 2019, 30, 2121-2126.	1.4	7
1320	The real-life management of overactive bladder: Turkish Continence Society multicenter prospective cohort study with short-term outcome. Neurourology and Urodynamics, 2019, 38, 2170-2177.	1.5	2
1321	ICS 2019 Gothenburg Scientific Programme. Neurourology and Urodynamics, 2019, 38, S1-S532.	1.5	7
1322	Updating the evidence on drugs to treat overactive bladder: a systematic review. International Urogynecology Journal, 2019, 30, 1603-1617.	1.4	31
1323	One-year results with selective bladder denervation in women with refractory overactive bladder. Neurourology and Urodynamics, 2019, 38, 2178-2184.	1.5	5
1324	Is nocturnal enuresis a predisposing factor for the overactive bladder?. Turkish Journal of Medical Sciences, 2019, 49, 703-709.	0.9	1
1325	Trends in the use of antimuscarinics and alpha-adrenergic blockers in women with lower urinary tract symptoms in Taiwan: A nationwide, population-based study, 2007-2012. PLoS ONE, 2019, 14, e0220615.	2.5	1
1326	The Prevalence and Forecast Prevalence of Overactive Bladder in the Medicare Population. Clinical Medicine Insights Urology, 2019, 12, 117956111984746.	0.4	1
1327	Is Vaginal Laser Effective for Overactive Bladder? Results of a Systematic Review. Current Bladder Dysfunction Reports, 2019, 14, 308-317.	0.5	0
1328	Evaluation of <i>in Vitro</i> and <i>in Vivo</i> Transdermal Absorption of Solifenacin Succinate. Chemical and Pharmaceutical Bulletin, 2019, 67, 1225-1231.	1.3	3
1329	Overactive Bladder in Diabetes Mellitus. Current Bladder Dysfunction Reports, 2019, 14, 324-330.	0.5	0
1330	Combination phosphodiesterase type 4 inhibitor and phosphodiesterase type 5 inhibitor treatment reduces non-voiding contraction in a rat model of overactive bladder. PLoS ONE, 2019, 14, e0220788.	2.5	3
1331	Neuromodulation – a therapeutic option for refractory overactive bladder. A recent literature review. Wideochirurgia I Inne Techniki Maloinwazyjne, 2019, 14, 476-485.	0.7	6
1332	Potential Role of Extracellular ATP Released by Bacteria in Bladder Infection and Contractility. MSphere, 2019, 4, .	2.9	25
1333	NK2 receptor-mediated detrusor muscle contraction involves Gq/11-dependent activation of voltage-dependent Ca ²⁺ channels and the RhoA-Rho kinase pathway. American Journal of Physiology - Renal Physiology, 2019, 317, F1154-F1163.	2.7	6
1334	Women With Overactive Bladder Exhibit More Unhealthy Toileting Behaviors: A Cross-sectional Study. Urology, 2019, 134, 97-102.	1.0	7

#	ARTICLE	IF	CITATIONS
1335	Precise characterization of urinary tract innervation using three-dimensional reconstruction: A contemporary review. <i>Actas Urológicas Españolas (English Edition)</i> , 2019, 43, 397-403.	0.2	0
1337	Characterizing the Health-Related Quality of Life Burden of Overactive Bladder Using Disease-Specific Patient-Reported Outcome Measures: A Systematic Literature Review. <i>Advances in Therapy</i> , 2019, 36, 548-562.	2.9	12
1338	A Prospective Study to Evaluate Efficacy Using the Nuro Percutaneous Tibial Neuromodulation System in Drug-Naïve Patients With Overactive Bladder Syndrome. <i>Urology</i> , 2019, 131, 77-82.	1.0	9
1339	Outcomes of Sacral Nerve Stimulation for Treatment of Refractory Overactive Bladder Among Octogenarians. <i>Neuromodulation</i> , 2019, 22, 738-744.	0.8	16
1340	Friction underwear for ease of pulling down in elderly patients with overactive bladder: A prospective randomized control trial. <i>Investigative and Clinical Urology</i> , 2019, 60, 216.	2.0	0
1342	Pathophysiology of refractory overactive bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019, 11, 177-181.	1.3	36
1344	Overactive bladder and associated psychological symptoms: A possible link to vitamin D and calcium. <i>Neurourology and Urodynamics</i> , 2019, 38, 1160-1167.	1.5	16
1345	Pelvic floor dysfunction in midlife women. <i>Climacteric</i> , 2019, 22, 270-276.	2.4	25
1346	Terminology for bladder health research in women and girls: Prevention of Lower Urinary Tract Symptoms transdisciplinary consortium definitions. <i>Neurourology and Urodynamics</i> , 2019, 38, 1339-1352.	1.5	22
1347	The influence of nebivolol on the activity of BRL 37344—the α_1 -adrenoceptor agonist, in the animal model of detrusor overactivity. <i>Neurourology and Urodynamics</i> , 2019, 38, 1229-1240.	1.5	3
1348	An external compress-release protocol induces dynamic elasticity in the porcine bladder: A novel technique for the treatment of overactive bladder?. <i>Neurourology and Urodynamics</i> , 2019, 38, 1222-1228.	1.5	9
1349	Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial. <i>International Urology and Nephrology</i> , 2019, 51, 417-424.	1.4	11
1350	Effects of Mirabegron on Anxiety and Depression in Female Patients with Overactive Bladder. <i>Urologia Internationalis</i> , 2019, 102, 331-335.	1.3	10
1352	Remotely programmed sacral neuromodulation for the treatment of patients with refractory overactive bladder: a prospective randomized controlled trial evaluating the safety and efficacy of a novel sacral neuromodulation device. <i>World Journal of Urology</i> , 2019, 37, 2481-2492.	2.2	13
1353	Association of Anticholinergic Risk Score With Functional Status in Patients Preparing for Pelvic Reconstructive Surgery. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2019, 25, 453-456.	1.1	0
1354	Use of Botulinum Toxin in the Genitourinary System. <i>Handbook of Experimental Pharmacology</i> , 2019, 263, 171-184.	1.8	4
1355	Effects of biofeedback-based sleep improvement program on urinary symptoms and sleep patterns of elderly Korean women with overactive bladder syndrome. <i>BMC Urology</i> , 2019, 19, 109.	1.4	5
1356	Advances in Pharmacotherapy for the Treatment of Overactive Bladder. <i>Current Bladder Dysfunction Reports</i> , 2019, 14, 377-384.	0.5	5

#	ARTICLE	IF	CITATIONS
1357	Development and Validation of a Machine Learning Algorithm for Predicting Response to Anticholinergic Medications for Overactive Bladder Syndrome. <i>Obstetrics and Gynecology</i> , 2019, 134, 946-957.	2.4	17
1358	Can we predict the success of prostatic surgery for male lower urinary tract symptoms: ICIâ€™S 2018?. <i>Neurourology and Urodynamics</i> , 2019, 38, S111-S118.	1.5	1
1359	Efficacy of novel β_3 -adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A postâ€™hoc analysis of a randomized, doubleâ€™blind, placeboâ€™controlled phase 3 study. <i>International Journal of Urology</i> , 2019, 26, 369-375.	1.0	17
1360	Prevalence and impact of lower urinary tract symptoms: Results of the epic survey in Egypt. <i>Neurourology and Urodynamics</i> , 2019, 38, 637-643.	1.5	18
1361	Prevalence, Risk Factors, and Treatment for Overactive Bladder in a Racially Diverse Population. <i>Urology</i> , 2019, 126, 70-75.	1.0	33
1362	The effect of overactive bladder treatment with anticholinergics on female sexual function in women: a prospective observational study. <i>International Urology and Nephrology</i> , 2019, 51, 27-32.	1.4	7
1363	Subjective and objective responses to PTNS and predictors for success: a retrospective cohort study of percutaneous tibial nerve stimulation for overactive bladder. <i>International Urogynecology Journal</i> , 2019, 30, 1253-1259.	1.4	21
1364	The mysteries of menopause and urogynecologic health: clinical and scientific gaps. <i>Menopause</i> , 2019, 26, 103-111.	2.0	46
1365	Electroacupuncture Versus Pelvic Floor Muscle Training Plus Solifenacin for Women With Mixed Urinary Incontinence: A Randomized Noninferiority Trial. <i>Mayo Clinic Proceedings</i> , 2019, 94, 54-65.	3.0	24
1366	Metaâ€™analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder. <i>Neurourology and Urodynamics</i> , 2019, 38, 22-30.	1.5	27
1367	Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial. <i>European Urology</i> , 2019, 75, 274-282.	1.9	51
1368	Frontal executive function and the bladder: A study of dementia with Lewy bodies. <i>Neurology and Clinical Neuroscience</i> , 2019, 7, 22-25.	0.4	2
1369	Physiologically-based pharmacokinetic modeling for mirabegron: a multi-elimination pathway mediated by cytochrome P450 3A4, uridine 5'-diphosphate-glucuronosyltransferase 2B7, and butyrylcholinesterase. <i>Xenobiotica</i> , 2019, 49, 912-921.	1.1	6
1370	A prospective randomized clinical trial comparing two doses of AbobotulinumtoxinA for idiopathic overactive bladder. <i>Neurourology and Urodynamics</i> , 2019, 38, 660-667.	1.5	4
1371	Costâ€™effectiveness of overactive bladder treatments: from the US payer perspective. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 61-71.	1.4	25
1372	Pharmacological characterization of DA-8010, a novel muscarinic receptor antagonist selective for urinary bladder over salivary gland. <i>European Journal of Pharmacology</i> , 2019, 843, 240-250.	3.5	11
1373	Risk of Psychiatric Disorders in Overactive Bladder Syndrome: A Nationwide Cohort Study in Taiwan. <i>Journal of Investigative Medicine</i> , 2019, 67, 312-318.	1.6	15
1374	National and International Guidelines for Overactive Bladder. , 2019, , 67-83.		0

#	ARTICLE	IF	CITATIONS
1376	Antimuscarinic use and discontinuation in an older adult population. Archives of Gerontology and Geriatrics, 2019, 80, 1-11.	3.0	12
1377	Prevalence of overactive bladder in China, Taiwan and South Korea: Results from a cross-sectional, population-based study. LUTS: Lower Urinary Tract Symptoms, 2019, 11, 48-55.	1.3	74
1378	Safety and effectiveness of mirabegron in patients with overactive bladder aged ≥75 years: Analysis of a Japanese post-marketing study. LUTS: Lower Urinary Tract Symptoms, 2019, 11, 30-38.	1.3	17
1379	Associations Between Risk Factors and Overactive Bladder: A Meta-analysis. Female Pelvic Medicine and Reconstructive Surgery, 2019, 25, 238-246.	1.1	31
1380	Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases. LUTS: Lower Urinary Tract Symptoms, 2019, 11, O53-O58.	1.3	19
1381	Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?. International Urogynecology Journal, 2019, 30, 239-244.	1.4	5
1382	Urinary tract infection and drug-resistant urinary tract infection after intradetrusor onabotulinumtoxinA injection versus sacral neuromodulation. International Urogynecology Journal, 2020, 31, 871-879.	1.4	6
1383	Prevalence and clinical characteristics of overactive bladder in systemic sclerosis. Modern Rheumatology, 2020, 30, 327-331.	1.8	4
1384	Overactive Bladder Syndrome Treatments and Their Effect on Female Sexual Function: A Review. Sexual Medicine, 2020, 8, 1-7.	1.6	7
1385	Efficacy, safety, and tolerability of mirabegron in patients aged ≥65 yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). European Urology, 2020, 77, 211-220.	1.9	50
1386	Consideration of pelvic floor myofascial release for overactive bladder. Journal of Bodywork and Movement Therapies, 2020, 24, 144-150.	1.2	3
1387	Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson's disease. World Journal of Urology, 2020, 38, 2013-2019.	2.2	16
1388	Impact of sex, androgens, and prostate size on C57BL/6J mouse urinary physiology: urethral histology. American Journal of Physiology - Renal Physiology, 2020, 318, F617-F627.	2.7	3
1389	Effect of mirabegron on erectile function in sexually active men with bothersome overactive bladder symptoms. Journal of the Chinese Medical Association, 2020, 83, 55-59.	1.4	4
1390	Urinary Incontinence in Older Adults. American Journal of Nursing, 2020, 120, 57-62.	0.4	8
1391	Use of Ultrasound Urodynamics to Identify Differences in Bladder Shape Between Individuals With and Without Overactive Bladder. Female Pelvic Medicine and Reconstructive Surgery, 2020, 26, 635-639.	1.1	11
1392	A Preliminary Study on the Impact of Detrusor Overactivity on the Efficacy of Selective Bladder Denervation for the Treatment of Female Refractory Overactive Bladder. Urology, 2020, 136, 88-94.	1.0	1
1393	Beyond the bladder: poor sleep in women with overactive bladder syndrome. American Journal of Obstetrics and Gynecology, 2020, 222, 600.e1-600.e13.	1.3	6

#	ARTICLE	IF	CITATIONS
1394	Prevalence and risk factors of overactive bladder in Chinese children: A population-based study. <i>Neurourology and Urodynamics</i> , 2020, 39, 688-694.	1.5	17
1395	A mobile telehealth program for behavioral treatment of urinary incontinence in women veterans: Development and pilot evaluation of MyHealth <i><i>e</i></i> Bladder. <i>Neurourology and Urodynamics</i> , 2020, 39, 432-439.	1.5	20
1396	Association between urinary urgency and falls among rural dwelling older women. <i>Journal of Advanced Nursing</i> , 2020, 76, 846-855.	3.3	2
1399	Optimizing Nonsurgical Treatments of Overactive Bladder in the United States. <i>Urology</i> , 2020, 145, 52-59.	1.0	2
1400	Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patientsâ€œâ€œ¥â€œ%65Âyears with Overactive Bladder-Wet. <i>Drugs and Aging</i> , 2020, 37, 665-676.	1.0	14
1401	O-1602, an Agonist of Atypical Cannabinoid Receptors GPR55, Reverses the Symptoms of Depression and Detrusor Overactivity in Rats Subjected to Corticosterone Treatment. <i>Frontiers in Pharmacology</i> , 2020, 11, 1002.	3.5	15
1402	Protocol for a multicenter randomized, double blind, controlled pilot trial of higher neural function in overactive bladder patients after anticholinergic, beta-3 adrenergic agonist, or placebo. <i>Contemporary Clinical Trials Communications</i> , 2020, 19, 100621.	1.1	2
1404	Are Beta 3 Adrenergic Agonists Now the Preferred Pharmacologic Management of Overactive Bladder?. <i>Current Urology Reports</i> , 2020, 21, 49.	2.2	10
1405	Impact of Cold Indoor Temperatures on Overactive Bladder: A Nationwide Epidemiological Study in Japan. <i>Urology</i> , 2020, 145, 60-65.	1.0	3
1406	Evaluation and treatment of urinary incontinence in the aging male. <i>Postgraduate Medicine</i> , 2020, 132, 9-17.	2.0	7
1407	Increased Healthcare Resource Utilization and Direct and Indirect Costs in Patients with Depression and Comorbid Overactive Bladder: Evidence From a Retrospective, Matched Caseâ€œControl Cohort Analysis. <i>Advances in Therapy</i> , 2020, 37, 4599-4613.	2.9	2
1408	<p>Insights into the Management of Overactive Bladder with Transdermal Oxybutynin: A Practical Review</p>. <i>Research and Reports in Urology</i> , 2020, Volume 12, 321-330.	1.0	5
1409	Impact of smoking habit on overactive bladder symptoms and incontinence in women. <i>International Journal of Urology</i> , 2020, 27, 1078-1086.	1.0	15
1410	Cognitive behavioral therapy for overactive bladder in women: study protocol for a randomized controlled trial. <i>BMC Urology</i> , 2020, 20, 129.	1.4	8
1411	Treatment of Overactive Bladder in the Frail Patient. <i>Current Bladder Dysfunction Reports</i> , 2020, 15, 386-392.	0.5	0
1413	Undertreatment of overactive bladder among men with lower urinary tract symptoms in the United States: A retrospective observational study. <i>Neurourology and Urodynamics</i> , 2020, 39, 1378-1386.	1.5	8
1414	Racial and Socioeconomic Factors Influence Utilization of Advanced Therapies in Commercially Insured OAB Patients: An Analysis of Over 800,000 OAB Patients. <i>Urology</i> , 2020, 142, 81-86.	1.0	18
1415	Does age alone negatively predict the outcome of sacral neuromodulation? A single-centre retrospective observational study. <i>BMC Urology</i> , 2020, 20, 55.	1.4	5

#	ARTICLE	IF	CITATIONS
1416	Tibial nerve stimulation in the treatment of overactive bladder syndrome: technical features of latest applications. <i>Current Opinion in Urology</i> , 2020, 30, 513-518.	1.8	10
1417	The clinical pharmacology of the medical treatment for overactive bladder in adults. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 707-720.	3.1	8
1418	Ceftriaxone inhibits stress-induced bladder hyperalgesia and alters cerebral micturition and nociceptive circuits in the rat: A multidisciplinary approach to the study of urologic chronic pelvic pain syndrome—research network study. <i>Neurourology and Urodynamics</i> , 2020, 39, 1628-1643.	1.5	7
1419	Overactive Bladder in Frail Older Adults. <i>Drugs and Aging</i> , 2020, 37, 559-565.	2.7	12
1420	Hand cleaning with ash for reducing the spread of viral and bacterial infections: a rapid review. <i>The Cochrane Library</i> , 0, , .	2.8	9
1421	Re:Shi H, Chen H, Zhang Y, Cui Y. The efficacy and safety of Vibegron in treating overactive bladder: A systematic review and pooled analysis of randomized controlled trials. <i>Neurourology and Urodynamics</i> . 2020. <i>Neurourology and Urodynamics</i> , 2020, 39, 1904-1905.	1.5	0
1422	Vibegron 50Âmg is the optimal algorithm in the pharmacologic management of overactive bladder: outcomes from a systematic review and meta-analysis. <i>International Urology and Nephrology</i> , 2020, 52, 2215-2221.	1.4	4
1423	Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR). <i>BMC Geriatrics</i> , 2020, 20, 109.	2.7	45
1424	The Effect of a Sharp Increase in Estrogen Levels on Overactive Bladder Symptoms in Women Undergoing Ovulation Induction. <i>Urology</i> , 2020, 140, 34-37.	1.0	1
1425	A Novel Alternative in the Treatment of Detrusor Overactivity? In Vivo Activity of O-1602, the Newly Synthesized Agonist of GPR55 and GPR18 Cannabinoid Receptors. <i>Molecules</i> , 2020, 25, 1384.	3.8	12
1426	22. Neuropelveology—“the medicine of the pathologies of the pelvic nerves and plexuses.”, 2020, , 247-254.		0
1427	Brain functional network alterations caused by a strong desire to void in healthy adults: a graph theory analysis study. <i>Neurourology and Urodynamics</i> , 2020, 39, 1966-1976.	1.5	3
1428	Medium-term outcomes of sacral neuromodulation in patients with refractory overactive bladder: A retrospective single-institution study. <i>PLoS ONE</i> , 2020, 15, e0235961.	2.5	9
1429	The Brain and the Bladder: Forebrain Control of Urinary (In)Continence. <i>Frontiers in Physiology</i> , 2020, 11, 658.	2.8	22
1430	EDITORIAL COMMENT. <i>Urology</i> , 2020, 136, 93-94.	1.0	0
1431	A randomized, controlled trial of transcutaneous tibial nerve stimulation to treat overactive bladder and neurogenic bladder patients. <i>Canadian Urological Association Journal</i> , 2020, 14, E297-E303.	0.6	12
1432	Current management of refractory overactive bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2020, 12, 109-116.	1.3	11
1433	8 versus 12Âweeks of percutaneous tibial nerve stimulation and response predictors for overactive bladder. <i>International Urogynecology Journal</i> , 2020, 31, 905-914.	1.4	8

#	ARTICLE	IF	CITATIONS
1434	OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single-dose treatment from a phase III, randomized, double-blind, placebo-controlled trial (interim analysis). <i>International Journal of Urology</i> , 2020, 27, 227-234.	1.0	22
1435	Risk factors for mild depression in older women with overactive bladder syndrome—A cross sectional study. <i>PLoS ONE</i> , 2020, 15, e0227415.	2.5	7
1436	Female Pelvic Surgery. , 2020, , .		0
1437	Effectiveness of Combined Behavioral and Drug Therapy for Overactive Bladder Symptoms in Men. <i>JAMA Internal Medicine</i> , 2020, 180, 411.	5.1	41
1438	Overactive Bladder in Women: an Update for Primary Care Physicians. <i>Current Bladder Dysfunction Reports</i> , 2020, 15, 44-52.	0.5	0
1439	Meta-Analysis of Randomized Controlled Trials Using Botulinum Toxin A at Different Dosages for Urinary Incontinence in Patients With Overactive Bladder. <i>Frontiers in Pharmacology</i> , 2019, 10, 1618.	3.5	14
1440	Management of Patients with Overactive Bladder in Brazil: A Retrospective Observational Study Using Data From the Brazilian Public Health System. <i>Advances in Therapy</i> , 2020, 37, 2344-2355.	2.9	5
1442	Impact of OAB symptoms on work, quality of life and treatment-seeking behavior in Brazil. <i>Current Medical Research and Opinion</i> , 2020, 36, 1403-1415.	1.9	11
1443	Is imidafenacin an alternative to current antimuscarinic drugs for patients with overactive bladder syndrome?. <i>International Urogynecology Journal</i> , 2021, 32, 1117-1127.	1.4	9
1444	Percutaneous tibial nerve stimulation maintenance therapy for overactive bladder in women: long-term success rates and adherence. <i>International Urogynecology Journal</i> , 2021, 32, 617-625.	1.4	8
1445	Treatment for refractory overactive bladder: a systematic review and meta-analysis of sacral neuromodulation and onabotulinumtoxinA. <i>International Urogynecology Journal</i> , 2021, 32, 477-484.	1.4	9
1446	Inhibitory effects of a minimally invasive implanted tibial nerve stimulation device on non-nociceptive bladder reflexes in cats. <i>International Urology and Nephrology</i> , 2021, 53, 431-438.	1.4	2
1447	The Correlation between Severity of Overactive Bladder Symptoms with Female Sexual Dysfunction and Sexual Satisfaction of Partners. <i>Urologia Internationalis</i> , 2021, 105, 124-130.	1.3	7
1448	A retrospective longitudinal evaluation of new overactive bladder patients in an FPMRS urologist practice: Are patients following up and utilizing third-line therapies?. <i>Neurourology and Urodynamics</i> , 2021, 40, 391-396.	1.5	7
1449	Which drugs are best for overactive bladder? From patients' expectations to physicians' decisions. <i>International Journal of Clinical Practice</i> , 2021, 75, e13870.	1.7	3
1450	Identification and Characterization of a Novel Large-Conductance Calcium-Activated Potassium Channel Activator, CTIBD, and Its Relaxation Effect on Urinary Bladder Smooth Muscle. <i>Molecular Pharmacology</i> , 2021, 99, 114-124.	2.3	2
1451	Overactive bladder syndrome – focus onto detrusor overactivity. <i>Scandinavian Journal of Urology</i> , 2021, 55, 56-60.	1.0	5
1452	Long-term outcomes of sacral neuromodulation for lower urinary tract dysfunction: A 23-year experience. <i>Neurourology and Urodynamics</i> , 2021, 40, 461-469.	1.5	10

#	ARTICLE	IF	CITATIONS
1453	Shifting the treatment paradigm in idiopathic overactive bladder. International Journal of Clinical Practice, 2021, 75, e13847.	1.7	4
1454	The impact of overactive bladder on health-related quality of life in Korea: based on the results of a Korean Community Health Survey. Quality of Life Research, 2021, 30, 1017-1024.	3.1	3
1455	Lower urinary tract symptoms in older Chinese American women: prevalence and risk factors. International Urogynecology Journal, 2021, 32, 703-708.	1.4	3
1456	Bladder Outlet Obstruction and Overactive Bladder in Males. Urodynamics, Neurourology and Pelvic Floor Dysfunctions, 2021, , 67-85.	0.0	1
1457	¿Es más efectivo el tratamiento combinado de electroestimulación transcutánea del nervio tibial y electroestimulación vaginal que el tratamiento en monoterapia de electroestimulación del nervio tibial para la vejiga hiperactiva? Un ensayo controlado aleatorizado. Actas Urológicas Españolas, 2021, 45, 64-72.	0.7	9
1458	Promoting patient followup treatment with intra-detrusor onabotulinumtoxinA. Canadian Urological Association Journal, 2021, 15, E405-E411.	0.6	0
1459	Is the addition of vaginal electrical stimulation to transcutaneous tibial nerve electrical stimulation more effective for overactive bladder treatment? A randomized controlled trial. Actas Urológicas Españolas (English Edition), 2021, 45, 64-72.	0.2	2
1460	The First Injection: Rates of Urinary Retention in Women With Urgency Incontinence Treated With Intravesical OnabotulinumtoxinA Injection. Female Pelvic Medicine and Reconstructive Surgery, 2021, 27, e118-e121.	1.1	1
1461	Bladder Outlet Obstruction and Overactive Bladder in Females. Urodynamics, Neurourology and Pelvic Floor Dysfunctions, 2021, , 53-65.	0.0	0
1462	Persistence in Percutaneous Tibial Nerve Stimulation Treatment for Overactive Bladder Syndrome is Best Predicted by Patient Global Impression of Improvement Rather Than Symptom-Specific Improvement. Urology, 2021, 148, 93-99.	1.0	3
1463	Clinical Consensus Statement: Association of Anticholinergic Medication Use and Cognition in Women With Overactive Bladder. Female Pelvic Medicine and Reconstructive Surgery, 2021, 27, 69-71.	1.1	21
1464	Antibiotic regimen and route of administration do not alter rates of urinary tract infection after intravesical botulinum toxin injection for overactive bladder. International Urogynecology Journal, 2022, 33, 703-709.	1.4	6
1465	Efficacy of salt reduction for managing overactive bladder symptoms: a prospective study in patients with excessive daily salt intake. Scientific Reports, 2021, 11, 4046.	3.3	3
1466	Cognitive components of behavioral therapy for overactive bladder: a systematic review. International Urogynecology Journal, 2021, 32, 2619-2629.	1.4	7
1467	Efficacy of Daily Intake of Dried Cranberry 500 mg in Women with Overactive Bladder: A Randomized, Double-Blind, Placebo Controlled Study. Journal of Urology, 2021, 205, 507-513.	0.4	2
1468	Can We Rely Solely on the International Prostate Symptoms Score to Investigate Storage Symptoms in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Enlargement? Findings from a Cross-sectional Study. European Urology Focus, 2021, , .	3.1	0
1469	Overactive Bladder Prescribing Considerations: The Role of Polypharmacy, Anticholinergic Burden, and CYP2D6 Drug-Drug Interactions. Clinical Drug Investigation, 2021, 41, 293-302.	2.2	12
1470	Anticholinergic prescribing pattern changes of urogynecology providers in response to evidence of potential dementia risk. International Urogynecology Journal, 2021, 32, 2819-2826.	1.4	13

#	ARTICLE	IF	CITATIONS
1471	Social media analytics of overactive bladder posts: what do patients know and want to know?. International Urogynecology Journal, 2021, 32, 2729-2736.	1.4	7
1472	Placebo Response in Patients with Oral Therapy for Overactive Bladder: A Systematic Review and Meta-analysis. European Urology Focus, 2022, 8, 239-252.	3.1	12
1473	Clustering of patients with overactive bladder syndrome. BMC Urology, 2021, 21, 41.	1.4	4
1474	The Effect of Symptomatic Stress Urinary Incontinence on Catheterization Rates After Intradetrusor OnabotulinumtoxinA Injections. Female Pelvic Medicine and Reconstructive Surgery, 2021, Publish Ahead of Print, 676-680.	1.1	1
1475	Validation of the Arabic linguistic version of the International Consultation on Incontinence Questionnaire-overactive bladder (ICIQ-OAB). African Journal of Urology, 2021, 27, .	0.4	3
1476	Outcomes of a single trigone-only vs. 20 trigone-sparing injections of OnabotulinumtoxinA for refractory overactive bladder (OAB). International Urology and Nephrology, 2021, 53, 1067-1072.	1.4	4
1477	Basic Evaluation of Urinary Incontinence. Clinical Obstetrics and Gynecology, 2021, 64, 276-286.	1.1	0
1478	Twelve-month Durability of a Fully-implanted, Nickel-sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence: A Single-Arm, Prospective Study. Urology, 2021, 157, 71-78.	1.0	4
1479	Effects of overactive bladder syndrome on female sexual function. Medicine (United States), 2021, 100, e25761.	1.0	7
1480	Treatment Response of Botulinum-A Toxin Intradetrusor Injections for Overactive Bladder (OAB) and Neurological Detrusor Overactivity (NDO) Refractory to Anticholinergics and Beta3-Adrenoceptor Agonists. Journal of Pharmaceutical Research International, 0, , 231-238.	1.0	0
1481	Dissatisfaction with school toilets is associated with bladder and bowel dysfunction. European Journal of Pediatrics, 2021, 180, 3317-3324.	2.7	6
1482	Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study. Current Medical Research and Opinion, 2021, 37, 1303-1313.	1.9	3
1483	Review of the rechargeable sacral neuromodulation system to treat refractory overactive bladder. Therapeutic Delivery, 2021, 12, 353-362.	2.2	0
1484	Efficacy and safety of desmopressin on frequency and urgency in female patients with overactive bladder and nocturia, current clinical features and outcomes: A systematic review. Asian Journal of Urology, 2021, 9, 27-34.	1.2	2
1485	Epidemiologic Study of Female Urinary Incontinence in South Khorasan, Iran. Journal of Obstetrics, Gynecology and Cancer Research, 2021, 6, 134-142.	0.1	0
1486	Sexual Function Before and After Mid-Urethral Sling Procedure for Stress Urinary Incontinence. Journal of Obstetrics and Gynecology of India, 2021, 71, 609-614.	0.9	1
1488	Cost-Effectiveness Analysis Between Sacral Neuromodulation and OnabotulinumtoxinA for the Treatment of Refractory Overactive Bladder in Women: A Systematic Review. Female Pelvic Medicine and Reconstructive Surgery, 2021, 27, 481-487.	1.1	0
1489	The effects of simulated childbirth trauma on the gene expression of neurotransmitter receptors in the bladder of female rats. Journal of the Formosan Medical Association, 2021, 120, 1305-1313.	1.7	2

#	ARTICLE	IF	CITATIONS
1490	Gene Therapy for Overactive Bladder: A Review of BK-Channel α -Subunit Gene Transfer. Therapeutics and Clinical Risk Management, 2021, Volume 17, 589-599.	2.0	11
1491	Placement of a coin-sized implantable tibial neurostimulator (eCoin device) for urgency urinary incontinence. Urology Video Journal, 2021, 10, 100079.	0.2	0
1492	Do we need more patient-friendly treatment options for overactive bladder (OAB)?. Neurourology and Urodynamics, 2021, 40, 1433-1440.	1.5	1
1493	Effectiveness and safety of tibial nerve stimulation versus anticholinergic drugs for the treatment of overactive bladder syndrome: a meta-analysis. Annals of Palliative Medicine, 2021, 10, 6287-6296.	1.2	2
1494	Effect of systemic atherosclerosis on overactive bladder symptoms in men with benign prostatic hyperplasia. LUTS: Lower Urinary Tract Symptoms, 2022, 14, 35-40.	1.3	2
1495	Factors Associated With Long-Term Use of Percutaneous Tibial Nerve Stimulation for Management of Overactive Bladder Syndrome. Female Pelvic Medicine and Reconstructive Surgery, 2021, 27, 444-449.	1.1	5
1496	Axonics® system for treatment of overactive bladder syndrome and urinary urgency incontinence. Expert Review of Medical Devices, 2021, 18, 727-732.	2.8	1
1497	Sleep Quality and Fatigue in Women with Overactive Bladder: A Case-Control Study. Shiraz E Medical Journal, 2021, 22, .	0.3	0
1498	Inhibition of LIM kinase reduces contraction and proliferation in bladder smooth muscle. Acta Pharmaceutica Sinica B, 2021, 11, 1914-1930.	12.0	8
1499	Treatment of overactive bladder symptoms in women with Diurnorm®: preliminary results report. Urology Herald, 2021, 9, 100-110.	0.4	0
1500	NMDAR in bladder smooth muscle is not a pharmacotherapy target for overactive bladder in mice. PeerJ, 2021, 9, e11684.	2.0	2
1501	Efficacy of Yun-Type Optimized Pelvic Floor Training Therapy for Middle-Aged Women With Severe Overactive Bladder: A Randomized Clinical Trial. Frontiers in Surgery, 2021, 8, 670123.	1.4	2
1502	Hip and Pelvic Floor Muscle Strength in Women With and Without Urgency and Frequency-Predominant Lower Urinary Tract Symptoms. Journal of Women's Health Physical Therapy, 2021, 45, 126-134.	0.8	7
1503	A systematic review of neurocognitive dysfunction with overactive bladder medications. International Urogynecology Journal, 2021, 32, 2693-2702.	1.4	20
1504	Real-world Compliance With Percutaneous Tibial Nerve Stimulation Maintenance Therapy in an American Population. Urology, 2021, 153, 119-123.	1.0	9
1505	Early and Consistent Improvements in Urinary Symptoms and Quality of Life With OnabotulinumtoxinA in Patients With Overactive Bladder and Urinary Incontinence: Results From a Randomized, Placebo-controlled, Phase IV Clinical Trial. Female Pelvic Medicine and Reconstructive Surgery, 2021, 27, 450-456.	1.1	5
1506	Forward-Looking Ultrasound Wearable Scanner System for Estimation of Urinary Bladder Volume. Sensors, 2021, 21, 5445.	3.8	8
1507	Intravaginal 6.5Âmg prasterone administration in postmenopausal women with overactive bladder syndrome: A pilot study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 263, 67-71.	1.1	8

#	ARTICLE	IF	CITATIONS
1508	Anticholinergic Burden and Associated Healthcare Resource Utilization in Older Adults with Overactive Bladder. <i>Drugs and Aging</i> , 2021, 38, 911-920.	2.7	3
1509	Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review. <i>Current Urology</i> , 2021, 15, 153-160.	0.6	2
1510	Prevalence and trends in urinary incontinence among women in the United States, 2005â€“2018. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 166.e1-166.e12.	1.3	79
1511	Six-Month Outcomes of Reimplantation of a Coin-Sized Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome With Urgency Urinary Incontinence. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2022, 28, 287-292.	1.1	4
1512	Epidemiology of Frequent/Urgent Urination in Older Adults in China: A Multicenter, Cross-Sectional Study. <i>Frontiers in Public Health</i> , 2021, 9, 669070.	2.7	6
1513	Overactive Bladder: Where We Are and Where We Are Going. <i>Soci�t� Internationale D'urologie Journal</i> , 2021, , 311-322.	0.4	0
1514	Potential Targets for Overactive Bladder in Older Men Based on Urinary Analysis of Metabolomics. <i>Urologia Internationalis</i> , 2021, , 1-7.	1.3	0
1515	Chronic Urinary Infection in Overactive Bladder Syndrome: A Prospective, Blinded Case Control Study. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 752275.	3.9	4
1516	Beta 3 Adrenoreceptor Agonist for the Management of Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia: A Systematic Review. <i>International Neurourology Journal</i> , 2021, 25, 182-191.	1.2	5
1517	Urine-incontinentie. , 2021, , 477-490.		0
1518	Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged �65 and �75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study. <i>Drugs and Aging</i> , 2021, 38, 137-146.	2.7	17
1519	Effects of different urodynamic characteristics on therapeutic outcomes of overactive bladder medication in a real-life clinical practice. <i>Tzu Chi Medical Journal</i> , 2022, 34, 441.	1.1	3
1520	Survey on disease insight and prevalence of urinary incontinence in women. <i>Investigative and Clinical Urology</i> , 2021, 62, 577.	2.0	4
1521	Evaluating the safety and potential activity of UR0�02 (hMaxia�) gene transfer by intravesical instillation or direct injection into the bladder wall in female participants with idiopathic (non�neurogenic) overactive bladder syndrome and detrusor overactivity from two double�blind, imbalanced, placebo�controlled randomized phase 1 trials. <i>Neurourology and Urodynamics</i> , 2020, 39, 744-753.	1.5	25
1522	Nocturia and Overactive Bladder. , 2012, , 109-114.		1
1523	The Biology of Aging and the Development of Lower Urinary Tract Dysfunction and Disease. , 2014, , 13-35.		2
1524	Neural Prostheses for Neurotrauma. , 2016, , 457-478.		1
1525	Diagnosing Incontinence and Pelvic Floor Problems: An Efficient, Cost-Effective Approach for Primary Care Providers. , 2007, , 40-59.		1

#	ARTICLE	IF	CITATIONS
1526	A comparison of antibiotic prophylaxis regimens to decrease the risk of post-procedure urinary tract infection after onabotulinum toxin A injection. International Urogynecology Journal, 2020, 31, 1907-1912.	1.4	11
1527	Overactive Bladder. , 2012, , 1947-1957.e2.		5
1528	Evaluation and Nonsurgical Management of Benign Prostatic Hyperplasia. , 2012, , 2611-2654.e8.		17
1529	Cost-Effectiveness of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: Results of the ROSETTA Randomized Trial. Journal of Urology, 2020, 203, 969-977.	0.4	26
1530	Etiology and Treatment of Overactive Bladder in Women. Southern Medical Journal, 2011, 104, 34-39.	0.7	9
1531	Lower urinary tract symptoms, nocturia and overactive bladder in patients with depression and anxiety. Psychiatria Polska, 2016, 50, 417-430.	0.5	40
1532	Survey on prevalence of lower urinary tract symptoms in an Asian population. Hong Kong Medical Journal, 2019, 25, 13-20.	0.1	7
1533	Medical Attendance for Lower Urinary Tract Symptoms Is Associated with Subsequent Increased Risk of Outpatient Visits and Hospitalizations Based on a Nationwide Population-Based Database. PLoS ONE, 2013, 8, e57825.	2.5	10
1534	Developing an Internationally-Applicable Service Specification for Continence Care: Systematic Review, Evidence Synthesis and Expert Consensus. PLoS ONE, 2014, 9, e104129.	2.5	24
1535	Urinary Nerve Growth Factor Could Be a Biomarker for Interstitial Cystitis/Painful Bladder Syndrome: A Meta-Analysis. PLoS ONE, 2014, 9, e106321.	2.5	22
1536	Analysis of the prevalence and associated factors of overactive bladder in adult Korean men. PLoS ONE, 2017, 12, e0175641.	2.5	14
1537	Analysis of the prevalence of and factors associated with overactive bladder in adult Korean women. PLoS ONE, 2017, 12, e0185592.	2.5	13
1538	THE EFFICACY OF FRACTIONAL CO2 LASER TREATMENT FOR THE TREATMENT OF OVERACTIVE BLADDER SYNDROME IN MENOPAUSAL WOMEN- A THREE MONTH PILOT STUDY. Journal of Evolution of Medical and Dental Sciences, 2018, 7, 5440-5446.	0.1	1
1539	A Study on Korean Medical Clinical Management of Female Overactive Bladder. The Journal of Korean Obstetrics and Gynecology, 2014, 27, 83-102.	0.4	4
1540	Comparison effects of solifenacin, darifenacin, propiverine on ocular parameters in eyes: A prospective study. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2020, 46, 185-193.	1.5	5
1541	Attenuated BK channel function promotes overactive bladder in a rat model of obesity. Aging, 2019, 11, 6199-6216.	3.1	6
1542	A systematic review and meta-analysis of effectiveness and safety of therapy for overactive bladder using botulinum toxin A at different dosages. Oncotarget, 2017, 8, 90338-90350.	1.8	11
1543	Activation of bitter taste receptors (tas2rs) relaxes detrusor smooth muscle and suppresses overactive bladder symptoms. Oncotarget, 2016, 7, 21156-21167.	1.8	25

#	ARTICLE	IF	CITATIONS
1544	Baseline patient reported outcomes data shows high prevalence of overactive bladder, sexual dysfunction, depression and anxiety in Canadian men with newly diagnosed localized prostate cancer. Translational Andrology and Urology, 2020, 9, 2046-2053.	1.4	6
1545	Transdermal oxybutynin in the treatment of overactive bladder. Clinical Interventions in Aging, 2006, 1, 99-105.	2.9	9
1546	Treatment of overactive bladder in the aging population: focus on darifenacin. Clinical Interventions in Aging, 2006, 1, 309-316.	2.9	6
1547	Antimuscarinic Treatment in Overactive Bladder. Drugs and Aging, 2012, 29, 539-548.	2.7	1
1548	Quality of Life in Patients with Overactive Bladder. Clinical Drug Investigation, 2012, 32, 523-532.	2.2	18
1549	Effect of Anticholinergic Use for the Treatment of Overactive Bladder on Cognitive Function in Postmenopausal Women. Clinical Drug Investigation, 2012, 32, 1.	2.2	12
1550	Bladder ultrasonography for diagnosing detrusor overactivity: test accuracy study and economic evaluation. Health Technology Assessment, 2016, 20, 1-150.	2.8	25
1551	Changing practice in dementia care in the community: developing and testing evidence-based interventions, from timely diagnosis to end of life (EVIDEM). Programme Grants for Applied Research, 2015, 3, 1-596.	1.0	28
1552	Overactive bladder: evaluation and management in primary care.. Cleveland Clinic Journal of Medicine, 2005, 72, 149-156.	1.3	13
1553	Overactive bladder: recognition requires vigilance for symptoms.. Cleveland Clinic Journal of Medicine, 2007, 74, S21-S21.	1.3	17
1554	Correlation between Overactive Bladder Syndrome and Obsessive Compulsive Disorder in Women. Korean Journal of Family Medicine, 2016, 37, 25.	1.2	13
1555	What is the prevalence of overactive bladder symptoms in a lower socioeconomic female population? A suggestion for a study in India. Indian Journal of Urology, 2007, 23, 192.	0.6	2
1556	Efficacy of interferential low frequency therapy for elderly wet overactive bladder patients. Indian Journal of Urology, 2008, 24, 178.	0.6	8
1557	Role of botulinum toxin-A in management of refractory idiopathic detrusor overactive bladder: Single center experience. Indian Journal of Urology, 2008, 24, 182.	0.6	5
1558	The surgical management of the refractory overactive bladder. Indian Journal of Urology, 2010, 26, 263.	0.6	4
1559	Medical management of overactive bladder. Indian Journal of Urology, 2010, 26, 270.	0.6	12
1560	Overactive Bladder. Korean Journal of Urology, 2007, 48, 1191.	0.2	16
1561	Expression of Large Conductance, Voltage- and Ca ²⁺ -Activated K ⁺ (BK) Channels in Human Urinary Bladder: Alteration of Subunit Expression Profile in Association with Bladder Outlet Obstruction. Open Journal of Urology, 2013, 03, 47-52.	0.1	1

#	ARTICLE	IF	CITATIONS
1562	Effect of sacrocolpopexy and retropubic sling on overactive bladder symptoms. Journal of the Turkish German Gynecology Association, 2017, 18, 9-14.	0.6	6
1563	Constitution and Validation of a New Symptom Assessment Tool for Overactive Bladder: Marmara Overactive Bladder Questionnaire (M-OBQ). Journal of Urological Surgery, 2014, 1, 24-27.	0.1	1
1566	Role of percutaneous posterior tibial nerve stimulation either alone or combined with an anticholinergic agent in treating patients with overactive bladder. Turkish Journal of Urology, 2015, 41, 208-214.	1.3	12
1567	The attitudes of Urologists and Gynecologists about overactive bladder and treatment of it in Turkey: A questionnaire survey. Turkish Journal of Urology, 2017, 43, 68-74.	1.3	6
1568	Assessment of Proportion of Hidden Patients Having Symptoms of Overactive Bladder and Why Has It Been Hidden in Female Outpatients Admitted to Hospital. International Neurourology Journal, 2006, 20, 47-52.	1.2	4
1569	Overview of the Epidemiology of Lower Urinary Tract Dysfunction in South Korea. International Neurourology Journal, 2016, 20, 91-100.	1.2	13
1570	Association Between Overactive Bladder and Polyneuropathy in Diabetic Patients. International Neurourology Journal, 2016, 20, 232-239.	1.2	7
1571	Sacral Neuromodulation in Patients With a Cardiac Pacemaker. International Neurourology Journal, 2016, 20, 270-272.	1.2	6
1572	Evaluation of Overactive Bladder in Male Antidepressant Users: A Prospective Study. International Neurourology Journal, 2017, 21, 62-67.	1.2	6
1573	Potential Biomarkers for Diagnosis of Overactive Bladder Patients: Urinary Nerve Growth Factor, Prostaglandin E2, and Adenosine Triphosphate. International Neurourology Journal, 2017, 21, 171-177.	1.2	12
1574	Urinary Nerve Growth Factor as a Potential Biomarker of Treatment Outcomes in Overactive Bladder Patients. International Neurourology Journal, 2017, 21, 270-281.	1.2	10
1575	Is There Any Difference Between Depression and Anxiety in Overactive Bladder According to Sex? A Systematic Review and Meta-Analysis. International Neurourology Journal, 2017, 21, 204-211.	1.2	17
1576	Urodynamic and Bladder Diary Factors Predict Overactive Bladder-wet in Women: A Comparison With Overactive Bladder-dry. International Neurourology Journal, 2019, 23, 69-74.	1.2	18
1577	Korean Translation and Linguistic Validation of Urgency and Overactive Bladder Questionnaires. International Neurourology Journal, 2020, 24, 66-76.	1.2	6
1578	The Influence of an Overactive Bladder on Falling: A Study of Females Aged 40 and Older in the Community. International Neurourology Journal, 2011, 15, 41.	1.2	20
1579	The Impact of Overactive Bladder on Health-Related Quality of Life, Sexual Life and Psychological Health in Korea. International Neurourology Journal, 2011, 15, 143-151.	1.2	41
1580	Socioeconomic Costs of Overactive Bladder and Stress Urinary Incontinence in Korea. International Neurourology Journal, 2012, 16, 23.	1.2	12
1581	Psychometric Properties of the Korean Version of the Overactive Bladder Questionnaire (OAB-q) in a Korean Population. International Neurourology Journal, 2012, 16, 77.	1.2	14

#	ARTICLE	IF	CITATIONS
1582	Relationship between Body Mass Index and Overactive Bladder in Women and Correlations with Urodynamic Evaluation. International Neurourology Journal, 2012, 16, 126.	1.2	16
1583	Effect of Long-term Exercise on Voiding Functions in Obese Elderly Women. International Neurourology Journal, 2013, 17, 130.	1.2	16
1584	Population-Based Survey on Disease Insight, Quality of Life, and Health-Seeking Behavior Associated With Female Urinary Incontinence. International Neurourology Journal, 2015, 19, 39-46.	1.2	19
1585	Cognitive Function and Urologic Medications for Lower Urinary Tract Symptoms. International Neurourology Journal, 2020, 24, 231-240.	1.2	16
1586	A multicenter cross-sectional study on the prevalence of overactive bladder and its impacts on the quality of life in gynecologic outpatients. Obstetrics and Gynecology Science, 2020, 63, 181-186.	1.6	4
1587	Patients with medication-refractory OAB symptoms should be further treated with neuromodulation. Canadian Urological Association Journal, 2011, 5, 283-284.	0.6	3
1588	Urinary Continence and Sexuality. Bal \ddot{A} kesir Sa \ddot{Y} l \ddot{A} k Bilimleri Dergisi, 2015, 4, 60-64.	0.0	4
1589	Effects of Overactive Bladder Symptoms in Stroke Patients' Health Related Quality of Life and Their Performance Scale. Annals of Rehabilitation Medicine, 2017, 41, 935.	1.6	7
1591	Sleep Disruption and Interstitial Cystitis Symptoms in Women. Urologic Nursing, 2011, 31, 159.	0.1	8
1592	Overactive bladder: A review and update. Experimental and Therapeutic Medicine, 2021, 22, 1444.	1.8	13
1593	The Microbiome's Function in Disorders of the Urinary Bladder. Applied Microbiology, 2021, 1, 445-459.	1.6	3
1594	A Systematic Review of Racial/Ethnic Disparities in Female Pelvic Floor Disorders. Urology, 2022, 163, 8-15.	1.0	19
1595	Prevalence of overactive bladder symptoms and their impact on health-related quality of life of medical and dentistry students: a multicenter cross-sectional study. BMC Urology, 2021, 21, 142.	1.4	1
1596	The patient pathway for overactive bladder management: A quantitative analysis. Neurourology and Urodynamics, 2022, 41, 290-295.	1.5	3
1597	A Scoping Review of the Economic Burden of Non-Cancerous Genitourinary Conditions. Urology, 2022, 166, 29-38.	1.0	5
1598	The Psychosocial Consequences of Prostate Cancer Treatments on Body Image, Sexuality, and Relationships. Frontiers in Psychology, 2021, 12, 765315.	2.1	4
1599	Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial. Blood Pressure Monitoring, 2022, 27, 128-134.	0.8	6
1600	Trigonal-Sparing vs. Trigonal-Involved OnabotulinumtoxinA Injection for the Treatment of Overactive Bladder: A Systematic Review and Meta-Analysis. Frontiers in Neurology, 2021, 12, 651635.	2.4	5

#	ARTICLE	IF	CITATIONS
1601	Voiding Dysfunctions in Primary Care Practices. Taehan Uihak Hyophoe Chi the Journal of the Korean Medical Association, 2005, 48, 744.	0.1	0
1602	Treatment options for the overactive bladder syndrome. Therapy: Open Access in Clinical Medicine, 2005, 2, 921-936.	0.2	0
1603	Treatment options for the overactive bladder syndrome. Therapy: Open Access in Clinical Medicine, 2005, 2, 921-936.	0.2	0
1604	Wat zijn de langetermijneffecten van botulinum toxine-A bij overactieve blaas?. , 2006, , 3315-3317.		0
1606	Overactive Bladder Syndrome and Nocturia. , 2007, , 353-376.		2
1607	The Prevalence and Risk Factors of Overactive Bladder in Korean Children: A Comparative Analysis according to Definition. Korean Journal of Urology, 2008, 49, 1131.	0.2	1
1608	Overactive Bladder. , 2008, , 246-252.		0
1609	The Different Mechanisms of Awake Micturitions between Male and Female Rats Using an Overactive Model with Intravesical PGE2 Instillation. Korean Journal of Urology, 2008, 49, 837.	0.2	0
1610	Síndrome de vejiga hiperactiva y nicturia. , 2008, , 363-385.		0
1611	Pharmacotherapy of Male Incontinence. , 2009, , 411-421.		0
1612	Pharmacotherapy of Urgency Incontinence. , 2009, , 191-201.		0
1613	Age Related Changes of Voiding Patterns in Women with Overactive Bladder. Journal of the Korean Continence Society, 2009, 13, 37.	0.1	2
1614	A Short-Term Analysis of Parameters Affecting the Outcome of Sacral Neuromodulation. Korean Journal of Urology, 2009, 50, 135.	1.2	0
1615	Alternative Therapies for Urinary Urgency Incontinence: Acupuncture and Herbology. , 2009, , 203-215.		0
1616	The Relating Factor and Quality of Life of Overactive Bladder in Adults. Korean Journal of Family Medicine, 2009, 30, 872.	1.2	3
1617	Impact of Overactive Bladder on Sexual Function in Women: A Prospective Comparison Study. Journal of the Korean Continence Society, 2009, 13, 102.	0.1	0
1618	CONSTRUCTION AND VALIDATION OF A MALAY VERSION OF THE OVERACTIVE BLADDER SCREENER FOR ASSESSING URINARY TRACT SYMPTOMS IN A MALAYSIAN POPULATION. Journal of the University of Malaya Medical Centre, 2009, 12, 74-82.	0.0	0
1619	Treatment of Overactive Bladder Symptoms with Extended Release Fesoterodine Fumarate. Clinical Medicine Reviews in Therapeutics, 0, 2, 103-113.	0.2	0

#	ARTICLE	IF	CITATIONS
1620	Aging of the Urinary Tract. , 2010, , 111-116.		0
1621	Impact of Self-Perceived Bothersomeness, Quality of Life and Overactive Bladder. , 2010, , 2195-2210.		0
1622	Farmacologia de la solifenacina. Archivos Espanoles De Urologia, 2010, 63, .	0.2	4
1623	Incontinencia de orina oculta en mujeres con prolapso genital severo, evidenciada por una prueba mAnimamente invasiva. Archivos Espanoles De Urologia, 2010, 63, .	0.2	1
1624	Solifenacina: evidencia cientÃfica en el tratamiento de la vejiga hiperactiva. Archivos Espanoles De Urologia, 2010, 63, .	0.2	5
1628	Sensory Urgency. Female Pelvic Medicine and Reconstructive Surgery, 2010, 16, 313-319.	1.1	0
1629	Overactive Bladder: An Urgent Problem. Southern Medical Journal, 2011, 104, 7-8.	0.7	1
1630	Overactive Bladder and Nocturia in Middle-Age American Women: Symptoms and Impact Are Significant. Urologic Nursing, 2011, 31, 106.	0.1	0
1631	Overactive Bladder and Idiopathic Detrusor Overactivity. , 2011, , 61-78.		0
1632	The Pathophysiology of Overactive Bladder. , 2012, , 21-39.		0
1635	Urinary Tract Disorders. , 2012, , 899-927.		1
1638	Preoperative Factors as Predictors of Outcome of Midurethral Sling in Women with Mixed Urinary Incontinence. , 0, , .		0
1639	Fesoterodine fumarate for the treatment of overactive bladder in the elderly â€“ a review of the latest clinical data. Clinical Investigation, 2012, 2, 825-833.	0.0	1
1641	Pharmacology of Detrusor Activity. , 2013, , 133-146.		0
1642	A Study on Factors Influencing Medical Treatment Decision-Making for Overactive Bladders in Female Patients over 40 - Data from Clinical Trial Participants -. The Journal of Korean Obstetrics and Gynecology, 2013, 26, 69-81.	0.4	1
1643	Overactive bladder syndrome: etiology, pathogenesis, treatment. Fiziologichnyi Zhurnal (Kiev,) Tj ETQq1 1 0.784314 rgBT /Overlock 107	0.6	0
1644	Factors Influencing Illness Intrusiveness of the Sexual Life in Women with Overactive Bladder. Journal of Muscle and Joint Health, 2013, 20, 62-71.	0.4	1
1645	Association of Statin Use with Storage Lower Urinary Tract Symptoms: Data Mining of Claims Database. Journal of Pharmacovigilance, 2014, 02, .	0.2	1

#	ARTICLE	IF	CITATIONS
1646	Other Varieties of Dysfunction. Current Clinical Urology, 2014, , 65-73.	0.0	0
1647	Botulinum Toxin Therapy for Voiding Dysfunction and the Female Pelvic Floor. , 2015, , 253-266.		0
1648	Treatment of Overactive Bladder in Elderly Patients: Clinical Considerations. Clinical Medicine Insights: Geriatrics, 0, 8, 11-20.	0.0	0
1649	Urinary incontinence and overactive bladder. Journal of the Korean Medical Association, 2015, 58, 886.	0.3	2
1650	Urination disorders occurring in the elderly – point of view of a physiotherapist. Medical and Biological Sciences, 2015, 29, 17.	0.2	0
1651	Intravesical Sodium Chondroitin Sulphate to Treat Overactive Bladder: Preliminary Result. International Neurourology Journal, 2015, 19, 85-89.	1.2	1
1652	Lower Urinary Tract Symptoms. , 2016, , 129-148.		0
1653	Efficacy and safety of onabotulinum toxin A for overactive bladder. World Journal of Clinical Urology, 2016, 5, 75.	0.0	0
1654	Evaluation of Overactive Bladder in Type 2 Diabetes Patients with a Questionnaire-Based Study. Haseki Tip Bulteni, 2016, 54, 19-25.	0.3	0
1655	Factors Influencing Overactive Bladder Symptom Severity in Community Residents. Journal of Muscle and Joint Health, 2016, 23, 39-48.	0.4	2
1656	Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 1076-1090.	0.9	0
1657	Insomnia in Patients with Comorbid Medical Problems. , 2017, , 199-219.		0
1658	The effectiveness of foot reflexology and behavior treatment in patient with overactive bladder syndrome: A case report. Journal of Human Sciences, 2016, 13, 4446.	0.2	0
1659	Cost Utility Analysis of Sacral Neuro-Modulation vs Botox A in the Treatment of Overactive Bladder in Colombia. Urology & Nephrology Open Access Journal, 2016, 3, .	0.1	0
1660	Overactive Bladder (OAB) in the Elderly with Contemporary Notions on Treatment Including Sacral Nerve Stimulation (SNS). , 2017, , 195-209.		0
1661	Applications of Botulinum Toxin in the Urinary Tract. , 2018, , 49-65.		0
1664	Changes of Bladder Function Related to the Effects of Menopause. Women's Health Bulletin, 2017, 5, .	0.7	0
1665	Sacral Neuromodulation for Overactive Bladder. , 2018, , 25-46.		2

#	ARTICLE	IF	CITATIONS
1667	Expression and Clinical Significance of NGF and PGE ₂ in the Urine of Female Patients with Overactive Bladder. Biophysics, 2018, 06, 9-14.	0.2	0
1669	The effects of urinary incontinence subtypes on quality of life: does it matter urinary incontinence subtype on doctor consultation. Ortado AYu T A p Dergisi, 2018, 10, 8-12.	0.1	4
1670	Harninkontinenz. , 2019, , 211-252.		1
1671	The Microbiome in Female Urology. , 2019, , 119-124.		0
1673	A Korean Postmarketing Study Assessing the Effectiveness of OnabotulinumtoxinA for the Treatment of Neurogenic Detrusor Overactivity or Idiopathic Overactive Bladder Using a Validated Patient-Reported Outcome Measure. International Neurourology Journal, 2019, 23, 30-39.	1.2	1
1675	Medical evaluation and management of male and female voiding dysfunction: a review. Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne, 2019, 57, 220-232.	0.6	0
1676	Caracterizaci3n precisa de la intervaci3n del tracto urinario mediante reconstrucci3n tridimensional: una revisi3n contempor3nea. Actas Urol3gicas Espa3olas, 2019, 43, 397-403.	0.7	0
1677	The Correlation between Overactive Bladder Symptoms and Urodynamic Findings in Men and Women. Medical Journal of the University of Cairo Faculty of Medicine, 2019, 87, 5299-5308.	0.0	0
1678	The use of botulinum toxin for the treatment of patients with overactive bladder. Pomeranian Journal of Life Sciences, 2019, 64, 9-13.	0.1	0
1679	Symptoms Complexes in Urology. , 2020, , 87-96.		1
1680	OVERACTIVE BLADDER. World Science, 2020, 1, 15-19.	0.1	0
1681	Urinary incontinence frequency, type, severity, and risk factors in female patients undergoing physical rehabilitation: A single center experience. Journal of Surgery and Medicine, 0, , .	0.1	0
1682	Seasonal variations in overactive bladder drug prescription rates in women: a nationwide population-based study. World Journal of Urology, 2021, 39, 877-882.	2.2	0
1683	Overactive bladder in an integrated delivery system: a longitudinal cohort study. BMC Health Services Research, 2020, 20, 447.	2.2	2
1684	Profile of sexuality and symptoms of lower urinary tract in non-institutionalized elderly. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2020, 46, 374-380.	1.5	3
1685	Fesoterodine for the treatment of overactive bladder: pharmacological bases and clinical results. Urologicheskie Vedomosti, 2020, 10, 163-171.	0.3	5
1686	Botulinum Toxin Therapy for Voiding Dysfunction. , 2020, , 255-282.		0
1687	The Prevalence of Overactive Bladder Symptoms in Women in Algeria, Egypt, Jordan and Lebanon: A Cross-Sectional Population-Based Survey. Advances in Therapy, 2021, 38, 1155-1167.	2.9	9

#	ARTICLE	IF	CITATIONS
1688	Variable frequency stimulation of sacral neuromodulation in black-zone overactive bladder patients: a case report. Translational Andrology and Urology, 2020, 9, 2842-2847.	1.4	2
1689	Cost-Effectiveness Analysis and Budget Impact: Antimuscarinics and Mirabegron for the Treatment of Patients With Urge Urinary Incontinence: The Brazilian Public Health System Perspective. Value in Health Regional Issues, 2020, 23, 85-92.	1.2	1
1690	Efficacy and Safety of Desmopressin with Anticholinergics in Female Patients with Overactive Bladder. Journal of SAFOG, 2020, 12, 178-181.	0.2	0
1691	Botulinum Toxin Treatment in Urological Disorders. , 2020, , 297-308.		0
1692	Sleep disturbance changes in women after treatment of refractory overactive bladder with sacral neuromodulation. Investigative and Clinical Urology, 2020, 61, 231.	2.0	1
1693	Contemporary Management of Urinary Incontinence. , 2020, , 457-473.		0
1694	Management of Refractory Overactive Bladder with Incontinence -A Novel Approach. Journal of Evidence Based Medicine and Healthcare, 2020, 7, 259-263.	0.0	0
1695	Urinary incontinence in Chilean women: A prevalence study of the health profile and associated factors. Medwave, 2020, 20, e7977-e7977.	0.5	3
1696	Incontinence in the Elderly. , 2008, , 293-305.		0
1697	Darifenacin: a selective M3 muscarinic receptor antagonist for the treatment of overactive bladder. Therapy: Open Access in Clinical Medicine, 2006, 3, 723-732.	0.2	0
1698	Metabolik Sendrom A°liÅŸkili Parametrelerin AAŸÄ±rÄ± Aktiv Mesane Åœezerine Etkisi. Yeni Åœeroloji Dergisi, 0, , .	0.1	0
1699	Evaluation of urodynamics parameters in different age and incontinence group of women. Journal of Surgery and Medicine, 2020, 4, 1-1.	0.1	0
1700	Relationship of Bladder Pain With Clinical and Urinary Markers of Neuroinflammation in Women With Urinary Urgency Without Urinary Incontinence. Female Pelvic Medicine and Reconstructive Surgery, 2021, 27, e418-e422.	1.1	3
1701	Interactions between Drugs and Surgery in the Treatment of LUTS and Advanced Renal Cancer. Current Drug Targets, 2020, 21, 1512-1514.	2.1	1
1702	Medical therapy for benign prostatic hyperplasia: new terminology, new concepts, better choices. Reviews in Urology, 2006, 8, 14-22.	0.9	6
1703	Treatment of the overactive bladder: where we stand in 2003. Reviews in Urology, 2003, 5 Suppl 8, S11-7.	0.9	0
1704	Oxybutynin: an overview of the available formulations. Therapeutics and Clinical Risk Management, 2006, 2, 19-24.	2.0	8
1705	Anticholinergics and central nervous system effects: are we confused?. Reviews in Urology, 2007, 9, 191-6.	0.9	22

#	ARTICLE	IF	CITATIONS
1706	The evolution of transdermal/topical overactive bladder therapy and its benefits over oral therapy. Reviews in Urology, 2009, 11, 1-6.	0.9	14
1707	InterStim Therapy: A Contemporary Approach to Overactive Bladder. Reviews in Obstetrics and Gynecology, 2009, 2, 18-27.	0.7	14
1708	Pharmacologic management of overactive bladder. Clinical Interventions in Aging, 2007, 2, 337-45.	2.9	22
1709	The evolution of transdermal/ topical overactive bladder therapy and its benefits over oral therapy. Reviews in Obstetrics and Gynecology, 2009, 2, 116-21.	0.7	5
1710	Male urinary incontinence: prevalence, risk factors, and preventive interventions. Reviews in Urology, 2009, 11, 145-65.	0.9	78
1711	Pharmacologic characteristics of bladder micturition function in anesthetized mice. Comparative Medicine, 2010, 60, 436-42.	1.0	1
1712	Sacral nerve stimulation for urinary urge incontinence, urgency-frequency, urinary retention, and fecal incontinence: an evidence-based analysis. Ontario Health Technology Assessment Series, 2005, 5, 1-64.	1.8	1
1713	Management of urinary incontinence. P and T, 2012, 37, 345-361H.	0.9	22
1714	Oxybutynin topical gel in the treatment of overactive bladder. Open Access Journal of Urology, 2010, 2, 91-8.	0.3	0
1715	Efficacy and safety of Baweidi Huang-wan in women with overactive bladder: a randomized, double blind, placebo controlled trial. International Journal of Clinical and Experimental Medicine, 2014, 7, 2744-53.	1.3	3
1716	Beta-3 adrenergic receptors could be significant factors for overactive bladder-related symptoms. International Journal of Clinical and Experimental Pathology, 2015, 8, 11863-70.	0.5	2
1717	Prevalence of overactive bladder syndrome (OABS) among women with gynaecological problems and its risk factors in a tertiary hospital, Negeri Sembilan, Malaysia: Implication for primary healthcare providers. Malaysian Family Physician, 2015, 10, 2-8.	0.6	2
1718	Evaluating Outcomes in Patients with Overactive Bladder within an Integrated Healthcare Delivery System Using a Treatment Patterns Analyzer. American Health and Drug Benefits, 2016, 9, 343-353.	0.5	4
1719	Comment on: Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo. Translational Andrology and Urology, 2020, 9, 2305-2307.	1.4	0
1720	Prevalence and predictors of nocturnal polyuria in females with overactive bladder syndrome. World Journal of Urology, 2021, , 1.	2.2	2
1721	Pooled analysis of the efficacy and safety of tibial nerve stimulation versus antimuscarinic agents in the management of overactive bladder syndrome. Medicine (United States), 2021, 100, e27745.	1.0	1
1722	Metabolic syndrome is associated with prostate enlargement: a systematic review, meta-analysis, and meta-regression on patients with lower urinary tract symptom factors. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882110662.	3.2	2
1723	Controlled Clinical Trial Effect of Noni Fruit Extract (Morinda citrifolia) Toward Overactive Bladder Women through Observation of High-Sensitivity C-reactive Protein in Urine Levels. Open Access Macedonian Journal of Medical Sciences, 2020, 8, 706-710.	0.2	0

#	ARTICLE	IF	CITATIONS
1724	Comment on: Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo. Translational Andrology and Urology, 2020, 9, 2305-2307.	1.4	0
1725	Sağlık Kuruluna Başvuran Hastalarda Acerojik ve İleştimsel Kaynaklı Nedenleri, Sıklıkları ve Dereceleri. Mersin Üniversitesi Tıp Fakültesi Lokman Hekim Tıp Tarihi Ve Folklorik Tıp Dergisi, 0, , .	0.7	0
1726	Learning Curve of Botulinum Toxin Bladder Injection for the Treatment of Refractory Overactive Bladder. International Journal of Women's Health, 2022, Volume 14, 1-7.	2.6	6
1728	Efficacy of percutaneous and transcutaneous posterior tibial nerve stimulation on idiopathic overactive bladder and interstitial cystitis/painful bladder syndrome: A systematic review and meta-analysis. Neurourology and Urodynamics, 2022, 41, 539-551.	1.5	9
1729	Overactive bladder as a dysfunction of the autonomic nervous system – A narrative review. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2022, 271, 102-107.	1.1	6
1731	Overactive Bladder during Pregnancy: A Prospective Longitudinal Study. Medicina (Lithuania), 2022, 58, 243.	2.0	2
1733	Frequency of overactive bladder (OAB) and the factors affecting it in patients with obstructive sleep apnea syndrome (OSAS). Urologia, 2022, , 039156032210782.	0.7	1
1734	What is the real burden of the overactive bladder? Results from a national prevalence study. Neurourology and Urodynamics, 2022, 41, 926-934.	1.5	5
1735	Prevalence of and Associated Factors for Overactive Bladder Subtypes in Middle-Aged Women: A Cross-Sectional Study. Medicina (Lithuania), 2022, 58, 383.	2.0	2
1736	Asynchronous telehealth visits for the treatment of overactive bladder. Menopause, 2022, 29, 723-727.	2.0	1
1737	Prevalence of Overactive Bladder Symptoms Among Women With Interstitial Cystitis/Bladder Pain Syndrome. Female Pelvic Medicine and Reconstructive Surgery, 2022, 28, e115-e119.	1.1	2
1738	The Prevalence of Lower Urinary Tract Symptoms and Overactive Bladder in South Korea: A Cross-Sectional, Population-Based Study. International Neurourology Journal, 2022, 26, 31-36.	1.2	4
1739	Multidisciplinary treatment for functional urological disorders with psychosomatic comorbidity in a tertiary pelvic care center – A retrospective cohort study. Neurourology and Urodynamics, 2022, 41, 1012-1024.	1.5	5
1740	Why Patients Fall Through the Cracks: Assessment of Patients' Overactive Bladder Treatment. Journal of Women's Health, 2022, 31, 1314-1319.	3.3	3
1741	Safety and Tolerability of Fesoterodine in Older Adult Patients with Overactive Bladder. Canadian Geriatrics Journal, 2022, 25, 72-78.	1.2	2
1742	Electronic Health Record – Triggered Research Infrastructure Combining Real-world Electronic Health Record Data and Patient-Reported Outcomes to Detect Benefits, Risks, and Impact of Medication: Development Study. JMIR Medical Informatics, 2022, 10, e33250.	2.6	1
1743	The Effect of Chronic Psychological Stress on Lower Urinary Tract Function: An Animal Model Perspective. Frontiers in Physiology, 2022, 13, 818993.	2.8	8
1744	Patient Experience of Antimuscarinic Treatment for Overactive Bladder: A Qualitative Exploration of Online Forum Content. Female Pelvic Medicine and Reconstructive Surgery, 2022, 28, e49-e54.	1.1	2

#	ARTICLE	IF	CITATIONS
1745	Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study). BMC Urology, 2022, 22, 40.	1.4	5
1746	Advances in Assistive Electronic Device Solutions for Urology. Micromachines, 2022, 13, 551.	2.9	3
1747	Anatomical and functional outcomes of non-obstetric urogenital fistula repair. International Urogynecology Journal, 2022, 33, 3221-3229.	1.4	1
1748	Efficacy and safety of skin-adhesive low-level light therapy for overactive bladder: a Phase III study. International Urogynecology Journal, 2022, , 1.	1.4	0
1749	Development and validation of prediction model for incident overactive bladder: The Nagahama study. International Journal of Urology, 2022, , .	1.0	0
1750	Correlación del grosor de la pared vesical con síndrome de vejiga hiperactiva y hallazgos urodinámicos. Revista Mexicana De Urología, 2021, 81, 1-11.	0.0	0
1751	Suppression of Inflammatory and Fibrotic Signals by Cinnamon (Cinnamomum cassia) and Cinnamaldehyde in Cyclophosphamide-Induced Overactive Bladder in Mice. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-13.	1.2	4
1752	The placebo and nocebo effects in functional urology. Nature Reviews Urology, 2022, 19, 171-189.	3.8	5
1753	Neural circuit control of innate behaviors. Science China Life Sciences, 2022, 65, 466-499.	4.9	13
1754	Gender differences of lower urinary tract symptoms in older Chinese Americans. Asian Journal of Urology, 2023, 10, 526-533.	1.2	0
1755	Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial. International Journal of Clinical Practice, 2022, 2022, 1-9.	1.7	4
1756	Medical Treatment of Overactive Bladder. Urologic Clinics of North America, 2022, 49, 249-261.	1.8	4
1757	Pharmacotherapy of Urgency Incontinence. , 2009, , 191-201.		0
1758	Alternative Therapies for Urinary Urgency Incontinence: Acupuncture and Herbology. , 2009, , 203-215.		0
1759	Pharmacotherapy of Male Incontinence. , 2009, , 411-421.		0
1765	Impact of combined usage of questionnaire forms with bladder diary for overactive bladder syndrome. Urologia, 2022, 89, 517-520.	0.7	3
1766	Adverse Events for Overactive Bladder Medications From a Public Federal Database. Female Pelvic Medicine and Reconstructive Surgery, 2022, 28, 429-435.	1.1	1
1767	OAB supraspinal control network, transition with age, and effect of treatment: A systematic review. Neurourology and Urodynamics, 2022, 41, 1224-1239.	1.5	2

#	ARTICLE	IF	CITATIONS
1768	Health disparities and access to advanced therapy for overactive bladder. <i>Neurourology and Urodynamics</i> , 2022, 41, 1940-1947.	1.5	4
1769	Effects of Information, Motivation, Behavioral Skills Model on Urinary Incontinence in Men With Overactive Bladder and Urge Incontinence. <i>Journal of Wound, Ostomy and Continence Nursing</i> , 2022, 49, 261-266.	1.0	1
1770	Comprehensive overview of the available pharmacotherapy for the treatment of non-neurogenic overactive bladder in children. <i>Expert Opinion on Pharmacotherapy</i> , 2022, , 1-12.	1.8	2
1771	Assessing comprehension of online information in the United States for third-line treatment of overactive bladder. <i>International Urogynecology Journal</i> , 2022, , 1.	1.4	3
1772	Combination and Novel Pharmacologic Agents for OAB. <i>Current Urology Reports</i> , 2022, , 1.	2.2	0
1773	Oral phenazopyridine vs intravesical lidocaine for bladder onabotulinumtoxinA analgesia: a randomized controlled trial. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 308.e1-308.e8.	1.3	3
1774	Relevance of dog as an animal model for urologic diseases. <i>Progress in Molecular Biology and Translational Science</i> , 2022, , 35-65.	1.7	5
1775	Trospium chloride in older patients with idiopathic overactive urinary bladder. <i>Russian Journal of Geriatric Medicine</i> , 2022, , 58-63.	0.6	0
1776	The association between overactive bladder and fibromyalgia: A systematic review and meta-analysis. <i>International Journal of Gynecology and Obstetrics</i> , 2022, 159, 630-641.	2.3	2
1777	Third-line therapy for overactive bladder in the elderly: Nuances and considerations. <i>Neurourology and Urodynamics</i> , 2022, 41, 1967-1974.	1.5	7
1779	Effects of β_2 Agonists and Anticholinergic Drugs on Defecation in Patients With Overactive Bladder. <i>In Vivo</i> , 2022, 36, 1847-1853.	1.3	0
1780	New Kid on the Block: The Efficacy of Phytomedicine Extracts Urox [®] in Reducing Overactive Bladder Symptoms in Rats. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	3.5	0
1781	Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder. <i>Medicina (Lithuania)</i> , 2022, 58, 825.	2.0	1
1782	302 THE PATIENT PATHWAY FOR OVERACTIVE BLADDER MANAGEMENT: A QUALITATIVE ANALYSIS. , 2022, 2, 1.		0
1783	Sacral Neuromodulation in Pregnant Women—A Case Report and Literature Review. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8340.	2.6	3
1784	Comparative dissolution studies of 3D-printed inserts in a novel biopharmaceutical bladder model. <i>International Journal of Pharmaceutics</i> , 2022, 624, 121984.	5.2	0
1785	Evaluation of pelvic floor muscle elasticity in patients with overactive bladder syndrome using real-time tissue elastography. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2022, 276, 9-13.	1.1	0
1786	Exposure to DEHP is potential to increase the risk of overactive bladder, evidence from NHANES 2003–2008. <i>Environmental Science and Pollution Research</i> , 2022, 29, 89643-89651.	5.3	2

#	ARTICLE	IF	CITATIONS
1787	Prevalence and Incidence of Nonmotor Symptoms in Individuals with and Without Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 961-966.	1.5	4
1788	Overactive Bladder and the Workplace. <i>Current Bladder Dysfunction Reports</i> , 0, , .	0.5	0
1789	The effect of oral medications on fMRI brain activation: A randomized, double blind, controlled pilot trial of older women with overactive bladder. <i>International Urogynecology Journal</i> , 0, , .	1.4	2
1790	Effects of Pelvic Floor Muscle Training on Sexual Dysfunction, Sexual Satisfaction of Partners, Urinary Symptoms, and Pelvic Floor Muscle Strength in Women With Overactive Bladder: A Randomized Controlled Study. <i>Journal of Sexual Medicine</i> , 2022, 19, 1421-1430.	0.6	1
1791	Efficacy and safety of transurethral resection of the prostate, holmium laser enucleation of the prostate, and photoselective vaporization of the prostate in management of overactive bladder symptoms complicating benign prostatic hyperplasia in patients with moderately enlarged prostates. <i>Canadian Urological Association Journal</i> , 2022, 17, .	0.6	1
1792	Trends in minimally invasive surgical therapies for overactive bladder management in Australia. <i>LUTS: Lower Urinary Tract Symptoms</i> , 0, , .	1.3	0
1793	Phenotyping of Urinary Urgency Patients Without Urgency Incontinence, and Their Comparison to Urgency Incontinence Patients: Findings From the LURN Study. <i>Journal of Urology</i> , 2023, 209, 233-242.	0.4	1
1794	The cumulative effect of unmet social needs on noncancerous genitourinary conditions and severity of lower urinary tract symptoms. <i>Neurourology and Urodynamics</i> , 2022, 41, 1862-1871.	1.5	3
1795	Long-term follow-up of intravesical abobotulinumtoxinA (Dysport®) injections in women with idiopathic detrusor overactivity. <i>Asian Journal of Urology</i> , 2024, 11, 93-98.	1.2	0
1796	An analysis of factors that influence patient preference of third-line therapy for overactive bladder. <i>Neurourology and Urodynamics</i> , 2022, 41, 1906-1913.	1.5	2
1797	Mental Health in Non-Oncologic Urology Patients. <i>Health Psychology Research</i> , 2022, 10, .	1.4	1
1798	Translation and validation of the Overactive Bladder Symptom Score (OABSS) in Chinese during the COVID-19 telehealth Surge. , 2022, , 100016.		0
1799	Associations Between Unmet Social Needs and Overactive Bladder. <i>Journal of Urology</i> , 2022, 208, 1106-1115.	0.4	4
1800	The T-type calcium channel CaV3.2 regulates bladder afferent responses to mechanical stimuli. <i>Pain</i> , 2023, 164, 1012-1026.	4.2	4
1801	Evaluating the demographic profile and mapping the prevalence of overactive bladder in benign prostrate hypertrophy patients: a retrospective, observational study. <i>International Journal of Scientific Reports</i> , 2022, 8, 323.	0.1	0
1802	Novel botulinum neurotoxin-A tibial nerve perineural injection to alleviate overactive bladder symptoms in male rats. <i>Animal Cells and Systems</i> , 2022, 26, 283-290.	2.2	0
1803	The Impact of Anticholinergic Use for Overactive Bladder on Cognitive Changes in Adults with Normal Cognition, Mild Cognitive Impairment, or Dementia. <i>European Urology Open Science</i> , 2022, 46, 22-29.	0.4	2
1804	The Epidemiology and Socioeconomic Impact of Female GU and Pelvic Floor Disorders. , 2022, , 1-11.		0

#	ARTICLE	IF	CITATIONS
1805	Comparison of patient characteristics, urinary incontinence behaviors, and quality of life among different types of urinary incontinence. Journal of Exercise Therapy and Rehabilitation, 2022, 9, 189-195.	0.2	0
1806	Psychology/Quality of Life and Pelvic Sensation. , 2022, , 161-167.		0
1807	Cost, resource utilization, and treatment-taking behaviors among patients with OAB initiating combination mirabegron and antimuscarinic therapy in the US. , 2023, 5, 100020.		2
1808	Comparison of Two Treatment Modalities in Overactive Bladder: a Rapid Overview. Medicinski Arhiv = Medical Archives = Archives De MÃ©decine, 2022, 76, 469.	0.9	0
1809	Overactive Bladder Patients With and Without Urgency Incontinence: A Spectrum of One Condition or Different Phenotypes?. , 2023, 29, 33-40.		2
1810	Overactive Bladder and Cognitive Impairment: The American Urogynecologic Society and Pelvic Floor Disorders Research Foundation State-of-the-Science Conference Summary Report. , 2023, 29, S1-S19.		8
1811	Efficacy and Safety of Vibegron for the Treatment of Overactive Bladder in Women: A Subgroup Analysis From the Double-Blind, Randomized, Controlled EMPOWUR Trial. , 2023, 29, 48-57.		1
1812	Risk of Retention After OnabotulinumtoxinA Injection for Overactive Bladder in a Diverse Urban Population With High BMI and Comorbidity Rates. , 2023, 29, 41-47.		0
1813	Evidence-Informed, Interdisciplinary, Multidimensional Action Plan to Advance Overactive Bladder Research and Treatment Initiatives: Directives From State-of-the-Science Conference on Overactive Bladder and Cognitive Impairment. , 2023, 29, S20-S39.		6
1814	Microhematuria in Women Presenting for Overactive Bladder. Current Urology Reports, 0, , .	2.2	0
1815	Comparison of the Effect of Oral Sodium Bicarbonate and Tolterodine in Women with Symptoms of Overactive Bladder with Acidic Urine- A Single-Blind Randomized Clinical Trial. Current Women's Health Reviews, 2023, 19, .	0.2	0
1816	Top 50 Most Cited Articles About OAB: A Bibliometric Analysis. Urology, 2022, , .	1.0	2
1817	CYP2D6 Substrate Dispensing Among Patients Dispensed Mirabegron: An Administrative Claims Analysis. Drugs - Real World Outcomes, 2023, 10, 119-129.	1.6	2
1818	OnabotulinumtoxinA discontinuation in patients with prior nerve stimulation. Neurourology and Urodynamics, 0, , .	1.5	0
1819	Vaginal Hormone Therapy for Conditions of the Lower Urinary Tract. Current Urology Reports, 2023, 24, 41-50.	2.2	2
1820	Reduced versus standard intradetrusor OnabotulinumtoxinA injections for treatment of overactive bladder. Neurourology and Urodynamics, 2023, 42, 366-374.	1.5	5
1821	Liposome-Encapsulated Botulinum Toxin A in Treatment of Functional Bladder Disorders. Toxins, 2022, 14, 838.	3.4	2
1822	Mechanism of traditional Chinese medicine in treating overactive bladder. International Urology and Nephrology, 2023, 55, 489-501.	1.4	1

#	ARTICLE	IF	CITATIONS
1823	Physical and Rehabilitation Therapy for Overactive Bladder in Women: A Systematic Review and Meta-Analysis. International Journal of Clinical Practice, 2023, 2023, 1-10.	1.7	2
1824	Assessing Quality-of-Life of Patients Taking Mirabegron for Overactive Bladder. Therapeutics and Clinical Risk Management, 0, Volume 19, 27-33.	2.0	1
1825	Real-Time Documentation of the Effect of Onabotulinumtoxin A Detrusor Injection in OAB Patients—Preliminary Results. Toxins, 2023, 15, 30.	3.4	2
1826	Prevalence, Risk Factors, and Psychological Effects of Overactive Bladder in Chinese University Students. International Neurourology Journal, 2022, 26, 342-348.	1.2	0
1828	Insights from the AQUA Registry: a retrospective study of anticholinergic polypharmacy in the United States. Therapeutic Advances in Urology, 2023, 15, 175628722211505.	2.0	1
1829	Sacral Nerve Stimulation for Gastrointestinal Disorders. , 2023, , 2319-2352.		0
1830	S��mantique, scores et cotation��: dysurie et incontinence urinaire. La Presse M��dicale Formation, 2023, 4, 26-31.	0.1	0
1831	Pre- versus Post-Menopausal Onset of Overactive Bladder and the Response to Vaginal Estrogen Therapy: A Prospective Study. Medicina (Lithuania), 2023, 59, 245.	2.0	0
1832	Despite Recommendations, Anticholinergics Account for the Majority of Prescriptions to Treat Overactive Bladder in the United States. , 2023, 29, 497-503.		1
1833	Real-time changes in brain activity during tibial nerve stimulation for overactive bladder: Evidence from functional near-infrared spectroscopy hype scanning. Frontiers in Neuroscience, 0, 17, .	2.8	1
1834	Role of circadian rhythms and melatonin in bladder function in heath and diseases. Autonomic Neuroscience: Basic and Clinical, 2023, 246, 103083.	2.8	6
1835	Cost��effectiveness of overactive bladder treatments from a US commercial and��payer perspective. Journal of Comparative Effectiveness Research, 2023, 12, .	1.4	0
1836	Urinary Biomarkers and Overactive Bladder Symptoms Before and After Prolapse Surgery. , 2023, 29, 266-272.		1
1837	Quality, Value, and Efficacy of Alternative Medicine in the Treatment of Overactive Bladder. Current Bladder Dysfunction Reports, 0, , .	0.5	2
1838	Discriminating Different Bladder and Bladder Outlet Dysfunctions by Urinary Biomarkers in Women with Frequency��Urgency Syndrome. Biomedicines, 2023, 11, 673.	3.2	1
1839	Microbiome in urological diseases: Axis crosstalk and bladder disorders. Investigative and Clinical Urology, 2023, 64, 126.	2.0	4
1840	The Relationship between the Presence of an Earlobe Crease and Overactive Bladder: A Cross-Sectional Case-Controlled Study. Medicina (Lithuania), 2023, 59, 476.	2.0	0
1841	The peripheral nerve evaluation: determining which symptoms lead to a successful test. Obstetrics & Gynecology International Journal, 2023, 14, 26-29.	0.1	0

#	ARTICLE	IF	CITATIONS
1842	TOT in combination with solifenacin or intravaginal prasterone in postmenopausal women with mixed urinary incontinence: A retrospective analysis in 112 patients. LUTS: Lower Urinary Tract Symptoms, 0, , .	1.3	0
1843	Minimally Invasive Two-passage Electrical Genital Nerve Stimulation: A Human Cadaver Study of a New Technique. Journal of Minimally Invasive Gynecology, 2023, , .	0.6	0
1844	Efficacy of acupoint application in patients with overactive bladder: A randomized, placebo-controlled pilot trial. Explore: the Journal of Science and Healing, 2023, , .	1.0	0
1845	Difference in symptom manifestation between postmenopausal and premenopausal women in acute uncomplicated cystitis: A multi-institutional pilot study. Current Urology, 0, Publish Ahead of Print, .	0.6	0
1846	Urinary Incontinence, Depression, and Psychosocial Factors – A Review of Population Studies. European Medical Journal (Chelmsford, England), 0, , 58-67.	3.0	4
1847	The impact of postinjection urinary tract infection on efficacy of intravesical onabotulinumtoxinA – A secondary analysis. Neurourology and Urodynamics, 2023, 42, 1238-1244.	1.5	2
1848	Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder. BMC Urology, 2023, 23, .	1.4	2
1849	Update on Overactive Bladder Therapeutic Options. American Journal of Therapeutics, 0, Publish Ahead of Print, .	0.9	1
1850	Darifenacin Self-assembled Liquid Crystal Cubic Nanoparticles: a Sustained Release Approach for an Overnight Control of Overactive Bladder. AAPS PharmSciTech, 2023, 24, .	3.3	3
1851	A porcine bladder model of pre-clinical urodynamics demonstrates increased afferent nerve activity during filling. Neurourology and Urodynamics, 0, , .	1.5	0
1852	Assessment of Codispensing Patterns of Mirabegron and Prespecified CYP2D6 Substrates in Patients with Overactive Bladder. Drugs - Real World Outcomes, 0, , .	1.6	0
1853	Characteristics of Providers Who Prescribed Only Anticholinergic Medications for Overactive Bladder in 2020. American Journal of Obstetrics and Gynecology, 2023, , .	1.3	0
1854	Effect of androgens and estrogens on bladder/lower urinary tract function. , 2023, , 141-158.		0
1855	Neuro-urology research: a comprehensive overview. , 2023, , 1-28.		0
1856	Barrington's nucleus: a century of progress identifying neurons that control micturition. , 2023, , 31-51.		0
1857	The prevalence of overactive bladder and its impact on the quality of life: A cross-sectional study. Arab Journal of Urology Arab Association of Urology, 2024, 22, 39-47.	1.5	0
1858	Prevalence and influencing factors of lower urinary tract symptoms in female nurses: a cross-sectional study based on TARGET. Frontiers in Public Health, 0, 11, .	2.7	1
1859	Bladder capacity in women with overactive bladder syndrome: a cross-sectional study. Urology, 2023, , .	1.0	0

#	ARTICLE	IF	CITATIONS
1860	Spectrum of lower urinary tract symptoms in the women attending gynecological OPD in a tertiary care hospital in Northeast India. <i>Journal of Clinical Medicine of Kazakhstan</i> , 2023, 20, 88-93.	0.3	0
1861	One treatment with onabotulinumtoxinA relieves symptoms of overactive bladder in patients refractory to one or more oral medications. <i>Neurourology and Urodynamics</i> , 2023, 42, 1203-1213.	1.5	1
1862	Should the Preference-Based Index Set of Values Be Country or Disease Specific? An Analysis Using Data From Women With Symptoms of Overactive Bladder. <i>Value in Health Regional Issues</i> , 2023, 38, 1-8.	1.2	0
1863	Sex and Gender Differences in the Pharmacology of the Overactive Urinary Bladder. <i>Handbook of Experimental Pharmacology</i> , 2023, , .	1.8	0
1864	Therapeutic targets in the brain for overactive bladder: A focus on angiotensin II type 1 receptor. <i>Journal of Pharmacological Sciences</i> , 2023, 153, 69-72.	2.5	1
1865	Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2023, 45, 337-346.	0.8	4
1866	Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact. <i>Medicine (United States)</i> , 2023, 102, e32377.	1.0	3
1868	Efficacy and Safety of Eliapixant in Overactive Bladder: The 12-Week, Randomised, Placebo-controlled Phase 2a OVADER Study. <i>European Urology Focus</i> , 2024, 10, 90-97.	3.1	1
1869	The role of facebook support groups for women with benign urologic conditions. <i>Neurourology and Urodynamics</i> , 2023, 42, 1795-1801.	1.5	1
1870	Systematic review and meta-analysis of urinary incontinence prevalence and population estimates. <i>Neurourology and Urodynamics</i> , 2024, 43, 52-62.	1.5	0
1871	Exploring Concomitant Acetylcholinesterase Inhibitor and Overactive Bladder Anticholinergic Use and Risk of Hospitalization in Medicare and Dual-Eligible Medicare-Medicaid Populations in a Historic Database. <i>Pharmacy (Basel, Switzerland)</i> , 2023, 11, 140.	1.6	0
1872	Therapeutic potential and mechanisms of sacral nerve stimulation for gastrointestinal diseases. <i>Journal of Translational Internal Medicine</i> , 2023, 11, 115-127.	2.5	2
1873	Patient and Clinician Challenges with Anticholinergic Step Therapy in the Treatment of Overactive Bladder: A Narrative Review. <i>Advances in Therapy</i> , 2023, 40, 4741-4757.	2.9	3
1874	The Role of Sarcopenia in Overactive Bladder in Adults in the United States: Retrospective Analysis of NHANES 2011-2018. <i>Journal of Nutrition, Health and Aging</i> , 2023, 27, 734-740.	3.3	2
1875	Use of Fermented Red Clover Isoflavones in the Treatment of Overactive Bladder in Postmenopausal Women: A Randomized, Double-Blinded, Placebo-Controlled Trial. <i>Nutrients</i> , 2023, 15, 4165.	4.1	0
1876	Rationale and design of an implant procedure and pivotal study to evaluate safety and effectiveness of Medtronic's tibial neuromodulation device. <i>Contemporary Clinical Trials Communications</i> , 2023, 35, 101198.	1.1	0
1877	Impact of Sling at Time of Prolapse Surgery on Overactive Bladder. , 0, , .		0
1878	Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron 50 mg in Sexually Active Men With Bothersome Overactive Bladder Symptoms - A Multicenter, Randomized Study. <i>International Neurourology Journal</i> , 2023, 27, 182-191.	1.2	0

#	ARTICLE	IF	CITATIONS
1879	Analyzing Access and Costs of Oral Medications for Overactive Bladder: Uncovering Disparities. Urology, 2024, 183, 57-62.	1.0	0
1880	Overactive Bladder Management: Cognitive Risk With Anticholinergics and Alternative Management Options for the General Practitioner. Topics in Obstetrics & Gynecology, 2023, 43, 1-4.	0.0	0
1881	The Use of Metformin in Overactive Bladder: A Retrospective Nested Case-control, Population-based Analysis. Urology, 2024, 183, 70-77.	1.0	2
1882	Bladder training for treating overactive bladder in adults. The Cochrane Library, 2023, 2023, .	2.8	1
1883	Drug–Drug Interactions between Tamsulosin and Mirabegron in Healthy Individuals Do Not Affect Pharmacokinetics and Hemodynamic Parameters Significantly. Pharmaceuticals, 2023, 16, 1457.	3.8	0
1884	The Effects of Age, Gender, and Postvoid Residual Volume on Catheterization Rates After Treatment with OnabotulinumtoxinA for Overactive Bladder. European Urology Open Science, 2023, 57, 98-105.	0.4	1
1885	Associations between exposure to organophosphate esters and overactive bladder in U.S. adults: a cross-sectional study. Frontiers in Public Health, 0, 11, .	2.7	0
1886	Urinary beta 3-adrenoceptor as a diagnostic biomarker for overactive bladder in women. Scientific Reports, 2023, 13, .	3.3	0
1887	Progress in overactive bladder: novel avenues from psychology to clinical opinions. PeerJ, 0, 11, e16112.	2.0	0
1888	The role of botulinum toxin in the management of nonneurogenic overactive bladder in children: Highlights for clinical practice. A systematic review. Current Urology, 0, , .	0.6	0
1889	The Epidemiology and Socioeconomic Impact of Female GU and Pelvic Floor Disorders. , 2023, , 85-95.		0
1890	A Study Protocol of Micro-Ablative Fractional CO2 Laser in Postmenopausal Women With Overactive Bladder Syndrome. Cureus, 2023, , .	0.5	0
1891	Associations between overactive bladder and sleep patterns: a cross-sectional study based on 2007–2014 NHANES. BMC Urology, 2023, 23, .	1.4	2
1892	Fluid intake behavior in women with refractory overactive bladder undergoing third line therapy. Neurourology and Urodynamics, 2024, 43, 44-51.	1.5	0
1893	Flat Magnetic Stimulation for Urge Urinary Incontinence. Medicina (Lithuania), 2023, 59, 1999.	2.0	1
1894	Personalized approach to pharmacotherapy of overactive bladder. Urologicheskie Vedomosti, 2023, 13, 267-282.	0.3	0
1895	Factors Influencing Medication Selection for Management of Overactive Bladder: Trends and Insights From AUA Quality Registry. Urology, 2024, 184, 51-57.	1.0	0
1897	Investigation of intradetrusor onabotulinum toxin A efficacy and safety in older adults with urge urinary incontinence. International Urology and Nephrology, 0, , .	1.4	0

#	ARTICLE	IF	CITATIONS
1898	The brain, gut, and bladder health nexus: A conceptual model linking stress and mental health disorders to overactive bladder in women. <i>Neurourology and Urodynamics</i> , 2024, 43, 424-436.	1.5	1
1899	Factors associated with urinary incontinence among Hispanic/Latina women in the United States: Findings from The Hispanic Community Health Study/Study of Latinos (HCHS/SOL). <i>Neurourology and Urodynamics</i> , 2024, 43, 329-341.	1.5	0
1900	Prevalence of overactive bladder in Chinese women: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2023, 18, e0290396.	2.5	0
1901	Overactive Bladder in Late Pregnancy to 1 Year After First Vaginal Delivery. , 0, , .		0
1902	Real-world onabotulinumtoxinA treatment patterns in patients with overactive bladder. <i>Neurourology and Urodynamics</i> , 2024, 43, 396-406.	1.5	0
1903	Evaluation of Food Effect on the Pharmacokinetics of Velufenacin, a New Muscarinic Receptor Antagonist, in Healthy Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2024, 13, 128-133.	1.6	0
1904	The prevalence of probable overactive bladder and associated risk factors among medical students in Jordan: a cross-sectional study. <i>BMC Urology</i> , 2024, 24, .	1.4	0
1906	Trends in Age-Specific Prevalence of Lower Urinary Tract Dysfunction: A Nationwide Population-Based Cohort Study. <i>Urogenital Tract Infection</i> , 2023, 18, 101-106.	0.2	0
1907	Trial Design for Mixed Urinary Incontinence: Midurethral Sling Versus Botulinum Toxin A. , 2024, 30, 478-488.		0
1908	Psychometric Properties and Cutoff Value of the Turkish Overactive Bladder Symptom Score. , 0, , .		0
1909	Midurethral sling position and surgical outcome: A meta-analysis. <i>Medicine (United States)</i> , 2024, 103, e36115.	1.0	0
1910	Regular and Irregular Use and Reasons for Discontinuation of Solifenacin Therapy in Patients with Overactive Bladder Managed by Urologists. <i>Pharmaceuticals</i> , 2024, 17, 116.	3.8	0
1911	Exploring lifelong overactive bladder: Transitions, evidence, and clinical implications; A modified Delphi process. <i>Neurourology and Urodynamics</i> , 0, , .	1.5	0
1912	Distribution, course, and spatial relationships of the saphenous nerve: A 3D neuroanatomical map for nerve stimulation. <i>PLoS ONE</i> , 2024, 19, e0297680.	2.5	0
1913	Predictive Value of Urodynamic Studies for Overactive Bladder. <i>Current Bladder Dysfunction Reports</i> , 0, , .	0.5	0
1914	Pathophysiology of Overactive Bladder and Pharmacologic Treatments Including β -Adrenoceptor Agonists -Basic Research Perspectives-. <i>International Neurourology Journal</i> , 2024, 28, 12-33.	1.2	0
1915	Aktif Mesane Yânetiminde Sakral Nâromodâlasyon Uygulamalarâ. <i>Ege Tâp Dergisi</i> , 2024, 63, 151-156.		0
1916	Multicomponent Intervention for Overactive Bladder in Women. <i>JAMA Network Open</i> , 2024, 7, e241784.	5.9	0

#	ARTICLE	IF	CITATIONS
1917	Urodynamic insights: exploring the relationship between detrusor overactivity and pelvic organ prolapse in women with urge incontinence. Archives of Gynecology and Obstetrics, 0, , .	1.7	0
1918	Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis. Advances in Therapy, 2024, 41, 2086-2097.	2.9	0
1919	Pilot Study of a Digital Behavioral Therapy for Overactive Bladder in Women. , 0, , .		0
1920	A Comparison of U.S. Individual and Family Plan Medication Coverage for Overactive Bladder. , 2024, 30, 214-222.		0
1921	Overactive Bladder Medication Access. , 2024, 30, 369-373.		0
1922	Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database. Frontiers in Pharmacology, 0, 15, .	3.5	0
1923	Comparing Impact of Overactive Bladder Therapies on Nocturia. , 2024, 30, 264-271.		0
1924	Understanding the Pursuit of Third-Line Therapies for Overactive Bladder: A Mixed Methods Study. , 2024, 30, 188-196.		0
1925	Pain Related to Intradetrusor BotulinumtoxinA: A Randomized Clinical Trial. , 2024, 30, 337-344.		0